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 1 Summary 
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1 Summary 
Regulatory  T  cells  (Treg  cells)  are  crucial  mediators  of  peripheral  self-tolerance,  and  their 
specific  ablation  causes  catastrophic  autoimmunity.  The  protein  Foxp3  has  been  described  as 
the  key  transcription  factor  delineating  cells  of  this  lineage.  In  this  thesis,  we  investigate 
different levels of transcriptional control in Foxp3-expressing Treg cells:  
At first, we identified CpG rich regions along the Foxp3 gene and investigated them for their 
epigenetic  profile.  We  were  able  to  validate  already-described  Treg-specific  demethylated 
regions, but we also identified new Treg-specific demethylation patterns along the Foxp3 gene. 
These  patterns  are  initiated  during  thymic  Treg  development  and  persist  in  circulation,  and 
remain intact also in DNA-methyltransferase deficient mice. Next, we explored the epigenetic 
control of Treg cells on a broader scale. We isolated tissue-resident Treg cells from fat, skin, 
liver, and lymph nodes and subjected them to whole-genome tagmentation-based methylation 
analysis  in  correlation  with  RNA  expression  profiling.  This  enables  us  to  investigate  tissue-
specific epigenetic patterns that drive and manifest Treg cell adaption to local tissues. 
Additionally,  we  observed  that  the  Foxp3  core  promoter  is  completely  demethylated  also  in 
Foxp3 non-expressing cell types. Therefore, we identified binding partners to the Foxp3 gene 
promoter  in  a  novel  procedure  called  inverted  Chromatin  IP.  We  validated  the  suppressive 
nature of these target proteins via luciferase-based screens, tested their differential expression 
profile in different cell types, and investigated the effect of their virus-mediated overexpression 
on in-vitro Treg cell induction. 
Finally,  we  investigated  the  role  of  one  specific  transcriptional  regulator  in  Treg  cells:  Rbpj, 
commonly known as an important co-factor of Notch signaling. While we did not find evidence 
that Notch signaling was active in bona fide Treg cells, we still measured an upregulation of 
Rbpj mRNA in Treg cells compared to their conventional T-cell (Tconv) counterparts in many 
different tissues. Upon Treg-specific Rbpj gene deletion, we observed a steady increase in Treg 
frequency and number in several anatomical locations, finally leading to autoimmune pathology 
despite the presence of otherwise functionally-intact Treg cells. We identified the IL7-receptor, 
an  important  growth-promoting  cytokine  receptor,  to  be  specifically  upregulated  in  Rbpj-
deficient Treg cells, whereas Dtx-1, a paramount anergy-promoting factor, was strongly 
downregulated. Furthermore, gene expression profiling and antibody staining revealed that both 
Treg and Tconv cells gained T H subset lineage profiles, indicating an inability of Treg cells to 
control (auto) immune responses in-vivo. Our data suggest a novel, Notch-independent function 
of Rbpj to specifically regulate Treg cell proliferation and functionality. 
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2 Zusammenfassung 
Regulatorische T-Zellen sind wichtige Bausteine für die periphere Immun-Selbsttoleranz, und 
ihre  Abwesenheit  führt  zu  schweren  Autoimmunerkrankungen.  Das  Foxp3-Protein  wurde  als 
Hauptfaktor  für  die  Entstehung  dieser  Zellen  beschrieben.  In  dieser  Arbeit  untersuchen  wir 
mehrere Ebenen der molekularen Kontrolle dieses Zelltyps sowie seines Hauptgens Foxp3: 
Zuerst  identifizierten  wir  Regionen  im  Foxp3-Gen,  die  sich  durch  eine  hohe  Dichte  an  CG-
Dinukleotiden auszeichnen. Diese wurden epigenetisch untersucht, wodurch wir bereits 
bekannte regulatorische T-Zell-spezifische Regionen validieren konnten, aber auch neue 
differenziell-methylierte Regionen identifizierten. Diese Methylierungsmuster werden im 
Thymus angelegt, bleiben während der Zirkulation dieser Zellen erhalten und bestehen ebenfalls 
in  DNA-Methyltransferase-defizienten  Mäusen.  Des  Weiteren  haben  wir  die  epigenetischen 
Merkmale  von  regulatorischen  T-Zellen  über  das  Gesamtgenom  bestimmt.  Hierzu  haben  wir 
Zellen aus Fett, Haut, Leber, und Lymphknoten isoliert und über Ganzgenomsequenzierung in 
Korrelation  mit  Genexpressionbestimmungen  analysiert.  Mit  diesem  Datensatz  können  wir 
gewebespezifische  Anpassungsmuster  von  regulatorischen  T-Zellen  identifizieren.  In  unseren 
epigenetischen Studien haben wir auch den zentralen Foxp3 Promoter untersucht und 
festgestellt, dass dieser in Foxp3-negativen Zelltypen demethyliert ist. Daher haben wir diesen 
Promoter mit einer invertierten Chromatin-Immunopräzipitation nach Bindefaktoren untersucht. 
Die gensuppressive Natur der in dieser Methode identifizierten Kandidaten wurde über 
Luziferase-Messungen getestet, und ihr differenzielles Expressionprofil über eine Vielzahl von 
Zelltypen bestimmt. Schlußendlich wurden die Faktoren in induzierten regulatorischen T-Zellen 
überexprimiert, um ihren Einfluß auf die Expression des Foxp3 Gens zu untersuchen. 
In  einem  weiteren  Projekt  haben  wir  uns  mit  dem  Rbpj  Protein,  einem  wichtigen  Faktor  im 
Notch-Signalweg, und seiner Rolle in regulatorischen T-Zellen beschäftigt. Das Rbpj Protein ist 
in diesem Zelltyp überexprimiert, obwohl keine Notch-Aktivität nachzuweisen ist. Daher haben 
wir  dieses  Protein  in  regulatorischen  T-Zellen  deletiert,  was  zu  einer  systemweiten  Zunahme 
dieser Zellen und der Entstehung einer Autoimmunerkrankung führte. Rbpj-defiziente 
regulatorische T-Zellen zeigten eine charakteristische Überexpression des 
wachstumsstimulierenden IL7-Oberflächenrezeptors sowie eine starke Herunterregulierung von 
Dtx-1, einem Anergie-fördernden Transkriptionsfaktor. Genexpressionsanalysen deuten auf eine 
Differenzierung der regulatorischen T-Zellen sowie der Effektor T-Zellen in TH-
Subpopulationen hin. Unsere Daten lassen auf eine bisher unbeschriebene, Notch-unabhängige 
Rolle von Rbpj für die Regulation von Proliferation und Funktion regulatorischer T-Zellen  im 
Gleichgewichtszustand hin. 
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4 Background 
4.1 T cells originate from hematopoietic stem cells 
In  adults,  immune  cells  originate  from  hematopoietic  stem  cells  (HSCs)  in  the  bone 
marrow. Already there, a distinct lineage-decision is made: whereas common lymphoid 
progenitors  (CLPs)  give  rise  to  B-,  T-,  and  NK  cells,  common  myeloid  progenitors 
(CMP) can differentiate into lineages of granulocyte/macrophage cells (GMP) or 
megakaryocytes/erythrocytes (MEP). Each progenitor will end-differentiate into a 
specific subset, as shown in Figure 1. But not all cell lineages end-differentiate in the 
bone marrow – T cells are trained and specialized in the thymus, an organ situated at the 
base of the heart in the upper thorax. T-cell progenitors travel to this organ via the blood 
stream  and  give  rise  to  thymocytes,  which  undergo  highly  controlled  selection  and 
quality control measures while they mature into CD4 pos or CD8 pos T cells. Afterwards, 
they re-enter the blood stream to take on effector functions 1. 
 
Figure 1: The origin of immune cells in the hematopoietic system. 
This graph depicts the development of lymphoid and myeloid cells from the hematopoietic stem 
cell (HSC). CLP = common lymphoid progenitor; CMP = common myeloid progenitor; GMP = 
granulocyte/macrophage progenitor; MEP = megakaryocyte/erythrocyte progenitor; DC = 
Dendritic cell; NK cell = Natural Killer cell. 
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4.2 Central tolerance is mediated by thymus-resident TEC 
Our body requires a portfolio of protective systems to prevent harmful immune 
responses  towards  self-peptides  and  harmless  environmental  antigens.  This  tolerance 
relies  on  both  central  and  peripheral  mechanisms.  Negative  selection  of  self-reactive 
lymphocytes during their development in thymus (T cells) or bone marrow (B cells) is 
part  of  the  central  tolerance  mechanism,  and  is  supplemented  by  self-antigen  binding 
causing anergy, lack of APC-derived co-stimulation against self-peptides, and 
expression of inhibitory receptors 2. In addition, regulatory T cells (Tregs) are important 
mediators  of  peripheral  tolerance  in  tissues  and  circulation.  But  what  happens  if  the 
thymus,  and  its  tolerance-inducing  mechanism,  is  absent?  When  newborn  mice  have 
their thymus removed (thymectomy) very early after birth (between day 2 and day 4), 
immediate  adverse  events  such  as  autoimmune  disease  are  followed  by  long-term 
immunodeficiency,  increased  tumor  incidence  and  overall  increased  mortality.  These 
findings lead to the appreciation of the thymus as central organ for the proper 
development of functionally intact CD4pos and CD8pos T cells (reviewed in 3). 
Looking at thymic T cell development in more detail, while thymocytes differentiate, 
they migrate through two different anatomical parts of the thymus, the medulla and the 
cortex. The cortex contains more immature thymocytes alongside of macrophages and 
cortical epithelial cells (cTECs). The medulla, including its Hassall’s corpuscles as sites 
of massive cell death, contain more mature thymocytes accompanied by dendritic cells 
(DCs)  and  medullary  TECs  (mTEC).  Early  precursor  thymocytes  enter  the  thymic 
cortex via the corticomedullary junction and engage TECs. At this stage, active Notch-
ligand  expression  on  mTECs  commits  early  precursor  thymocytes  to  the  lymphoid 
lineage. This close interaction with the stroma and stroma-resident APCs accompanies 
thymocytes  along  their  way  through  the  thymus.  First,  thymocytes  enter  the  double 
negative  1  (DN1)  stage  where  they  express  Kit  and  CD44,  but  TCR-α  and  β  chains 
remain  in  germline  configuration.  They  then  travel  to  the  cortex  where  they  closely 
interact with cTECs. There, they re-arrange the β chain and express CD25 to become 
DN2  thymocytes.  Once  V-D-J  rearrangement  of  the  TCR  β-chain  is  complete,  it  is 
paired with an unarranged α-chain to form the pre-T-cell receptor, which is the hallmark 
of DN3 stage thymocytes. Cells with incorrectly rearranged β-chains die at this stage. 
Finally, once CD25 expression is lost, DN4 cells start to express both CD4 and CD8 
and become double-positive (DP) thymocytes. They proliferate heavily, and account for 
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the  vast  majority  of  thymoyctes  at  any  given  time.  They  soon  start  with  α-chain 
rearrangement and stop extensive proliferation to undergo first quality control measures 
of  central  tolerance:  only  clones  with  intact  αβ-TCR  complexes  survive  interactions 
with  cTECs  and  become  small-resting  double-positive  thymocytes.  Now,  the  lineage 
decision into CD8 pos T cell or CD4 pos T cell is made and negative selection, mediated 
by TECs, APCs and macrophages, ensures that strongly self-reactive clones are 
eliminated.  Clones  with  an  intermediate-range  self-reactivity  can  become  Treg  cells, 
with the special mandate to downmodulate autoimmune reactions in the periphery 1. 
In summary, mTECs play an essential role to maintain tolerance towards self. They are 
involved in the negative selection of self-reactive T-cells as well as the development of 
thymus-generated Treg cells 4, 5. They have the ability to express essentially all of the 
body’s self antigens (so-called tissue-restricted antigens) and display them to maturing 
T  cells.  Once  maturing  T  cells  recognize  and  strongly  bind  to  self  peptide:  MHC 
complexes on TECs, they are deleted 6. Expression of these antigens on thymus-resident 
epithelial cells depends on the expression of the Aire protein, and a deficiency of this 
factor  causes  autoimmune  disease  in  both  mice  and  humans 7,  8.  Therefore,  one  can 
conclude that T-cell birth and education in the thymus is central for the development of 
a functional immune system, being able to determine friend from foe. But protection is 
not  complete  -  potentially  self-reactive  T  cells  still  escape  the  thymus  and  travel  the 
periphery. Here, a second mechanisms of immune tolerance comes into place – 
regulatory  T  cells,  either  born  and  educated  in  the  thymus  (tTreg)  or  induced  in  the 
periphery (pTreg), keep these potentially very harmful clones under control.  
 
4.3 Peripheral tolerance is mediated by regulatory T cells 
As mentioned in the earlier paragraph, postnatal thymectomy of newborn mice between 
day 2 and day 4 of age causes severe autoimmune disease, with lymphocyte infiltration 
into  peripheral  organs  and  the  presence  of  autoantibodies.  Interestingly,  the  adoptive 
transfer of immune cells from adult euthymic mice can prevent the onset of autoimmune 
disease,  which  was  indicative  of  a  transferable  cellular  mediator  protecting  against 
autoimmunity 9. This cellular “mediator” of peripheral tolerance was later identified as 
an IL-2 receptor α-chain (CD25) overexpressing T cell, and the adoptive transfer of this 
specific  cell  type  alone  can  rescue  the  autoimmune  phenotype  caused  by  postnatal 
thymectomy. More detailed studies showed that this cell type can also prevent 
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autoimmune events caused by the injection of CD25-depleted CD4pos T-cell 
suspensions  into  nu/nu  recipient  mice,  inhibit  transplant  rejection  events,  but  also 
promote  the  escape  of  tumors  from  immunological  surveillance 10, 11, 12, 13 .  Later,  the 
transcription factor Foxp3 was identified as key driver of regulatory T-cell phenotype 
and function. Once Foxp3 was retrovirally transduced into naive T-cells, they acquired 
a regulatory phenotype. When the gene was deleted, autoimmune syndromes 
reminiscent of early-life thymectomy arose 14, 15, 16. As with central tolerance and AIRE, 
mutations  in  the  forkhead  box  domain  of  the  Foxp3  gene  have  been  linked  to  severe 
autoimmune disease in mouse and man. In humans, a selective defect in the Foxp3 gene 
causes IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome),  which  is  accompanied  by  severe  autoimmune  syndromes  to  the  gastro-
intestinal tract, the epidermis, the pancreas (inducing insulin-dependent diabetes), and 
other  organs  in  a  varying  intensity.  Children  diagnosed  with  IPEX,  if  untreated,  die 
early  in  their  childhood 17.  This  disease  can  be  mirrored  in  scurfy  mice,  where  male 
mice with a mutation in the Foxp3 gene (“scurfin”) display skin adenopathies, 
infections,  gastroenetrophy,  and  ultimately  die  within  four  weeks  after  birth 18.  In 
addition to this, later studies using a selective depletion of Foxp3-positive Treg cells in 
newborn mice resulted in autoimmune pathologies, which finally validated the 
molecular link between CD4 posCD25posFoxp3pos regulatory T cells and their function to 
protect against autoimmune disease in a peripheral manner 19.  
Since  not  all  Treg  cells  are  generated  in  the  thymus,  the  Treg  population  has  been 
classified and denominated based on their origin or birthplace: thymus-born Treg cells 
(tTreg); peripherally-induced Treg cells (pTreg); in-vitro induced Treg cells (iTreg) 20. 
We will shortly review all three subsets in the following paragraph. 
 
4.4  tTreg  cells  are  born  in  the  thymus,  whereas  pTreg  cells 
are induced locally 
Treg  cells  can,  just  like  CD4pos  conventional  T  cells  (Tconv)  or  CD8pos  cytotoxic  T 
lymphocytes (CTL), leave the blood or lymph circulation and extravasate into tissues. 
There, they built a strong tissue compartment even in the absence of pro-inflammatory 
stimuli  and  take  on  tissue-protective  functions.  But  are  all  Treg  cell  populations  in 
tissues derived from the thymus, or can they also be induced locally? 
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To define the developmental origin of Treg cells, Fontenot and colleagues analyzed the 
development of Foxp3 GFP-positive Treg cells in the thymus using a transgenic mouse 
model where the Foxp3 promoter sequence, followed by a GFP reporter, was added to 
the  genome.  They  observed  that  CD25-positive  cells  arise  early  in  the  CD4  single-
positive  fraction,  whereas  Foxp3GFPCD25  double-positive  cells  slowly  increased  over 
the first 3 weeks of life to a final plateau of ~4% of CD4 single-positive thymocytes 21. 
In the thymus, high-affinity TCR binding to self-antigen presented on thymic APCs 22, 
23,  24  alongside  a  special  cytokine  environment 25  and  an  overall  low  frequency  of 
antigen-specific Treg cell clones 24, 26, 27 is pivotal for the generation of tTreg cells. First, 
Treg cells are primed by TCR- and APC-promoted signals (early Treg precursor cells, 
CD4posTCRβposCD69posCD25negFoxp3neg),  followed  by  expression  of  CD25,  causing 
the transformation into late Treg precursor cells 
(CD4posTCRβposCD69negCD25posFoxp3neg). Once late Treg precursor cells are 
stimulated by IL-2 and IL-15, Foxp3 gene expression is induced to generate tTreg cells 
(CD4posTCRβposCD69negCD25posFoxp3pos) 28,  29.    Another  study  by  Yang  S  et  al.  in 
2015 investigated the perinatal generation of Treg cells 30. They claim that a first wave 
of Treg cells, important for the prevention of early-onset autoimmune disease against 
specific targets, is induced by Aire-expressing thymic stromal cells and persists 
throughout life, supplementing the pool of Treg cells continuously produced by thymic 
output after birth. Therefore, Treg cell generation must be distinguished in a temporal 
manner (perinatal vs. aged) as well as a spatial/origin-specific (thymus vs. periphery) 
manner.  Based  on  origin,  two  anatomical  locations  of  Treg  induction  have  been 
described so far: Treg cell induction in the thymus, as described above, is supplemented 
by peripheral conversion of CD4posCD25negFoxp3neg Tconv cells into 
CD4posCD25posFoxp3pos pTreg cells.  This occurs predominantly in the colon and gut 
where a high load of food antigens and commensal bacteria requires a special 
tolerogenic environment 25, 31, 32, 33. It has been proposed that pTregs and tTregs can be 
distinguished  via  the  cell  surface  receptor  Nrp-1  and  the  intracellular  protein  Helios, 
further discussed in paragraph 4.6. 
If CD4posCD25negFoxp3neg Tconv cells are stimulated by CD3/28 microbeads together 
with  IL-2  and  TGF-β  in-vitro,  Foxp3  expression  can  be  induced  to  generate  in-vitro 
induced Treg cells (iTreg).  Although they express Foxp3 protein at high levels, their 
expression pattern is not as stable as ex-vivo isolated Treg cells, probably due to missing 
demethylation of the Treg-specific demethylated region in the Foxp3 gene 34, 35, 36. 
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4.5 Treg cells suppress pro-inflammatory effector cells  
 
Figure 2: T cell cytokine expression profile. 
Treg, Tconv and CD8 pos T cells were FACS-isolated and treated with PMA/Ionomycin or left 
unstimulated for eight hours at 37°C in the presence of transport inhibitors. Afterwards, cells 
were stained intracellularly for the presence of IL-2 and IL-10. The dot plots indicate that Treg 
cells make less IL-2 than Tconv or CD8 pos CTL, but more IL-10 than Tconv. Furthermore, Treg 
cells have a clear correlation between cytokine production and CD44 expression, indicating the 
antigen-experienced Treg cells are more readily induced to secrete cytokines. Red dots represent 
T cells treated with PMA/Ionomycin and transport inhibitors, black dots are transport inhibitor 
only treated T cells serving as unstimulated controls.  
 
Thymus-derived  tTreg  cells,  peripherally  induced  pTreg  cells,  and  in-vitro  induced 
iTreg cells all share conserved mechanisms to exert their immunosuppressive functions, 
reviewed in 37. They can secrete immunosuppressive cytokines such as IL-10 and IL-35 
to  create  an  anti-inflammatory  local  milieu.  The  cytokine  profile  of  Treg  cells  versus 
Foxp3-negative  Tconv  cells  and  CD8pos  T  cells  is  exemplified  in  Figure  2,  where  a 
CD44-based  stratification  allows  the  discrimination  between  naive  (CD44  low)  and 
antigen-experienced  (CD44  high)  cell  types.  Besides  the  very  low  endogenous  IL-2 
production of Treg cells, they can also starve effector T-cells of locally available IL-2 
via the high expression of the IL2 receptor α-chain (CD25) and binding of local IL-2 to 
the surface of Treg cells. Via the release of granzyme B or the expression of galectin-1, 
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they can either actively lyse target cells or induce apoptosis in those. Treg cells can also 
suppress  the  inflammation-inducing  effects  of  APCs  by  forced  downmodulation  of 
CD80  and  CD86  co-stimulatory  proteins  on  dendritic  cells  or  prevention  of  their 
maturation. Finally, they can just occupy binding sites at DCs, making them sterically 
inaccessible to effector cells 37. A consequence of these anti-inflammatory effects is the 
potential to suppress TCR-stimulated effector T cells in an in-vitro suppression assay, 
as exemplified in Figure 3. 
 
 
Figure 3: Classical in-vitro Treg suppression assay. 
A  classical  Treg  suppression  assay  was  performed  with  CFSE-labeled  T-responder  cells  and 
MHCII-positive  APCs  incubated  with  soluble  anti-CD3  mAb  for  six  days  at  37°C.  One  can 
appreciate that the addition of increasing numbers of Tconv cells does not hinder CFSE-dilution 
in T-responder cells: in both low (1:8) and high (4:1) relative presence of Tconv cells, active 
CFSE-dilution  is  still  between  64.3%  and  56.5%,  indicating  proper  APC-CD3-stimulated  cell 
division. On the other hand, escalating numbers of Treg cells increasingly disturb T-responder 
cell  proliferation  and  thereby  prevent  CFSE  dilution:  a  1:8  Treg  dilution  does  not  affect  cell 
proliferation (61.3% CFSE-diluting cells), whereas a high 4:1 relative Treg frequency 
effectively  prevents  T-responder  cell  proliferation  (only  3.1%  CFSE-diluting  cells).  White 
histograms indicate unstimulated controls (no CFSE dilution due to missing stimulation, CFSE 
signal >2x10 4 fluorescence units) or CFSE non-treated T-responder cells (CFSE signal <5.0x10 2 
fluorescence units).   
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4.6  Treg  cells  express  key  lineage  proteins  related  to  their 
function 
First, we want to take a look at key Treg-specific protein expression as shown in Figure 
4.  The  Treg  lineage-defining  marker  is  Foxp3,  but  it  only  induces  part  of  the  Treg-
specific gene signature. Forced Foxp3 expression alone is not sufficient to induce the 
full  Treg  phenotype,  since  it  is  also  expressed  in  activated  Tconv  cells  in  mouse  and 
human without inducing a regulatory phenotype 38, 39, 40 Therefore, Foxp3 regulates only 
a fraction of Treg-specific genes, and is mostly important for consolidation and stability 
of Treg lineage once initiated 41, 42, 43. 
Many  other  proteins  are  involved  to  generate  the  full  Treg  signature 44.  Some  of  the 
most paramount ones, such as Helios, Neuropillin-1, GITR, and CTLA-4, are reviewed 
in the following paragraph. 
 
 
Figure 4: Overview of Treg lineage-specific protein expression. 
What  makes  a  Treg  a  Treg?  In  A,  a  three-dimensional  dot  plot  displays  three  key  T-cell 
populations and their specific surface and intracellular protein expression profile: 
CD8posCD4negFoxp3neg cytotoxic T cells, CD8negCD4posFoxp3neg conventional T cells and 
CD8negCD4posFoxp3pos regulatory T cells. A typical gating strategy for Treg cells from spleen is 
also  shown  in  B,  where  they  constitute  about  10%-15%  of  all  CD4  T  cells.  In  C,  expression 
patterns of key Treg proteins such as CTLA-4, GITR, Helios, or Nrp-1 are shown. 
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One such characteristic protein, Helios, is a member of the Ikaros family of 
transcription factors. It is expressed pre-dominantly in Treg cells. It is dispensable for 
their suppressive function or the cytokine profile of Treg cells, but forced expression in 
iTreg cells enhanced suppressive function 45. It is thought to be a marker for thymic-
derived Treg cells due to its absence on pTreg and iTreg in human samples. Therefore, 
Helios enhances iTreg function in cooperation with Foxp3, but might be a dispensable 
co-factor/enhancer for tTreg function 46. 
Another  marker  specifically  expressed  on  thymus-derived  Treg  cells  is  Neuropillin-1 
(CD304), a cell surface transmembrane glycoprotein. Its ligands are semaphorin 3A and 
VEGF,  and  it  plays  roles  in  vascular  and  neuronal  development 47.  Identified  by 
comparative gene expression analysis in mice, it was shown to be expressed 
independently  of  activation  status  as  a  surface  marker  for  Treg  cells 48,  with  higher 
expression on tTreg than on pTreg or iTreg 49, 50. In the human system, Nrp-1 is induced 
on  activated  human  T-lymphocytes 51,  what  has  also  been  described  for  Foxp3  and 
CD25. 
Tumor necrosis factor receptor superfamily member 18 (TNFRSF18) or glucocorticoid-
induced TNFR-related protein (GITR, CD357) is expressed highly on Treg cells under 
steady-state  conditions.  It  is  involved  in  TCR-mediated  activation  of  T  cells  and 
protects from apoptotic cell death 52. Its ligands are expressed on APCs, and blocking of 
the ligand-GITR interaction causes autoimmune disease, highlighting its role to 
maintain self-tolerance 53. Since it is dispensable for Treg suppressive capacity in-vitro 
54,  its  role  has  been  defined  as  driver  of  Treg  cell  expansion  via  NFκB  signaling  in 
healthy mice and inducer of apoptosis under inflammatory conditions 55, 56. 
Finally,  cytotoxic  T-lymphocyte-associated  protein  4  (CTLA-4,  CD152),  which  is 
expressed on activated T lymphocytes 57 and highly expressed on Treg cells, 
participates  in  DC-Treg  binding  to  B7-1  and  B7-2  ligands  and  in  the  regulation  of 
tryptophan catabolism leading to suppression of effector T cells. It was also shown to be 
important  for  TCR  hyposignaling,  suppressive  function  and  anergy.  Interestingly,  in 
Treg cells, it is retained in submembrane vesicles that recycle to and from cell surface 
rapidly  upon  activation,  whereas  Tconv  cells  have  CTLA-4  retained  in  the  Golgi 
aparatus 58. It was shown to promote the expression of Foxp3 in-vitro and might also be 
involved in the induction of pTreg in the intestine 59. 
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4.7 Treg cells are distributed throughout the body and take on 
tissue-specific protective functions 
In the previous paragraphs, we described the cellular origin of Treg cells, their capacity 
to suppress inflammatory reactions, and their specific protein expression profile. Now 
we  will  summarize  their  tissue-specific  distribution  and  their  importance  to  promote 
local  immune  homeostasis  (reviewed  in 60).  In  Figure  5,  the  tissue  distribution  and 
selected functions of Treg cells can be appreciated. 
 
 
Figure 5: Treg cells and their distribution in various tissues. 
Anatomical details of a mouse with relations to their Treg cell compartments. Each 
compartment has a distinct frequency of Treg cells, and they take over tissue-specific functions 
in many cases. The dot plots in the lower part of the graphs are representative examples of the 
presence of CD25 posFoxp3GFPpos Treg cells in tissues like lymph node, fat, skin and liver. 
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Several studies addressed the function of tissue-specific Treg cells. For example, Treg 
cells from visceral adipose tissue (VAT) were shown to display a dynamic frequency: 
they increase in number from an age of 5 weeks to 25 weeks to about 50% of all CD4 pos 
T cells, followed by a decline to about 10% in 40 week old animals, unlike Treg cells in 
lymphoid organs such as the spleen 61, 62. Also, they carry distinct gene expression and 
protein  signatures  compared  to  lymphoid  Treg  cells,  but  remain  positive  for  key 
proteins  such  as  CD25,  GITR,  CTLA-4,  or  Foxp3 63.  Fat-resident  Treg  cells  express 
peroxisome proliferator-activated receptor-γ (PPAR-γ) as key driver of VAT Treg cell 
accumulation, function and phenotype, and have an important role to modulate obesity-
induced  insulin  resistance  in  fat  tissue 64.  Treg  cells  also  protect  against  insulin 
resistance and diabetes induction in other organs. In the pancreatic duct, specific loss of 
Treg  cells  causes  Type  2  diabetes 17,  65,  66,  whereas  increased  Treg  infiltrations  have 
been  identified  in  pancreatic  ductal  carcinoma  patients  and  correlated  with  worse 
disease  prognosis 67.  In  the  skin,  Treg  cells  can  account  for  40  to  90  percent  of  all 
CD4pos  T  cells  in  mouse 68  and  human 69.  Relative  Treg  frequencies  and/  or  their 
suppressive capacity is modulated in psoriasis and other dermatological diseases, 
indicating  a  Treg-specific  role  to  prevent  autoimmune  disease  of  the  skin 70, 71.  Treg 
cells  are  also  implicated  in  common  lung  diseases  such  as  pulmonary  fibrosis  and 
asthma 72, where patients have either reduced numbers of Treg cells in the 
bronchoalveolar fluid 73 or impaired Treg suppressive capacity 74.The murine liver has 
5-10% of Treg cells 68, 75. In autoimmune hepatitis, a reduction of Treg frequency has 
been  noted 76,  77.  This  contrasts  the  increase  of  tumor-resident  Treg  cells  in  hepatic 
cancer  lesions 78,  79.  In  the  healthy  muscle,  10%  of  all  CD4pos  T  cells  are  Foxp3-
expressing Treg cells. They have a specific function to repair muscle damage via the 
release  of  amphiregulin 80.  Finally,  the  gastro-intestinal  tract  contains  an  increased 
number of locally induced pTreg cells, which are important to maintain the intestinal 
barrier  and  homeostasis  in  the  presence  of  harmless  commensal  bacteria  and  food 
antigens 81. 
We can summarize that Treg cells take on specific functions in many peripheral tissues, 
thereby protecting against autoimmune disease and tissue damage. Often, a 
dysregulation of the balance between Treg and Tconv cells in these tissues can cause a 
loss  of  tissue  function  and  pathological  effects:  a  depletion  of  Treg  cells  can  cause 
autoimmune  disease  and  infiltration  of  effector  cells  into  the  specific  tissue,  whereas 
enrichment of Treg cells in tumor tissues can dampen anti-tumor immunity and lead to 
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enhanced tumor growth. Therefore, careful therapeutic adjustment of the Treg-/Tconv 
balance  would  be  an  attractive  treatment  opportunity,  from  autoimmune  disease  to 
cancer. 
 
4.8 Treg cell depletion as cancer therapy 
Treg cells with their unique immunosuppressive capacities have been targeted for novel 
treatment  approaches  to  fight  cancer.  In  this  disease,  immunological  self-tolerance 
promoted by intra-tumoral Treg cells dampens a favorable anti-tumor immune response. 
Tumor  immunity  is  in  part  overlapping  with  autoimmunity,  since  tumors  are  derived 
from self-tissues and often display self-antigens. 
In  patients  suffering  from  tumors  of  head  and  neck,  breast,  lung,  liver,  pancreas,  the 
gastro-intestinal  tract,  the  ovaries  and  the  skin  (melanoma),  high  Treg  frequencies  in 
tumors and the draining lymph nodes have been described 82. Furthermore, a decreased 
ratio  of  CD8pos  T  cells  to  Treg  cells  can  be  a  negative  prognostic  marker  in  breast, 
gastric  and  ovarian  cancer.  In  contrast  to  this,  infiltrating  Foxp3pos  T  cells  improve 
prognosis  for  colon,  head/neck  cancer  and  Hodgkin’s  lymphoma  patients,  but  studies 
indicate that these Foxp3-positive cell populations are non-regulatory and secrete pro-
inflammatory  cytokines 83.  Taken  together,  these  studies  indicate  the  presence  of 
various Foxp3pos T-cell populations in tumors, some of which exert different functions. 
This needs to be addressed in more details and reliable surface and intracellular markers 
have to be defined to detect specific subtypes of tumor-resident Treg cells. 
Where do these tumor-resident Treg cells come from? Studies indicate that some tumors 
display  CCL22,  which  attracts  CCR4-expressing  Treg  cells  from  the  circulation.  In 
addition,  since  Treg  cells  have  a  higher  avidity  towards  self-peptide  and  a  generally 
heightened  antigen-primed  state,  peripheral  conversion  in-situ  into  pTreg  cells  is  also 
very likely 82. 
The  obvious  next  question  –  whether  Treg  cell  ablation  can  then  induce  anti-tumor 
immunity – has been addressed in many pre-clinical studies. A first study in 1999 used 
injections  of  anti-CD25  mAb  (PC61)  before  tumor  inoculation.  The  Treg-depleting 
effect  leads  to  an  eradication  of  syngeneic  tumors,  but  did  not  show  efficacy  if  the 
antibody  was  administered  later  than  day  2  after  tumor  inoculation 84.  Another  study 
combined the removal of Treg cells with CTLA-4 blockade. This improved the function 
of a tumor cell-based vaccine against melanoma, leading to tumor rejection 85. 
4 Background 
  19 
Additionally,  a  third  study  showed  that  the  transfer  to  Treg-depleted  CD4 pos  cells, 
together with the administration of tumor or self-reactive CD8 T cells, augmented the 
anti-tumor responses in a melanoma model 86. Two studies addressed the use of low-
dose cyclophosphamide for Treg cell depletion. The authors observed decreased Treg 
cell number and functionality alongside a downmodulation of GITR and Foxp3 
expression 87. Vaccination of cyclophosphamide-treated animals with HER-2/neu 
targeting vaccines raised strong CD8 T cell responses and protected from a HER2/neu 
expressing  tumor  challenge 88.  Finally,  in  a  gain-of-function  experiment,  it  has  been 
shown that the transfer of Treg cells from immunized mice enhanced metastatic spread 
and tumor growth and development 89. 
Two  studies  in  human  cancer  patients  also  addressed  the  issue  of  Treg-promoted 
tolerance  towards  tumors:  Treg  cells  actively  prevent  immune  responses  against  NY-
ESO-1 (human cancer/testis antigen expressed in many tumors) and tyrosinase 
(expressed in melanoma), and once peripheral blood lymphocytes had been depleted of 
Treg cells, CD4pos T cells could be re-activated by tumor-based peptide in-vitro 82. 
Taken together, these pre-clinical studies illustrate that intra-tumoral Treg cells 
downmodulate anti-tumor immune responses through the specific suppression of tumor-
resident CD4 T cells, CD8 cytotoxic T cells, NK cells, and NK-T cells. In addition, the 
selective eradication of Treg cells can ameliorate tumor burden and re-activate tumor-
and  self-reactive  T  cells  –  especially  in  combination  with  immune  system-boosting 
vaccine regimens 82. 
In  order  to  harness  the  potential  of  the  immune  system  to  destroy  tumor  cells,  a 
treatment strategy for the selective depletion of Treg cells, ideally only tumor-resident 
ones, is urgently needed. Several strategies are investigated, some of which already led 
to FDA-approved drugs. 
A  first  approach  is  the  use  of  chemotherapeutic  drugs  at  certain  dosage.  It  has  been 
shown  that  treatment  of  patients  with  cyclophosphamide  or  fludarabine  preferentially 
depletes  Treg  cells  due  to  their  higher  proliferation  rate,  and  that  the  combination  of 
chemotherapy  with  multiple  peptide  vaccines  increased  the  survival  of  renal  cancer 
patients while decreasing their Treg cell number 90. 
Another approach is the antibody-based depletion of Treg cells via their specific surface 
marker expression. In the human setting, CD25-depleting regimens cannot be used since 
activated T cells, also in the tumor, express CD25. In rodents, a selective depletion is 
functional (as described earlier). Clinical studies indirectly tested the depletion of Treg 
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cells with denileukin detox, a fusion protein of IL-2 and diphtheria toxin. A first study 
in 2005 identified no specific decrease in Treg cell numbers and their in-vitro 
suppressive capacity, causing no relevant regression in patients with advanced 
metastatic melanoma 91, while another study combined denileukin detox treatment with 
RNA-transfected  dendritic  cell  vaccination.  The  authors  could  show  significant  Treg 
depletion from PBMCs, no acute toxicity, and abrogated Treg suppressive capacity in-
vivo,  leading  to  improved  tumor-specific  responses.  Progression-free  survival  has  not 
been evaluated 92. Finally, a third study used daclizumab, a mAb directed against CD25, 
followed  by  DC  vaccination:  as  expected,  all  CD25-highly  expressing  cells  were 
depleted,  actually  leading  to  decreased  vaccine-specific  effector  T  cell  presence  in 
circulation. This translated into no changes in overall progression-free survival 93. These 
studies clearly indicate that targeting CD25 has rather negative effects for therapeutic 
treatment  of  patients.  Using  toxin-conjugated  recombinant  IL-2  can  induce  clinical 
benefits  in  the  right  context,  but  care  must  be  taken  since  tumor-attacking  effector  T 
cells also rely on IL-2. 
Other  surface  molecules  overexpressed  on  Treg  cells  have  also  been  targeted  for 
treatment.  One  of  those  is  CCR4,  specifically  expressed  by  antigen-experienced  Treg 
cells, but not naive Treg cells or effector T cells. Treatment with a CCR4-antibody was 
shown to improve CD4 T cells response to peptide in-vitro, comparable to an in-vitro 
Treg depletion, and clinical testing is under way. Another such target molecule is the 
Toll-like  receptor.  It  has  been  shown  that  LPS  or  CpG  can  block  Treg-suppressive 
mechanisms and increase IL-2 secretion by effector T cells, and trials using vaccination 
with TLR-stimulating viral or bacterial vectors are being conducted. This treatment is 
expected to break tolerance of effector T cells to tumor antigen. Additionally, OX40, 
overexpressed on Treg cells, has been targeted with anti-OX40 monoclonal antibodies. 
This regimen has shown to dampen Treg suppressive capacity, and intratumoral 
injection of the mAb can inhibit tumor growth while activating effector T cells in pre-
clinical  studies.  Finally,  GITR,  as  described  earlier,  can  be  targeted  with  anti-GITR 
mAb or GITR ligand. This was shown to inhibit Treg suppressive capacity and thereby 
increase anti-tumor CD4 and CD8 T-cell responses (all reviewed in 82, 94). 
A  very  exiting  new  strategy  was  the  development  of  so-called  immune  checkpoint 
inhibitors, leading to the treatment of patients with blocking antibodies against CTLA-4 
or PD-1. Blockade of CTLA-4 on Treg cells impairs suppressive function of Treg cells 
in tumor sites and breaks tolerance, while also augmenting effector T-cell activity. First 
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studies with ipilimumab ®, a humanized anti-CTLA-4 mAb, evaluated this antibody in 
combination with glycoprotein peptide vaccines in stage III or IV melanoma patients. 
Increased  overall  survival  of  patients  was  reported,  along  with  grade  3-4  immune-
related adverse events in 10-15% of patients 95. Based on clinical efficacy and due to 
available  therapeutic  options  to  manage  immune-related  adverse  events,  ipilimumab® 
was approved for treatment of malignant melanoma by the FDA. It was shown to also 
work  in  combination  with  chemotherapy 96.  Its  mode  of  action  is  more  likely  the 
selective Treg depletion rather than activation of effector T cells. It was shown that FC-
γ expressing macrophages delete tumor lesion-resident Treg cells 97, and decreased Treg 
numbers in tumor tissue following treatment correlates with better prognosis. 
Another  immune-checkpoint  inhibitor  is  PD-1.  Antibodies  have  been  engineered  to 
block  the  PD-1  receptor  (pidilizumab®  and  nivolumab®)  or  its  ligand,  PD-L1  (BMS-
936559/MDX-1105® and MPDL3280A ®). PD-1 is an inhibitory receptor expressed on 
T cells, B cells, monocytes, NK cells and, in general, on tumor-infiltrating lymphocytes 
as well as tumor-infiltrating Treg cells. Some tumors highly express PD-ligand 1, often 
leading to more aggressive growth and poor prognosis. PD-L1 binding to PD-1 inhibits 
T-cell proliferation, cytokine production and cell adhesion 98. A thorough clinical study 
with PD-1 immune checkpoint inhibitors reported grade 3-4 adverse events in 14% of 
patients diagnosed with melanoma, lung cancer, prostate cancer and colorectal cancer. 
Importantly, objective anti-tumor responses were observed in one in four/five patients. 
Response  to  treatment  is  probably  linked  to  the  level  of  PD-1  ligand  expression  on 
tumor cells 99. Currently, more than 50 Phase 1, 2 and 3 trials are under way to evaluate 
PD-1 based treatments in many different solid and hematological malignancies 98. Some 
patients  already  show  durable  responses  in  a  variety  of  cancers,  even  long  after 
treatment was completed.  
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4.9 Treg cell adoptive transfer to combat autoimmune disease 
In contrast to cancer, where the presence of tolerance-mediating Treg cells is unwanted, 
patients  suffering  from  autoimmune  disease  could  benefit  from  increased  numbers  of 
Treg cells. Studies have already addressed the functionality and frequency of Treg cells 
in various autoimmune diseases (reviewed in 100). In type-1 diabetes (T1D), patients and 
healthy  donors  have  similar  numbers  of  Treg  cells.  But  it  was  shown  that  Treg  cells 
from  T1D-patients  have  a  generally  decreased  suppressive  activity  together  with  a 
heightened resistance of pro-inflammatory T cells to Treg-mediated suppressive effects. 
Importantly,  ex-vivo  cultivation  of  Treg  cells  can  revert  their  defects  in  suppressive 
potential. 
Similar results have been obtained for patients suffering from systemic lupus 
erythematosus  (SLE):  Circulating  Treg  cells  in  the  blood  of  these  patients  are  less 
suppressive,  more  susceptible  to  apoptosis  and  therefore  also  decreased  in  overall 
frequency. In-vitro expansion normalizes Treg cell function and phenotype. 
In contrast to this, patients suffering from Sjörgen’s syndrome, an autoimmune disease 
affecting salivary and lacrimal glands, have functionally intact Treg cells, but 
significantly reduced numbers in both peripheral blood and target organs. 
In  multiple  sclerosis  patients,  Tregs  with  diminished  suppressive  capacity  have  been 
described, but it is yet to be investigated whether Treg function can be restored by in-
vitro cultivation and expansion protocols. 
Finally, patients suffering from autoimmune rheumatic disease have Treg cell 
populations  with  limited  ability  to  suppress  cytokine  production  in  autoimmune  T-
effector cells. Furthermore, Treg cells have defects in CTLA-4 expression, and they are 
unable to control IL-6 and TNF-induced inflammation. 
Taken  together,  all  these  studies  report  either  defects  in  Treg  suppressive  capacity  or 
their cellular frequency in patients of various autoimmune diseases. Interestingly, it is 
often possible to revert these defects by in-vitro cultivation and expansion of Treg cells. 
One  possible  therapeutic  treatment  method  could  be  the  ex-vivo  expansion  and  re-
infusion  of  functionally-corrected  and  frequency-increased  Treg  cells  into  patients 
(adoptive Treg cell therapy) to correct for the defects in Treg-mediated suppression. 
Pre-clinical testing of adoptive Treg cell therapy has already shown promise. In 
experimental  autoimmune  encephalitis,  a  mouse  model  of  SLE,  Treg  infusion  can 
prevent disease when injected before disease initiation, but efficacy is nearly lost when 
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Treg  cells  are  infused  once  the  disease  is  already  established.  In  mouse  models  of 
collagen-induced  arthritis,  total  body  irradiation  followed  by  infusion  with  expanded 
Treg cells significantly slows disease progression. In a model of proteoglycan-induced 
arthritis, peptide-induced Treg cells were able to suppress arthritis in a LAG3 
(lymphocyte activation gene 3 protein) positive manner with only a few thousand cells 
required for transfer 94. Another very prominent autoimmune scenario, graft-versus host 
disease (GvHD) following hematopoietic stem cell transplantation, has also been 
addressed  in  murine  studies.  Myeloablative  chemoradiotherapeutic  conditioning  for 
hematopoietic stem cell transplantation induces a systemic inflammatory environment 
despite multi-agent immunosuppressive drugs. If immune tolerance is protected in this 
time window, long-lasting tolerance without further immunosuppression might be 
possible.  Infusion  of  isolated  or  ex-vivo  expanded  Treg  cells  was  shown  to  be  highly 
effective to prevent acute and/or chronic GVHD, and activated donor or host Treg cells 
(expressing CD103) were able to prevent ongoing chronic GVHD 101. 
But  what  are  the  challenges  for  adoptive  Treg  cell  therapy  for  human  patients?  First, 
there is the absence of unique cell surface markers on human Treg cells, causing a very 
likely contamination of clinical products with CD4 posCD25pos activated effector T cells. 
Acceptable levels of “contamination” with Foxp3-negative cells upon expansion have to 
be defined, and precise parameters to measure Treg-suppressive capacity or potency are 
still  amiss.  To  prevent  conversion  of  Treg  cells  into  Tconv  cells  before  and  after 
infusion,  different  protocols  using  rapamycin  or  retinoic  acid  (stabilizes  Treg  cell 
expansion),  demethylating  agents  (stabilization  of  TSDR  demethylation)  or  HDACs 
(chromatin  remodeling)  for  expansion  protocols  are  being  tested.  Second,  there  is  a 
limited  availability  of  GMP-compatible  expansion  procedures,  especially  for  large 
doses  required  for  adoptive  Treg  transfer.  Finally,  system-wide  treatment  with  high 
doses  of  Treg  cells  might  enhance  global  immunosuppression,  leading  to  diminished 
responses to infectious agents or tumor cells (100 and 94). 
Besides  these  challenges,  different  Treg  expansion  protocols  are  in  development  and 
being  tested  in  first  clinical  trials  –using  Treg  cells  expanded  from  peripheral  blood, 
umbilical cord blood or HLA-matched third party blood. It has already been shown that 
in-vivo  expansion  by  low-dose  IL-2  with  or  without  rapamycin  showed  some  clinical 
benefits  in  human  GVHD  and  T1D  patients  -  now  adoptive  therapy  with  ex-vivo 
expansion and activation of allogeneic or autologous Treg cells has to prove its validity. 
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4.10 Scope of this thesis 
In  the  previous  paragraphs,  we  reviewed  current  knowledge  about  Treg  cells:  origin, 
molecular control, and tissue-specific distribution and function. We furthermore 
provided details about the potential use of Treg cells to modulate autoimmune disease 
and  cancer.  In  this  thesis,  we  now  describe  three  projects  investigating  the  molecular 
makeup of regulatory T cells: First, we performed an epigenetic analysis of the Foxp3 
gene, combined with an identification of transcription factors residing at the proximal 
Foxp3  promoter.  Second,  we  widened  this  approach  to  a  whole-genome  based  CG-
dinucleotide  methylation  analysis  of  fat,  skin,  liver  and  lymph  node  Treg  cells.  And 
third, we investigated the importance of Rbpj, an important cellular transcription factor, 
for the homeostasis and function of Treg cells. It was our ultimate goal to gain more 
insight  into  the  molecular  control  of  Treg  cells  and  Treg-specific  modes  of  action, 
which  could  lead  to  new  strategies  for  the  therapeutic  modulation  of  the  Treg/Tconv 
balance. This would allow the fine-adjustment of peripheral tolerance to combat 
autoimmunity or cancer. 
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5 Introduction 
5.1 Epigenetic control of the Foxp3 gene in Treg cells 
Epigenetics is the study of DNA methylation and histone/nucleosome modifications 
Epigenetics  is  the  study  of  heritable  changes  in  the  genome.  In  one  organism,  all 
somatic cells have the same genetic code, but tissue-resident cells still express different 
parts  of  the  genome  -  causing  a  variety  of  cell  types  and  tissues.  The  study  of 
epigenetics  provides  key  mechanisms  to  explain  the  interaction  between  DNA  and 
proteins  (transcription-inducing  factors,  factors  of  the  translational  machinery,  and  so 
on),  causing  a  regulation  of  gene  and  microRNA  expression  on  the  molecular  level. 
These changes in global gene expression translate into cellular differentiation, 
ultimately leading to their specific tissue adaptation. Already in embryogenesis, 
epigenetic  events  influence  proper  development  from  fertilized  egg  to  blastocyst.  In 
adults, epigenetic silencing is an important means of inactivating the second maternal 
X-chromosome in female mammals, and methylation of one in two alleles is 
responsible  for  the  mono-allelic  expression  of  genes.  On  the  chromosomal  level, 
hypermethylation of repetitive elements stabilizes chromosomal structure and integrity. 
Furthermore,  varying  epigenetic  patterns  can  re-organize  the  nuclear  framework  and 
promote  special  chromosomal  territories.  Finally,  genomic  imprinting  is  an  important 
means of transporting parental epigenetic modification patterns to the offspring 102.  
Epigenetics comprises three distinct categories: DNA methylation, histone modification 
and  nucleosome  positioning.  DNA  methylation,  also  the  focus  of  this  paper,  occurs 
almost  exclusively  at  CpG  dinucleotides  (Cytosine-phosphate-Guanine).  It  describes 
the addition of a methyl group to the 5’ position of the cytosine pyrimidine ring, and 
was already identified in 1951 103. Histone modification describes the composition of 
nucleosomes  with  regulatory  subunits.  An  assembly  of  H2.A-H2.B  dimers,  a  H3-H4 
tetramer,  and  a  H1  monomer  forms  nucleosomes.  Nucleosome-resident  histones  can 
undergo post-translational modifications, like acetylation, methylation, phosphorylation, 
and  many  others.  These  mechanisms  influence  transcriptional  activity,  DNA-repair 
mechanisms, DNA replication and splicing, as well as chromatin condensation. In fact, 
euchromatin is composed of high levels of acetylated and trimethylated histones H3K4, 
H3K36 and H3K79, allowing efficient transcription and translation. Heterochromatin, 
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on  the  other  hand,  is  transcriptionally  inert  and  shows  low  levels  of  acetylation  in 
concert  with  specific  methylation  of  H3K9,  H3K27  and  H4K20 104.  Besides  DNA 
methylation  and  histone  modifications,  nucleosome  positioning  is  a  third  means  of 
epigenetic  control.  The  precise  positioning  of  the  nucleosomes  can  pose  a  barrier  for 
transcription factor and polymerase access to DNA, especially at the transcription start 
site  (TSS).  Four  families  of  chromatin  remodeling  complexes  can  move,  eject  or  re-
structure nucleosomes to modify gene expression patterns (all reviewed in 102).  
 
Methylation of cytosine residues in CpG islands can control gene expression 
Generally,  mammalian  DNA  is  hypermethylated  at  most  of  its  CG  sites,  to  a  degree 
between  60%  and  90% 105.  In  particular,  gene  bodies  or  repeat  sequences  are  highly 
methylated,  and  loss  of  gene  methylation  is  linked  to  genomic  instability  of  these 
regions 106. But how does methylation affect the regulation of single genes? 
So-called “CpG islands” are areas of high CG density. They are generally 
underrepresented  in  vertebrate  DNA  since  they  occur  only  in  about  one-fifth  of  the 
expected  frequency  in  DNA 107,  108.  But  when  they  occur,  they  are  often  located  in 
promoter  and  first  exons  of  genes,  where  they  regulate  gene  expression.  They  are 
defined as regions of 200 bp or more, with a high GC content and on observed/expected 
ratio of CpG occurrence of more than 0.6 109. In the mammalian genome, approx. 20 
000 CpG islands can be detected, which incorporate about 5% of all CGs and about 1% 
of all nucleotides of the genome. 95% of the remaining CG dinucleotide in non-CpG 
islands are methylated 110.  
Promoters  can  be  classified  according  to  their  load  of  CG  dinucleotides.  CpG-rich 
promoters tend to be unmethylated and mostly regulate housekeeping genes, which are 
ubiquitously expressed and important for essential cellular functions. Here, 
demethylation often allows for efficient gene expression, and increases genetic stability 
and integrity. Demethylation can directly affect transcription factor binding efficiencies 
to the promoter, allowing more efficient recruiting of co-factors and RNA polymerase II 
111, 112 . Intermediate-density promoters can vary in methylation and, depending on the 
environment, regulate tissue-specific functions via selective methylation or 
demethylation. Low-CG-density promoters are mostly methylated in somatic cells, but 
still induce gene expression via the binding of special methylation-favoring 
transcription factors 113, although they are genetically rather unstable. 
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In  conclusion,  high  or  low  density  CpG  areas  are  regulatory  elements  where  specific 
methylation or demethylation can induce or repress gene expression based on the local 
environment. Therefore, treatment of cell lines with 5-Aza-2′-Deoxycytidine (5-aza), a 
globally demethylating agent, does not only induce gene expression through the release 
of  methylation-based  expression  blockade,  but  can  also  induce  gene  repression  by 
demethylation – this is based on the nature of the promoter or enhancer which controls 
the target gene 114. 
 
Sodium bisulfite sequencing and other methods to investigate DNA methylation 
First global CG methylation data were based on methylation-sensitive restriction 
enzyme  digestions  of  ribosomal  DNA  –  these  studies  identified  a  generally  high 
methylation level in somatic cells, while some sites were specifically unmethylated 105. 
Furthermore, they discovered that in highly methylated genomes, as seen in vertebrates, 
methylated CG dinucleotide can undergo deamination to TG (tyrosine-guanine) 
dinucleotides, which does not happen with unmethylated CGs. 
These findings lead to the development of the bisulfite conversion method in 1992 115. 
First, genomic DNA is purified and digested. Linearized DNA is incubated with sodium 
bisulfite and hydroquinone. Following the in-vitro deamination of unmethylated 
cytosine to tyrosine, several dialysis steps remove unreacted sodium bisulfite. Bisulfite-
converted DNA can now be used to generate PCR amplicons with specific primer pairs, 
which can ultimately be cloned into vectors for Sanger sequencing or analyzed via next-
generation sequencing. In this paper, we use sodium-bisulfite conversion via a 
commercial kit, followed by 454-pyrosequencing of PCR amplicons (see Figure 8). 
A first method for the genome-wide investigation of methylation events at CG 
dinculeotides  was  based  on  bisulfite  padlock  probing  technology  (BSPPs) 116.  The 
authors  used  100  nucleotide-long  DNA  probes,  which  specifically  hybridize  to  target 
DNA in a horseshoe manner: 3’ and 5’ end of the probe bind DNA, and the remaining 
nucleotide DNA forms a circle. The “gap” between 3’ and 5’ end of the probe is closed 
by PCR and the linearized vector is then analyzed by DNA sequencing. This technology 
allows the sequence-specific analysis of methylation hotspots and requires the design of 
probes  with  barcodes  and  sequencing  adaptors.  In  another  approach  published  in  the 
same study, the methyl sensitive cut counting assay (MSCC) was introduced 116. It uses 
the methylation sensitive HpaII restriction enzyme on DNA to cut only unmethylated 
5 Introduction 
  28 
CCGG palindromic sequences. The digested sequences are ligated to first and second 
adapter sequences followed by amplification and high-throughput sequencing. With this 
approach, no probe design was necessary, but efficiency of restriction enzyme digestion 
and the limitation to CCGG palindromic sequences restricted potential applications. In 
2005,  a  paper  introduced  methylated  DNA  immunoprecipitation-sequencing  (MeDIP-
seq) 117.  In  this  approach,  antibodies  directed  against  methylated  cytosine  are  used  to 
precipitate methylated DNA, followed by next-generation sequencing and mapping to 
the whole genome. The technology offers a resolution of 150bp to 200 bp, but areas of 
very  low  CG  density  may  not  be  recovered  by  the  chromatin  IP.  In  contrast  to  this, 
whole-genome bisulfite sequencing, which requires bisulfite-conversion of DNA 
followed by the ligation of adapter sequences via PCR and next-generation sequencing 
118, allows for the precise detection and evaluation of every single CG dinucleotide in 
the whole genome. One limitation, the relatively large amount of genomic input DNA 
required  for  this  method,  was  overcome  with  the  introduction  of  tagmentation-based 
whole genome bisulfite sequencing 119. In this method, transposase-fragmented DNA is 
linked to a sequencing adapter, followed by oligonucleotide replacement and gap repair 
events. Following a final PCR amplification, NGS reveals the methylation profile of the 
genome. Relatively low amounts of genomic DNA (less than 30 ng) can be analyzed for 
their methylational footprint. We use this method, with an even more advanced 
protocol, in Chapter 8 – there, we study the differential methylation of tissue-resident 
Treg  cells,  with  a  total  input  of  less  than  20,000  cells.  Finally,  some  commercial 
suppliers now offer bead chips for the analysis of methylation “hotspots” in a 
standardized procedure. 
 
Zygotes become demethylated and require DNA-methyltransferase to regain 
epigenetic control 
The above-described methods can be used to gain genome-wide information about CG 
methylation  and  have  been  used  in  various  contexts.  Several  studies  analyzed  the 
genome  of  the  “first  cell”,  the  fused  sperm  and  oocyte,  and  traced  its  methylation 
pattern. Fused sperm and oocyte initially carry highly methylated genomes. But then, 
right after the fertilization of the egg, the paternal genome becomes completely 
demethylated – this also erases the paternal epigenetic imprinting. After a first 
replication  cycle,  the  maternal  genome  becomes  demethylated  as  well,  but  imprinted 
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epigenetic  marks  are  conserved.  In  the  blastocyst  stage,  DNA  methyl  transferase  3 
(Dnmt3) restores the methylation level to the one of a pluripotent stem cell, right around 
the time of blastocyst implantation. When Dnmt activity is lost, so are pluripotency and 
differentiation potential of the growing embryo (110 and 120).  
In this context, DNA-methyl transferases have been studied extensively for their role to 
establish  and  maintain  methylation  at  CG  dinculeotides.  They  have  an  important 
function to maintain pluripotency, to conserve genomic imprinting and genome 
stability,  and  to  inactivate  one  X  chromosome  in  females.  There  are  three  classes  of 
methyl transferases with catalytic activity: Dnmt1, Dnmt3A, and Dnmt3B. Dnmt3A and 
B mediate, as described above, the de novo methylation during embryonic development. 
They  selectively  methylate  CG  dincleotides  based  on  a  proper  target  sequence  and 
presence  of  special  co-factors.  In  contrast  to  this,  Dnmt1  serves  as  a  maintenance 
methyl transferase preserving the methylation pattern during cell replication. It can bind 
the  replication  fork  in  the  S  phase  of  cell  division  and  detect  hemi-methylated  CG 
dinucleotides  on  the  template  strand.  It  catalyzes  the  methylation  of  the  respective 
palindromic  CG  dinucleotide  on  the  newly  synthesized  strand  as  well  and  thereby 
promotes genomic stability (reviewed in 121). 
 
Epigenetics and disease  
Global epigenetic changes have been observed in many forms of human disease. In one 
particular case, the malignant transformation of cells causing cancer, global changes in 
DNA methylation occur. In general, a specific loss of DNA methylation (20%-60%) has 
been noted for highly repetitive sequences in the genome of cancer cells. This causes 
chromosomal  instability,  thereby  inducing  translocation  events,  disrupting  the  gene 
architecture and even re-activating endoparasitic sequences. Demethylation events have 
also  been  described  for  specific  promoters  encoding  for  oncogenes,  unleashing  the 
expression  of  those.  In  contrast  to  this,  promoters  and  gene-controlling  elements  of 
DNA  repair  enzymes,  cell  cycle  control  proteins  and  apoptosis-regulating  factors  can 
become hypermethylated and thereby transcriptionally inactivated. Changes also occur 
on the level of histone modifications and chromatin remodeling factors, all in favor of 
more proliferative capacity and less cell cycle control in tumor cells. 
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Epigenetic  changes  have  also  been  observed  for  neurological  disorders,  such  as  Rett 
syndrome. Here, an enzyme recruiting histone deacetylase (HDAC) to methylated DNA 
(MeCP2) is specifically up-or downregulated via epigenetic marks, causing pathological 
symptoms associated with the disease. Involvement of epigenetic changes has also been 
identified for fragile X syndrome, Parkinson’s disease, Multiple Sclerosis, and Prader-
Willi and Angelman Syndrome. Furthermore, autoimmune syndromes such as 
Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE) and ICF syndrome 
(Immunodeficiency,  centromeric  instability  and  facial  anomalies)  have  been  linked  to 
epigenetic  changes.  This  highlights  the  central  role  of  epigenetics  to  modulate  gene 
expression and chromosomal stability, and demonstrates the consequences of 
disregulated epigenetic control (all reviewed in 102). 
 
Methylation  analysis  of  the  Foxp3  gene  reveals  the  Treg-specific  demethylated 
region (TSDR) 
When  sequence-comparing  mouse  and  human  Foxp3  genetic  code,  several  highly 
conserved  non-coding  sequences  can  be  identified  (Figure  11).  These  are  important 
binding  sites  for  transcription  factors,  as  reviewed  in  the  next  chapter.  In  terms  of 
epigenetic control, a histogram depicting areas of high CG density in the Foxp3 gene 
can identify CG hotspots (also in Figure 11). 
First studies identified the importance of methylation for the Foxp3 gene promoter in an 
indirect way. When NK cells were treated with 5-aza, IL-2 dependent Foxp3 induction 
in NK cells was restored. This was a first hint that methylation of CG nucleotides might 
be involved in Foxp3 gene expression regulation 122. Next, a 2007 study identified an 
area  in  the  first  Foxp3  gene  intron,  CNS2,  which  contains  both  a  TCR-responsive 
element, with a cyclic-AMP response element binding protein (CREB)/activating 
transcription  factor  (ATF)  binding  site,  and  an  area  of  high  CG  density  meeting  the 
criteria  of  a  CpG  island.  Again,  using  5-aza  or  a  knockdown  of  Dnmt1,  the  authors 
showed  that  methylation  of  the  CNS  2  locus  inversely  correlates  with  Foxp3  gene 
expression,  probably  by  downmodulating  CREB  binding  to  this  region  and  thereby 
reducing  Foxp3  gene  expression 123.  Since  this  study  was  based  entirely  on  5-aza 
treatments or Dnmt1 knockdown followed by Foxp3 expression analysis, sequencing-
based proof was still amiss. Therefore, another 2007 study used amplicon-based 
sequencing to validate that CNS2 is demethylated in human Treg cells. Furthermore, no 
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demethylation was observed in activated human Tconv cells, which only express Foxp3 
upon  TCR  stimulation,  or  in  TGFβ-treated  in-vitro  induced  Treg  cells.  Based  on  this 
finding, the authors conducted a genome-wide analysis of differentially methylated sites 
in  Treg  versus  Tconv  cells,  and  they  determined  CNS2  to  be  the  best  marker  to 
discriminate  Treg  cells  from  in-vitro  induced  iTreg  cells  or  activated  Tconv  in  the 
human  system 124.  Based  on  these  data,  the  CNS2  area  was  designated  Treg-specific 
demethylated region (TSDR). Since all studies mentioned above used human material, a 
third  2007  study  evaluated  the  methylation  status  of  the  TSDR  in  mice.  The  authors 
showed, again, the differential methylation of this area between Treg and Tconv, along 
with the identification of a TSDR-resident response element induced by 
PMA/Ionomycin treatment. They showed that, in Tconv cells, the TSDR is packed with 
condense, more inaccessible chromatin structures via histone acetylation and 
trimethylation events, adding to the gene-expression inhibiting effects of CG 
methylation  at  this  spot 125.  In  summary,  the  Foxp3  TSDR  has  been  investigated  and 
identified  as  a  methylation-sensitive  element  regulating  Foxp3  gene  expression.  Its 
demethylation  is  essential  to  promote  stable  Foxp3  gene  expression  and  Treg  lineage 
commitment, and it cannot be induced in macrophages, B cells or iTreg cells. Therefore, 
Foxp3 expression stability is tightly linked to TSDR demethylation 36, 126, 127. 
 
Aim of this subproject 
Is the TSDR the only demethylation-sensitive element in the Foxp3 gene? The highly 
conserved  Foxp3  promoter  or  other  Foxp3-resident  CG-rich  regions  have  not  been 
carefully evaluated for their CG methylation status. This motivated us to study all CG-
rich  regions  of  the  Foxp3  gene  promoter  in  more  detail.  We  want  to  answer  the 
following questions: Is the TSDR the only region with a specific demethylation pattern 
in  the  Foxp3  gene?  Are  there  other  regions  with  the  same  pattern?  What  is  the 
methylation  status  of  the  promoter  and  exons  in  the  Foxp3  gene?  When  during  Treg 
development in the thymus is Foxp3 gene demethylation established? And, finally, is 
the  specific  TSDR  methylation  also  present  in  Foxp3-negative  T  cells  from  DNA-
methyltransferase hypomorphic mice?  
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5.2  Transcriptional  and  epigenetic  control  of  tissue-specific 
Treg cells 
Previously, we discussed the role of the Treg-specific demethylated region (TSDR) in 
Treg  cells.  Specific  demethylation  at  this  site  is  a  pre-requisite  for  stable  and  long-
lasting Foxp3 expression, and deletion causes Treg instability and reversion to a non-
regulatory  phenotype  over  time.  One  specific  question  was  to  determine  whether  the 
methylation pattern seen at the TSDR is one of only few specific methylation events, or 
whether  there  is  a  unique  Treg-specific  epigenetic  signature  independent  of  Foxp3-
regulated mechanisms. Some observations would point into the direction of a Foxp3-
independent epigenetic signature: The retroviral overexpression of Foxp3 in Tconv cells 
promoted  a  suppressive  phenotype,  but  microarray-based  gene  expression  analysis 
revealed  substantial  differences  between  tTreg  and  Foxp3-transduced  Tconv  cells. 
Furthermore, mostly in the human system, Tconv cells transiently express Foxp3 upon 
TCR stimulation without becoming a stable regulatory lineage. In addition to this, Treg 
cells may lose Foxp3 expression under certain inflammatory conditions while they still 
remain lineage-committed. Therefore, one can assume that expression of Foxp3 protein 
alone  is  not  sufficient  to  induce  the  Treg  phenotype,  but  other  heritable  marks  could 
supplement  the  effects  of  this  transcription  factor 128.  Since  DNA  methylation  is  a 
heritable and stable means of cell subset definition, and Treg cells proliferate actively 
in-vivo, several studies addressed the epigenetic regulation of Treg cells. 
 
Global H3K4me3 and H3K27me3 study in Treg cells 
A pilot study investigated the H3K4me3 and H3K27me3 trimethylation in T H subsets 
and Treg cells, where H3K4me3 promotes gene-repressive state and H3K27me3 
promotes  gene  induction,  respectively.  Interestingly,  not  many  genes  were  different 
between Treg and Tconv cells or other T H subsets. Some genes, such as Foxp3, Il2ra, 
Ifng, Il4, Il17, and Rorc were differentially modified between Treg and Tconv cells, but 
these  changes  are  probably  mediated  by  Foxp3  downstream  regulation    (most  of  the 
above  mentioned  genes  are  directly  regulated  by  Foxp3)  and  not  by  an  independent 
regulatory complex 129. 
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Global MeDIP-Seq of Treg cells reveals 300 Treg-specific demethylated regions 
A  landmark  study  in  2012  investigated  the  genome-wide  CG  methylation  profile  of 
Treg vs. Tconv cells in mice via methylated DNA immunoprecipitation-sequencing 44, 
128, 130. The authors identified 160,000 methylation regions, 300 of which were 
specifically demethylated in Treg cells (about 0.19% of all methylation sites). 50% of 
those sites were located in gene bodies (coding regions and introns) and comprised 10 
or more CpG residues. Most promoter regions of genes were shown to be 
hypomethylated in both Tconv and Treg – which is true for the Foxp3 gene promoter as 
well.  From  the  150  differentially  methylated  regions,  gene  annotations  revealed  that 
demethylation-sensitive  regions  were  located  in  areas  related  to  Foxp3,  Ctla4,  Il2ra, 
Tnfrsf18  (GITR),  lkzf2  (Helios),  and  lkzf4  (Eos).  The  demethylation  pattern  of  these 
genes is specific for thymus-derived Treg cells and peripherally induced Treg cells, but 
not  in-vitro  induced  Treg  cells,  Foxp3-retrovirally  transduced  Tconv  cells,  activated 
Tconv  cells,  or  other  TH  subsets.  Furthermore,  these  regions  are  stably  induced  in 
Foxp3-IRES-GFP  knock-in  reporter  mice  and  mice  of  various  genetic  backgrounds. 
Importantly,  the  regions  are  also  induced  in  Foxp3-scurfy  mice  (carrying  a  Foxp3-
promoter GFP reporter, but no functional Foxp3 protein) or Foxp3-null mice despite the 
absence of Foxp3 protein. This indicates that the epigenetic framework is established 
independent  of  Foxp3  protein  expression  during  thymic  Treg  cell  generation.  Indeed, 
Foxp3  protein  consensus  binding  sites  (2800)  have  no  overlap  with  Treg-specific 
demethylated  gene  areas  except  the  Foxp3  TSDR.  Therefore,  one  can  infer  that  the 
epigenetic  pattern  induced  in  Treg  cells  provides  a  stable  and  functional  framework, 
whereas Foxp3 is required to induce the suppressive phenotype of these cells. This can 
be illustrated by the epigenetic-based induction of genes such as Ctla4 and Il2ra, which 
code  for  CTLA-4  protein  and  CD25  cell  surface  receptor,  hallmarks  of  Treg  cells. 
Foxp3, on the other hand, represses expression of pro-inflammatory genes encoding for 
IL-2 or IFN-γ, thereby promoting the anti-inflammatory phenotype of this cell lineage. 
This also illustrates that, while epigenetic modifications in Treg cells often release gene 
expression via selective demethylation, Foxp3 acts more as a repressor of gene 
transcription. 
Another 2013 study investigated the methylation of human Treg vs. Tconv cells with an 
Illumina Infinium Human Methylation 450K array. The authors isolated human naive 
resting T cells (CD45RA posCD25pos) and Tconv cells from male donors. Out of 450,000 
probes, 2315 single CG dinucleotides were differential between resting Treg and Tconv 
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cells (0.5% of total). 70% of those were associated with genes, and of those, 33% were 
located  in  gene  promoter  regions  and  40%  in  gene  bodies.  Interestingly,  the  CG 
dinucleotides  showed  an  even  distribution  of  hypo  –  and  hypermethylation  at  those 
sites, strongly contrasting the results presented in the murine cell-based study discussed 
previously. Furthermore, the authors identified an overlap between differentially 
methylated  genes  and  Foxp3  protein  bound  genes,  leading  to  the  conclusion  that 
methylation events might allow the specific binding of Foxp3 protein to its target genes. 
Furthermore, in this study, both Treg and Tconv cells were activated for six days with 
CD3/28 stimulation in the presence of IL-2 to study effects of TCR stimulation on the 
epigenetic profile. After six days, 85% of Treg cells and 30% of activated Tconv cells 
expressed Foxp3. The methylational profile of Treg cells was not affected by activation, 
but Tconv cells were, indicating plasticity of DNA methylation only in Tconv cells. But 
from  where  do  the  obvious  differences,  compared  to  the  previously  mentioned  study 
with mouse cells, originate? First, in the human system, there are no reliable markers for 
the isolation of Treg cells with high purity. Therefore, a certain level of contamination 
of Treg cells with activated Tconv cells is likely. Furthermore, the 450K Methylation 
Array only scans certain CG sites of the genome, but the vast majority of sites is not 
probed. Finally, system differences between human and mouse epigenetic marks might 
cause different conclusions from these studies. 
 
Aim of this subproject 
We use a novel tagmentation-based whole genome bisulfite sequencing method to study 
the epigenetic profile of infrequent tissue-resident Treg cells from different anatomical 
locations (skin, fat, liver and lymph node). This protocol had already been used to study 
hematopoietic stem cells and four multipotent progenitor populations in a pilot study 119, 
131, 132.  The  authors  identified  15,000  differentially  methylated  regions,  and  correlated 
their methylation data with RNA-sequencing and proteomics data. The study revealed 
specific expression clusters to operate in HSCs, and showed a dynamic modulation of 
loss – and gain of methylation during differentiation of HSCs. Therefore, this analysis 
provided a detailed overview of epigenetic changes during HSC differentiation, linking 
it to the gene expression changes and proteomics signature description. 
The aim of our work was to identify tissue-specific epigenetic patterns, which show that 
Treg cells have the potential to adapt to local tissue environments both on a 
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transcriptional and on an epigenetic level. For example, fat-resident Treg cells 
overexpress PPAR-γ, which mediates its function to suppress the development of type-2 
diabetes 64. We are now interested in linking the differential gene expression profile of 
Treg cells in fat tissue with epigenetic modifications. Already, some of our preliminary 
data suggest that the whole-genome methylation levels are very different in Treg cells 
from  fat,  liver,  or  skin,  compared  to  their  lymph  node  counterparts  (see  Chapter  7). 
Interestingly, the methylation levels between Treg and Tconv in the lymph nodes are 
almost equal. Since we know that only about 300 regions or 0.19% of all CG sites are 
differentially  methylated  (in  the  MeDIP-Seq  studies  mentioned  before),  this  is  not 
surprising. But the relatively high difference in overall CG methylation between tissue-
resident Treg cells might already implicate a tissue-specific adaption based on 
epigenetics. Furthermore, in correlation with gene expression data, we want to identify 
landmark tissue-specific transcription factors, as exemplified with PPAR-γ for fat Treg 
cells.  
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5.3 Transcription-factor based control of the Foxp3 gene 
In the previous paragraphs, we reviewed current literature about the epigenetic 
regulation of Treg cells and the Foxp3 gene. In this section, it was also mentioned that 
gene promoters are often demethylated, allowing the binding of the transcription factor 
machinery to these loci. Motivated by this, we investigated the Foxp3 promoter more 
closely and identified it to be completely demethylated in both Foxp3-expressing Treg 
cells  and  Foxp3-negative  Tconv  cells.  Therefore,  we  concluded  that  there  might  be 
additional  mechanisms  of  Foxp3  gene  repression  in  Tconv  cells  and  investigated  this 
hypothesis  with  a  novel  method  called  inverted  Chromatin-IP.  First,  we  summarize 
already-published signaling pathways at the Foxp3 locus, followed by a more detailed 
literature review of specific highly conserved TF binding sites along the Foxp3 gene. 
 
Gene conservation studies reveal highly conserved non-coding sequences (CNS) 
The Foxp3 gene is located on the X-chromosome (Xp 11.23). It contains 14 exons, three 
of which are not translated (-2a, -2b and -1). Just upstream of the transcription start site 
(TSS),  the  promoter  with  TATA  box,  GC  box,  and  CAAT  box  is  located.  When 
comparing the sequence homology between mouse and human Foxp3 genetic code (as 
already described in Chapter 5), a high degree of conservation can be appreciated for 
the coding exons, three regions in non-coding introns, and the promoter itself, as shown 
in Figure 6 below 18, 133. 
 
 
Figure 6: Conversation of the murine Foxp3 gene and identification of CNS1-2-3. 
 
As  depicted  in  the  graph,  there  are  three  distinct  conserved  regions  within  the  non-
coding intronic sequences of the Foxp3 gene. These were determined conserved non-
coding sequences 1, 2, and 3 (CNS1-3). Each CNS region has a distinct function in the 
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initiation or stabilization of Foxp3 gene expression, just like the core Foxp3 promoter 
(PRO). A putative enhancer can be detected 2000 bp upstream of the TSS (ENH), but 
no  functional  evaluation  of  this  region  has  been  performed  to  date.  In  the  following 
paragraphs, we will review literature about the specific role of the promoter and each 
CNS  region  for  the  induction  and  maintained  expression  of  the  Foxp3  gene  in  Treg 
cells. 
 
Signaling Pathways involved in the regulation of Foxp3 gene expression 
Treg precursor cells in the thymus receive various signals during their maturation. First, 
Treg lineage fate decision depends on signals received by the T-cell receptor through 
the  binding  of  self-ligands.  Proper  TCR:  self-peptide  signaling  strength  together  with 
CD28  co-stimulation  and  cytokines  promotes  Treg  cell  development  in  a  two-stage 
model: First, TCR signals prime Treg cells.  Then, common γ-chain cytokines such as 
IL-2, IL-7 and IL-15 induce Foxp3 gene expression via STAT5 signaling cascades. If 
all three cytokines are absent in the thymus, Treg cells cannot be induced 134. 
In contrast to these Foxp3-promoting signaling pathways, the PI3K-Akt-mTOR 
pathway  acts  as  a  repressor  of  Foxp3  gene  induction.  It  is  triggered  by  TCR/CD28 
signaling events, by common γ -chain cytokines such as IL-2, by specific complement 
factors, or by Programmed Death-1 (PD-1) receptor ligation. Binding to these receptors 
mediates the selective phosphorylation of Foxo proteins, in turn inhibiting Foxp3 gene 
induction. Overexpression of pathway components, such as Akt, impairs Foxp3 
induction, and inhibition of pathway components by small molecules, in turn, induces 
Foxp3 gene expression – as observed with Rapamycin, an inhibitor of mTOR, which 
can be used to expand Treg cells in-vitro and in-vivo 135. The suppressive function of the 
PI3K-Akt-mTOR pathway seems to contradict the need of TCR-stimulation required for 
Foxp3 induction in the two-stage model proposed above.  But the duration of the Treg-
precursor cell priming by thymic epithelial cells is short, and no more TCR signals are 
required to complete the Treg differentiation program afterwards. Additionally, this fail-
safe  mechanism  prevents  the  induction  of  Treg  cells  from  pro-inflammatory  T  helper 
cells  in  the  periphery  once  they  detect  their  cognate  antigen  (e.g.  foreign  antigen  or 
virus-infected cells). To prime Treg cells in the periphery, TGF-β can promote Foxp3 
gene expression via NFAT and SMAD signaling, as discussed later. 
5 Introduction 
  38 
Another  important  signaling  pathway  involved  in  Treg  cell  induction  is  the  classical 
NFκB signaling pathway. When Active Inhibitor of NFκB (iKκB) is overexpressed in T 
cells,  leading  to  the  degradation  of  NFκB  signaling  inhibitors,  Foxp3  expression  is 
induced.  If  NFκB  signaling  components  are  deleted,  Foxp3  expression  is  impaired 
(pathways reviewed in 136 and 60). 
 
The Foxp3 promoter can bind several TF to induce Foxp3 gene transcription 
The precise location of the Foxp3 promoter and the true TSS were identified by rapid 
amplification of 5’ ends (RACE): mRNA transcription starts at the TSS, as expected, 
indicating that the core promoter is indeed the area where polymerase and expression-
promoting TF bind to initiate DNA-dependent RNA transcription of Foxp3 pre-mRNA. 
In  the  same  study,  Foxp3  protein  expression  was  induced  in  EL4  T  cells  by  TCR 
stimulation  and  cytokine  treatment  with  TGF-β.  Interestingly,  the  Foxp3  promoter, 
more precisely the region of  -1702 to +174 (relative to the TSS), showed no luciferase 
reporter  activity  in  Foxp3-induced  EL4  T  cells  compared  to  non-induced  Foxp3-
negative EL4 cells 137. This indicates that the Foxp3 gene promoter does not translate 
TGF-β-signals to induce Foxp3 gene expression. Eventually, other studies identified a 
TGF-β response element at the conserved non-coding 1 (CNS1) region, as discussed in 
the next paragraph. 
Tone  and  co-workers  also  identified  NFAT  (Nuclear  Factor  of  Activated  T  cells) 
binding  to  the  Foxp3  promoter  via  electromobility  shift  assays  (EMSA).  The  Foxp3 
promoter  contains  six  NFAT  and  AP-1  (Activator  protein  1)  binding  sites,  which 
translate  T-cell  receptor  signals  into  promoter  activity.  Mutations  in  the  binding  sites 
disrupt  its  activity.  Also,  treatment  with  cyclosporine  A  disrupts  NFAT  activity:  it 
blocks  NFAT  translocation  to  the  cell  nucleus  and  thereby  inhibits  Foxp3  promoter 
activation by this TF. Furthermore, if mice are deficient of STIM1/2 calcium sensors, 
NFAT cannot enter the nucleus and Foxp3 expression is impaired (138 and 139). 
Together, these studies indicate that the promoter can respond to T-cell receptor signals, 
but not to the TGF-β mediated pathway, for Foxp3 induction. 
As mentioned earlier, Foxo proteins bind the Foxp3 promoter as part of the PI3K-Akt-
mTOR pathway. Specific deletion of Foxo1 and Foxo3a causes multifocal 
inflammatory disorder. Also, Treg conversion via TGF-β is diminished in T cells devoid 
of Foxo transcription factors 140, 141. 
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Another factor mentioned previously, STAT5, has also been detected at the Foxp3 gene 
promoter. Cytokine-derived signals promote STAT5 activation and Treg cell 
differentiation,  and  its  selective  deletion  prevents  Treg  cell  development.  It  has  been 
hypothesized  that  STAT5  can  bind  to  the  promoter  only  when  the  CNS2  regions  is 
demethylated, indicating an indirect regulation of promoter activity by epigenetic events 
elsewhere 142, 143. 
Another interesting example of direct Foxp3 promoter regulation by epigenetic events is 
the study of Nr4a family members. Mice devoid of all three family members (Nr4a1, 
Nr4a2, Nr4a3) cannot produce Treg cells and die of systemic autoimmunity, but single 
knockouts  have  no  effects,  probably  due  to  compensatory  mechanisms.  It  has  been 
shown that Nr4a factors are induced by TCR binding to self peptides in Treg cells, and 
that  all  members  bind  to  the  Foxp3  promoter  in  different  affinities  to  induce  Foxp3 
protein  expression.  It  is  proposed  that  Nr4a2,  which  can  recruit  histone  modification 
enzymes, can open the Foxp3 promoter epigenetically and thereby allow the binding of 
the RNA translation machinery 144, 145. 
In  2009,  Ruan  and  co-workers  identified  a  complex,  the  c-Rel  enhanceosome,  at  the 
Foxp3 promoter. Interestingly, this complex is first initiated by binding of Smad to Creb 
(cAMP  response  element-binding  protein)  at  Foxp3  enhancer  sites,  and  afterward 
moves to the Foxp3 promoter to link with c-Rel, p65, and NFAT. Once c-Rel is deleted, 
the enhanceosome cannot form anymore and the Treg cell number decreases by about 
90% 146. 
One more complex has been described by three studies in 2009. They identified Runt-
related  transcription  factor  (Runx)  proteins,  induced  by  TGF-β,  to  bind  the  Foxp3 
promoter at the Runx binding sites. Their binding is co-operatively increased by their 
co-factor Core-binding factor subunit β (Cbf-β). Inhibition of both the co-factor Cbf-β 
or Runx1/3 reduces Foxp3 expression or silences the Foxp3 gene promoter completely, 
leading  to  impaired  suppressive  capacity  in-vitro  and  in-vivo  as  well  as  higher  IL-4 
expression. The complex also binds the Foxp3 gene at its regulatory regions CNS2 and 
CNS3,  making  it  important  for  not  only  the  induction,  but  also  the  maintenance  of 
Foxp3 gene expression 147, 148.  
Finally, the E2A-Id3 signaling axis has been identified as a negative regulator of T H2 
differentiation  in  Treg  cells.  First,  TGF-β  signaling  can  induce  Id3  protein.  Id3  then 
enriches  for  E2A,  which  in  turn  binds  the  Foxp3  promoter  at  specific  E-boxes  and 
induces Foxp3 transcription. When Id3 was deleted, Treg cell generation was defective. 
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Besides promoting Foxp3 promoter gene activity, E2A can actively replace trans-acting 
T-cell-specific transcription factor GATA-3 at the Foxp3 promoter 149. GATA-3 is, once 
expressed,  an  important  lineage-defining  factor  of  TH2  cells,  but  also  a  repressor  of 
Foxp3  gene  transcription  at  the  Foxp3  promoter 150.  Two  studies  in  2011  further 
investigated  the  impact  of  GATA-3  in  Treg  cells.  Once  it  was  specifically  deleted, 
inflammatory  disorder  was  induced.  GATA-deficient  Treg  cells  could  not  promote 
peripheral  homeostasis  and  lost  suppressive  function,  and  they  gained  a  TH17  pro-
inflammatory phenotype. As mentioned earlier, GATA-3 binding to the promoter has 
rather Foxp3-suppressive effects – but its binding to the Foxp3 CNS2, induced by TCR 
and  IL-2  cytokine  stimulation,  and  to  other  cis-acting  elements  in  the  Foxp3  gene  is 
important for proper Foxp3 protein expression 151, 152. 
Taken together, we here summarized various binding partners to the Foxp3 promoter. 
They  modulate  their  downstream  functions  via  direct  binding  to  the  promoter  and 
initiation of transcription, via the recruitment of co-activators, by the selective 
displacement of repressive TFs, or by epigenetic modulation of the promoter. But some 
of these factors are not expressed differentially in bona fide Treg vs. Tconv cells, and it 
is believed that many factors operate in a context-dependent manner in a multiprotein 
network  occupying  the  Foxp3  promoter.  It  was  therefore  our  rationale  to  gain  more 
insight  into  the  Foxp3  core  promoter  and  to  identify  binding  partners  in  an  unbiased 
way by the inverted Chromatin IP, as described later.  
 
The  CNS1  region  is  important  for  peripheral,  but  not  thymic,  induction  of  Treg 
cells 
The conserved non-coding sequence 1 region (CNS1) has been defined to be precisely 
between +2079 and +2198 bp downstream of the TSS (Figure 6). Probing the Foxp3 
promoter  with  400-1200  bp  long  luciferase  reporter  fragments  identified  this  specific 
area. Besides the transcription-inducing activity, this region is highly conserved 
between species. It contains a CD3 response element, promoting TCR signal 
transduction  to  the  Foxp3  gene.  Furthermore,  it  contains  a  TGF-β  response  element, 
which  is  important  for  the  peripheral  conversion  into  pTreg  cells:  The  CNS1  region 
becomes strongly activated upon treatment with TGF-β in concert with TCR-
stimulation by CD3 and CD28 ligation. Otherwise, the region has only weak activity in 
non-stimulated T cells. 
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Importantly,  the  region  contains  selected  NFAT  and  Smad3  binding  sites  –  these 
promote deacetylation of the CNS1 region and thereby maintain Foxp3 expression. The 
binding sites of NFAT and Smad3 are highly conserved not only between human and 
mouse, but also chimpanzee, elephant, horse, goat, rat, and guinea pig 137. 
A complete CNS1 knockout showed that CNS1 is dispensable for the thymic generation 
of Treg cells, but is important for the induction of peripherally induced Treg cells via 
TGF-β. CNS1-deficient mice have a normal thymic Treg output, but decreased 
frequency of Treg cells in the mesenteric lymph nodes, indicating decreased peripheral 
conversion rates. No immune-mediated lesions in the gastro-intestinal tract have been 
reported under steady state-conditions upon CNS1 deletion 153, 154. 
In summary, CNS1 is an important TGF-β -sensitive enhancer region for the induction 
of pTreg and iTreg, but not relevant for thymic Treg cell generation. 
 
The CNS2 stabilizes Foxp3 gene expression by selective CG demethylation 
In contrast to the previously mentioned region CNS1, the conserved non-coding 
sequence 2 (CNS2) has no function for Foxp3 gene induction. It is located approx. 4000 
bp downstream of the TSS (Figure 6) and contains a high degree of CpG sites – in fact, 
the  regions  just  fits  the  definition  of  a  CpG  island.  As  mentioned  in  Chapter  5,  it 
becomes demethylated upon Foxp3 expression and has an important function to 
stabilize  this  expression  in  tTreg  and  pTreg 125.  When  the  region  was  deleted,  no 
differences  were  observed  in  young  mice.  In  more  aged  mice,  Treg  cell  frequencies 
decrease, probably by peripheral conversion of tTreg cells into Tconv cells. This also 
happened once Treg cells from CNS2 KO mice were transferred into another host – a 
certain  fraction  of  congenically  labeled  Treg  cells  lost  Foxp3  expression  after  the 
transfer. Therefore, one can conclude that the CNS2 module is responsible for 
strengthening heritable Foxp3 expression in dividing cells 155. 
Besides epigenetic regulation, the CNS2 region also contains TF binding sites. In 2007, 
binding of CREB (cyclic-AMP response element binding protein) to the demethylated 
CNS2 regions has been described: it is thought to actively keep CNS2 in its 
demethylated state, thereby preventing conversion of Treg into Tconv cells 123. 
Furthermore,  it  was  identified  that  CNS2  has  two  binding  sites  for  ETS-1  (Avian 
Erythroblastosiosis Virus E26 Oncogene Homolog-1). It is believed that this 
transcription factor is required to maintain its demethylation, just as CREB. Once the 
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ETS-1 TF was deleted, methylation at CNS2 increased and Treg cells showed reduced 
Foxp3 protein and transcript levels, finally leading to systemic autoimmune disease 156.  
In summary, we can conclude that the CNS2 or TSDR has an important role to stabilize 
Foxp3  gene  expression.  Furthermore,  some  factors  specifically  bind  this  region  to 
stabilize the demethylated phenotype. 
 
CNS3 is a pioneer element required for efficient induction of Foxp3 transcription 
The last one of the intronic regulatory regions, the conserved non-coding sequence 3, is 
about 7000 bp downstream of the TSS. Its specific deletion caused an approx. 5 fold 
decrease in thymic Treg output, indicating its importance as a pioneer element used in 
early  Foxp3  induction.  Mice  with  a  CNS3  knockout  evade  autoimmune  disease  by 
compensating for the loss of thymic Treg output by increased Treg cell proliferation. It 
seems that CNS3 is only important for the induction of Foxp3, but not its maintained 
expression. 
Two studies identified binding partners to the CNS3. To initiate Foxp3 gene expression, 
c-Rel can bind to CNS3 once triggered by CD3 and CD28 stimulation 155. Furthermore, 
the CNS3 region contains a binding site of the atypical inhibitor of NFκB (iKκB): iKκB 
deficiency  reduces  Treg  cell  numbers,  but  not  their  stability.  Finally,  Treg  cells  from 
iKκB deficient mice have a reduced ability to induce Foxp3 in-vitro, again indicating 
the role of CNS3 to increase the probability of Foxp3 gene expression 157. 
 
Aim of this subproject 
We described the to-date published regulatory elements at the Foxp3 promoter and the 
conserved non-coding sequences. We were now interested to identify the complex at the 
Foxp3 promoter in an unbiased manner with a new technology (inverted Chromatin IP). 
In this study, we used Foxp3 non-expressing EL4 T cells and isolated nuclear protein, 
followed by in-vitro binding reactions to Foxp3 promoter fragments. Afterwards, these 
binding  partners  were  identified  by  mass  spectrometry  and  cloned  into  eukaryotic 
expression  vectors.  The  proteins  were  then  evaluated  for  their  gene  function  at  the 
Foxp3 promoter, their expression pattern in T cells, and for their effects once 
overexpressed in primary T cells.  
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5.4 Rbpj and its function for Treg cell homeostasis 
That far, we discussed the epigenetic and transcription factor-based control of Treg cells 
and the Foxp3 gene in particular. Now, we are selecting only one specific transcription 
factor, Rbpj, to study its role for the homeostasis and function of Treg cells. First, we 
will  summarize  current  literature  about  Rbpj  and  Notch  signaling,  followed  by  the 
specific implications of this pathway for T cell subset differentiation. 
 
The Notch Signaling Pathway 
The Notch Signaling Pathway is a highly conserved system for cell-cell communication. 
It  was  first  discovered  in  1914:  Notch  heterozygous  mutants  showed  a  pronounced 
“notch”  in  the  drosophila  melanogaster  wing.  Later  research  identified  four  different 
Notch  receptors  in  mammals:  Notch  1,  2,  3,  and  4.  They  are  synthesized  as  single-
transmembrane  proteins  in  the  endoplasmatic  reticulum  and  afterwards  transported  to 
the  Golgi  apparatus  (see  Figure  7).  There,  they  undergo  S1  cleavage  and  become 
heterodimeric receptors, consisting of a large extracellular domain and a small 
intracellular domain, to be transported to the cell surface 158. All four receptors share the 
Notch  extracellular  domain  (NECD)  consisting  of  EGF-like  and  Lin-Notch  repeat 
sequences. The Notch transmembrane and intracellular domain (NTMIC) is connected 
to  the  NECD  via  their  heterodimerization  domain,  linking  them  non-covalently 159. 
Once the Notch receptor binds its cognate ligands, single-pass transmembrane proteins 
of  the  DSL  (Delta/Serrate/LAG-2)  family,  the  heterodimeric  receptor  is  separated  via 
mechanotransduction  (S2  cleavage):  the  extracellular  domain  is  degraded,  and  the 
remaining Notch extracellular truncated domain (NEXT) remains attached to the 
membrane. NEXT then undergoes cleavage by ADAM metalloproteases and γ-
secretases  (S3  cleavage),  which  liberate  the  Notch  intracellular  domain  (NICD).  This 
potent  transcription  factor  is  composed  of  several  domains,  amongst  which  the  RAM 
(Rbp-associated  molecule  domain),  TAD  (transactivation  domain)  and  NLS  (nuclear 
localization signal) domains take part in the downstream effector functions 159. Once the 
NICD is liberated from the cell membrane, its nuclear localization signal mediates the 
import into the cell core. There, it can displace co-repressors at target genes and bind 
co-activators such as Rbpj (CSL/CBF-1/suppressor of hairless/Lag-1) and Mastermind. 
Upon establishment of the NICD-RBPJ complex, it can induce target gene transcription, 
for example at Hes1, Hey1 and Dtx1 gene loci 158. 
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Figure 7: Simplified illustration of the Notch / Rbpj signaling pathway. 
The Notch receptor is assembled in the Golgi apparatus and transported to the cell membrane. 
Upon  ligand  binding  and  cleavage,  the  NICD  translocates  to  the  nucleus  and  binds  Rbpj  to 
induce or repress target gene transcription. We show the NICD-Rbpj dependent effects on three 
target genes Hes1, Hey1, and Dtx1. 
 
Notch ligands induce Notch signaling to regulate many aspects of mammalian life 
In  mammals,  there  are  five  canonical  Notch  ligands.  They  are  type  1  transmembrane 
proteins  of  the  Serrate  family  (Jagged  1:  Jag1  and  Jagged  2:  Jag2)  and  of  the  Delta 
family  (Delta-like  1:  Dll1;  Dll3;  Dll4).  They  all  contain  DSL  (Delta/Serrate/LAG-2, 
DOS (Delta and OSM-11-like proteins) and EGF motifs. Both DSL and DOS domains 
take part in Notch receptor binding. Non-canonical Notch ligands lack DSL and DOS 
motifs  and  work  in  a  secreted  form  or  as  GPI-anchored  proteins,  although  their 
physiological functions remain elusive 159. Notch signaling is involved in the 
homeostasis of multiple organs and tissues, for example in neuronal development and 
function, angiogenesis, embryonic development, generation and expansion of 
hematopoietic  stem  cells,  cardiac  valve  homeostasis,  cell-fate  decisions  in  mammary 
glands  and  the  gut,  and  T-cell  lineage  commitment.  The  dysregulation  of  Notch 
pathway components has been implicated in many diseases. Mutations in the Dll3 gene 
can  cause  Spondylocostal  dysostosis,  a  skeleton  segmentation  disorder,  and  patients 
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with Jag1 mutations show a diverse phenotype with bile duct paucity, cardiac defects, 
spine defects and deafness (Alagille syndrome). Mutations in Notch1 have been 
implicated in the development of T-cell acute lymphoblastic leukemia and aortic valve 
disease. Dysfunctions in essentially every member of the Notch pathway cause clinical 
pathology, highlighting the importance of this conserved mechanisms for development 
and homeostasis 158. 
 
Notch signaling in hematopoietic stem cell development and cell fate decision 
The hematopoietic system is generated in three waves during embryonic development: a 
primitive, a transient definitive, and a definitive wave. 
The primitive wave consists of maturing primitive erythrocytes forming blood islands 
and is generated in the murine yolk sac around embryonic development day 7.5 (E7.5). 
It contains some macrophages, megakaryocytes, and mast cells, but no hematopoietic 
stem cells (HSCs). Notch signaling is of no relevance for this wave, since Notch1 or 
Rbpj mutants display a normal number of primitive erythrocytes. 
The  transient  definitive  wave,  emerging  from  yolk  sac  cells  around  E9,  consists  of 
erythromyeloid  progenitors,  neutrophils,  and  definitive  erythrocytes.  Progenitor  cells 
can  colonize  the  blood  stream  and  fetal  liver,  but  Notch  signaling  has,  again,  no 
importance during this second wave. 
The definitive wave, initiated at E11.5, is not produced in the yolk sac, but the Aorta-
Gonad-Mesenephros  (AGM),  an  embryonic  mesodermal  region.  It  contains  HSCs, 
which then migrate to the fetal liver and later colonize the bone marrow niche. Notch1, 
Rbpj or Dll4 mutants cannot establish the arterial program and therefore cannot produce 
HSCs. This indicates that Notch signaling is a pre-requisite for the proper development 
of the blood-forming system outside the yolk sac. It is believed that Notch signaling is 
important  not  only  for  HSC  differentiation,  but  also  to  maintain  stemness  of  the 
developing HSCs in the AGM. Once HSCs leave the AGM and travel to the fetal liver, 
no more Notch-based signals are required for their amplification. Once they enter the 
BM niche and colonize it to form the blood system, Notch signaling is again implicated 
in cell fate decisions at this stage: high Notch dosage induces T-lymphocyte 
differentiation, whereas low Notch levels cause myeloid-lineage commitment 160. 
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Notch signaling controls thymic T-cell development 
Previously, we reviewed the importance of Notch signaling for the generation of HSCs 
and  the  lymphoid/myeloid  fate  decision  process  in  the  bone  marrow.  Once  the  T-
lymphocyte differentiation program has been initiated, the BM-derived lymphomyeloid 
progenitor  cells  enter  the  thymus  via  the  corticomedullary  junction.  They  are  then 
denominated  as  early  T-lineage  progenitors  or  double-negative  1  cells  and  interact 
closely with thymus-resident TECs. Expression of Notch-ligands in adult thymic cTECs 
is restricted to the Dll4 ligand, the most relevant ligand for T-cell development in the 
thymus. Other ligands, such as Dll1, Jag1, and Jag2 are expressed in the E16 thymus, 
and to a certain extent also in adult thymi. When deleting Dll4, T-cell development was 
interrupted  and  B  cells  suddenly  emerged  in  the  thymus.  Dll1  deletion  had  no  such 
consequences. Interestingly, mice with modifications in Jag1 and Jag2 display normal 
T-cell development, but have a reduced commitment to the γδ T-cell lineage. Studies 
indicate that FoxN1, a pivotal transcription factor required for proper TEC 
differentiation, regulates Notch ligand expression in the thymus 161. 
In  order  to  receive  signals  via  Notch  ligands  expressed  on  thymic  epithelial  cells, 
thymocytes need to express Notch receptors. Indeed, expression of Notch receptor 1, 2, 
and 3 on developing thymocytes has been identified. Notch 1 and 2 are highly expressed 
in  DN  1  and  2  thymocytes  and  steadily  decrease  after  the  DN4  stage  during  further 
maturation.  In  contrast  to  this,  γδ  T  cells  retain  their  high  Notch  1  and  Notch  2 
expression. Notch 3 is expressed mostly at the DN3 stage. 
But  what  does  TEC-thymocyte  signaling  via  Notch  promote?  First,  Notch  signaling 
strengthens  the  T-cell  commitment  of  the  developing  thymocyte.  It  then  progresses 
through the DN2 and DN3 stage, expresses the IL7R and starts to proliferate, triggered 
by  TEC-provided  local  IL7.  Notch  signaling  actually  induces  IL7R  expression,  as 
discussed in the following paragraph. IL7R-expressing thymocytes proliferate 
extensively and mature their T-cell receptor to undergo positive and negative selection 
by  thymic  APCs,  as  summarized  in  Chapter  4.  Selected  cells  then  exit  the  thymus 
through the cotricomedullary junction. 
Therefore, we can summarize that Notch signals determine the T-cell fate in the thymus 
and bone marrow. Furthermore, they are required for T-cell survival, proliferation and 
further differentiation. Notch signaling is also involved in VDJ recombination and the 
β-selection checkpoint control. Finally, this pathway regulates αβ or γδ T-cell lineage 
commitment 160, 161. 
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The IL7R is induced by Notch/Rbpj and promotes T-cell expansion and survival  
Following the ETP to DN2 transition, developing thymocytes undergo massive cellular 
expansion, which is dependent on their concomitant expression of the IL7R. This marks 
the  first  Notch-promoted  checkpoint  in  thymic  T-cell  development,  followed  by  gene 
rearrangement and αβ or γδ lineage decision. The IL7R is composed of the IL7Rα chain 
and  the  common  γ  chain  receptor.  When  ETPs  in  transition  to  DN2  upregulate  the 
IL7Rα chain, IL7 produced by thymic epithelium can cross-link IL7Rα and γ chain to 
form an actively signaling heterodimer: this promotes T-cell survival and proliferation. 
In the bone marrow, stroma cells also secrete IL7 and promote survival and expansion 
of B cells. In transgenic mice with IL7R deficiency, T-cell development is blocked at an 
early stage, and B-cell development is severely impaired 162. In human patients with X-
linked severe combined immunodeficiency, deficiencies in IL7R expression have been 
linked to severe T-cell paucity, but had no impact on B-cell or NK-cell development 163. 
Typical target genes of IL7R signaling are Bcl-2 family members, cycline D1, SOCS, 
and c-myc. Therefore, the constitutive expression of Bcl-2 in IL7R or IL7 KO mice can 
rescue T-cell development, indicating that this pathway is important to promote 
survival. Once DN2 thymocytes use IL7R stimulation to expand and proceed to DN3 
stage, no more IL7R signaling is required at this point. Therefore, IL7Rα expression is 
downregulated  thereafter  and  completely  terminated  between  β-selection  and  positive 
selection. Once positive selection is complete, IL7R expression is restored to provide 
the homeostatic proliferation potential of peripheral mature T cells. 
But  what  induces  IL7Rα  expression  in  ETPs?  Interestingly,  the  expression  profile  of 
Notch1  in  early  thymopoiesis  closely  mimics  the  IL7Ra  expression  profile.  A  2009 
study  investigated  this  link  carefully:  in  a  loss-of-function  experiment,  the  authors 
inhibited  Notch  signaling  by  the  ectopic  expression  of  a  dominant  negative  form  of 
mastermind-like 1 (dnMAML1), normally a co-activator of Notch signaling. Inhibiting 
Notch  signaling  resulted  in  impaired  IL7Rα  expression.  In  contrast  to  this,  NICD-
transduced T-cell progenitors upregulated IL7Rα expression, indicating that Notch1 is 
indeed involved in the regulation of the IL7R expression pathway. When transducing an 
IL7Rα  promoter  luciferase  vector  into  cell  lines,  it  was  shown  that  co-transfection  of 
NICD significantly increases luciferase activity, which was abrogated by co-
transfection  of  dnMAML1.  Since  the  NICD  can  promote  target  gene  expression  via 
Rbpj, and the IL7Ra gene has a putative Rbpj binding site in its promoter (consensus 
sequence CTTGGGAA, -936 bp upstream of TSS), it was proposed that Notch1 
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regulates IL7R gene expression via Rbpj. In fact, IL7R promoter luciferase studies in 
RBPJ-deficient  or  heterozygous  cultures  showed  that  Rbpj  is  required  for  Notch1-
mediated IL7R induction. Site-directed mutagenesis of the putative binding site 
impaired IL7R expression upon ectopic NICD expression. Furthermore, Chromatin-IP 
studies indicated that Notch1 indeed binds the Rbpj binding site at the IL7R promoter.  
In  conclusion,  the  above-mentioned  study  clearly  states  that  Notch  1  in  combination 
with Rbpj induces IL7Rα expression in T cells 160, 164.  
 
Peripheral T cells express Notch receptors upon activation 
T cells upregulate Notch1 receptor 4 hours after TCR-stimulation, and express it until 
48 hours post activation. Also, Notch2 is upregulated upon anti-CD3 stimulation in T 
cells, but expression levels peak at 24 hours and already returns to basal expression 48 
hours post TCR engagement. Interestingly, Notch receptors co-localize with CD4 upon 
T-cell activation. T cells binding Notch ligands become activated even without 
additional TCR stimulation, with Dll4-based activation reminiscent of anti-CD3 
stimulation, and Dll1 and Jag1 less potent to promote T-cell activation. Ongoing Notch 
signaling  in  activated  T  cells  is  then  involved  in  the  regulation  of  IFN-γ  and  IL-2 
production  as  well  as  IL2Rα  (CD25)  expression.  Activated  T  cells  can  bind  Notch 
ligands,  which  in  turn  determines  their  differentiation  potential  (in  combination  with 
other  factors  such  as  antigen  presentation  and  cytokine  milieu):  Dll  family  members 
drive  TH1  responses,  and  Jagged  ligands  promote  differentiation  into  T H2  lineage. 
Notch  signaling  is  also  implicated  in  TH17  and  Treg  lineage  maturation 165.  We  will 
discuss the Notch-driven TH subset differentiation program in the following paragraphs. 
 
Dll ligands can induce TH1 differentiation of peripheral T cells 
First  insights  into  T H  differentiation  bias  by  Notch  signaling  were  based  on  co-
transfection  studies.  When  T-cells  were  transfected  with  Notch3-ICD  (N3ICD),  they 
secreted more IFN-γ and less IL-4, reminiscent of a T H1 phenotype. Furthermore, they 
expressed  Tbx21/Tbet,  the  master  TF  of  TH1  cells.  Transfection  of  Notch1-ICD  also 
resulted in increased IFN-γ secretion and upregulation of Tbx21/Tbet. Treatment with 
γ-secretase  inhibitors  (GSI)  reduced  TH1  polarization  in-vitro,  indicating  that  Notch 
signaling  is  important  to  drive  TH  subset  differentiation.  In  contrast  to  this,  in-vitro 
genetic  loss-of-function  studies  with  Rbpj  or  Notch1/2  deficient  T  cells  showed  no 
5 Introduction 
  49 
skewing  of  TH  subset  generation.  To  fully  address  this  question,  in-vivo  studies  with 
Notch1, Notch2, or Notch1/2 double-knockout T cells were conducted. Single 
knockouts of Notch 1 or 2 had no effect, pointing to a redundant role of both receptors 
in  this  system.  But  a  double  Notch  1/2  knockout  had  decreased  numbers  of  IFN-γ 
secreting T H1 cells, leading to the inability to clear an experimental bacterial infection 
166. A 2004 study by Tanigaki and co-workers addressed the need of Notch signaling for 
T-cell  subset  development  with  a  conditional  T-cell  Rbpj-deficient  mouse.  Once  they 
crossed their Rbpj-floxed mouse with Lck Cre (expressed early in thymic development), 
the  block  in  Notch  signaling  caused  enhanced  γδ  T-cell  production,  while  αβ  T-cell 
differentiation arrested at the DN3 stage. These data are in accordance with the notion 
that DN3 cells require Notch signaling to pass the β-selection checkpoint in thymic T 
cell development. The same paper also crossed CD4 Cre mice with Rbpj floxed animals. 
Interestingly,  these  mice  had  normal  numbers  of  CD4pos  and  CD8pos  T  cells  in  the 
periphery. In general, a reduced proliferation capacity of peripheral CD4 pos T cells in 
the  presence  of  APCs  was  noted,  but  no  (auto)immune  pathology  evolved  from  this. 
Upon analysis of the T-cell differentiation potential, a bias towards T H1 specialization 
in-vitro  and  in-vivo  was  observed.  Furthermore,  peripheral  blood  serum  contained 
decreased IgG1 and IgE immunoglobulin levels, also indicating a T H1 response. Finally, 
expression levels of GATA-3, an inhibitor of T H1 differentiation, were reduced by 50% 
in Rbpj-deficient T cells, paving the road towards a T H1 bias 167. Another 2014 study 
investigated the effects of Rbpj deletion in CD4pos T cells upon challenge with 
experimental  autoimmune  uveoretinitis  (EAU).  Rbpj  deficiency  in  T  cells  decreased 
EAU  disease  severity  due  to  decreased  IL-22  secretion.  GSI-treatment  had  beneficial 
effects on EAU clinical scores, indicating that Notch pathway components also regulate 
IL-22 signaling 168.  
 
Jagged ligands promote TH2 subset differentiation 
In  contrast  to  TH1  promoting  Dll  ligands,  Jagged  ligands  expressed  on  APCs  pre-
dominantly induce a T H2 phenotype in T cells. Immature dendritic cells express Jagged 
1, which in turn induces GATA-3 and IL-4 expression in T cells, key markers for a T H2 
phenotype.  When  these  immature  DCs  undergo  TLR  ligation,  Jagged-1  expression  is 
reduced and Dll4 expression is upregulated, switching the T-cell response to a T H1 bias. 
In-vitro co-cultivation experiments with Jagged-ligand expressing DCs induce IL-4 and 
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IL-5  secretion,  what  can  be  inhibited  by  GSI  treatment,  again  indicating  that  Notch 
signals  drive  this  phenotype.  In-vivo  studies  with  Jagged1-Fc  fusion  proteins  showed 
that  these  ligands  drive  TH2  immune  responses  in  animal  models  of  EAE  and  lung 
asthma. A Notch pathway interruption via T-cell specific Rbpj deletion interrupted T H2 
differentiation  upon  SEA  or  antigen  immunization  in  mice.  Furthermore,  Notch1  or 
Notch2 deficiency in T cells impaired their IL-4 secretion and T H2 differentiation in-
vivo.  In  addition  to  this,  dominant  expression  of  the  Notch  inhibitor  dnMAML1  or 
treatment  with  GSI  prevented  TH2  induction  in  response  to  infection.  Again,  in-vitro 
studies did not substantiate that Notch1 or Notch2 are required for T H2 differentiation, 
similar  to  in-vitro  studies  for  TH1  bias.  To  explain  the  TH2-inducing  role  of  Notch 
signaling on a molecular basis, inverted Chromatin IP studies have been performed with 
Rbpj and Notch1 antibodies. These studies revealed that both Rbpj and Notch1 bind the 
IL4  promoter,  and  Rbpj  consensus  binding  sequences  have  been  detected  at  the  3’ 
enhancer  of  IL4.  No  IL-4  response  was  possible  once  Rbpj  was  deleted  in  T  cells. 
Luciferase  studies  indicate  that  the  IL-4  promoter  responds  to  Notch  signals  via  IL-4 
resident  Rbpj 169,  170.  Furthermore,  Notch1  has  been  reported  to  bind  the  GATA-3 
promoter together with Rbpj, regulating its transcription 166.  
 
Dll4 ligand drives TH17 subset differentiation 
The overexpression of Dll4 ligands on dendritic cells has been shown to increase IL-17 
secretion  by  T  cells,  whereas  Dll4  neutralization  reverted  this  effect.  In-vivo  studies 
with  an  anti-Dll4  mAb  followed  by  challenge  with  mycobacteria  infection  lead  to 
increased granulomas and a decreased IL-17 secretion by T cells. Furthermore, 
treatment  of  EAE-induced  mice  with  GSI  reduced  IL-17  secretion  levels,  and  also 
affected  the  TH1/TH2  balance,  as  described  previously.  A  deletion  of  Notch  had  no 
consequences in terms of T H17 differentiation, but influenced IL-17 cytokine secretion 
levels – therefore, it is hypothesized that Rbpj can bind the Il17 promoter and regulate 
cytokine expression in concert with Notch signals 166. The precise role of Notch signals 
for the development of Treg cells will be reviewed in the discussion part of this thesis 
and linked to data generated with our experiments presented in the following chapters. 
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Aim of this subproject 
Until now, we summarized the role of Notch signaling for the generation of T cells and 
for their differentiation into T-cell subpopulations. It was now our aim to study another 
aspect  of  the  Notch  signaling  axis:  Rbpj  and  its  Notch-independent  functions.  We 
observed  that  Rbpj  is  upregulated  in  bona  fide  Treg  cells  from  many  tissues  (Figure 
30),  while  studies  with  our  NotchGFP  reporter  mouse  clearly  indicated  that  Treg  cells 
under steady-state conditions do not signal via the Notch axis (Figure 31). What is the 
function or Rbpj in this context? Is there a Treg-specific, Notch-independent role of this 
protein? When we deleted Rbpj in Treg cells, mice develop severe lymphoproliferative 
disease despite strongly increased numbers of Treg cells. Is there a function of Rbpj to 
control Treg cell homeostasis? Or does it mediate the potential to suppress a specific 
TH1, T H2, or other T-cell subpopulation, or even all of them? These questions will be 
addressed in the following thesis. 
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6 Materials and Methods 
6.1 Epigenetic control of the Foxp3 gene in Treg cells 
Mice 
Animals  were  housed  under  specific  pathogen-free  conditions  at  the  DKFZ,  and  the 
governmental  committee  for  animal  experimentation  approved  all  experiments.  We 
used either wild type B/6 mice, Foxp3GFP, DTR, CD90.1 B/6 mice 171 or Dntm1chip 
mice 172. Dntm1chip mice were housed at the university clinics Münster, and 
splenocyte  preparations  were  transported  to  our  laboratories  for  experimental  testing. 
Because the Foxp3 gene is located on the X chromosome, we only used male animals 
for methylation analyses. More detailed information about mouse strains is provided in 
the appendix section. 
 
Cell isolation and cell sorting 
Lymphoid tissues such as spleen and lymph nodes were isolated and single-cell 
suspensions established. Red blood cells were lysed with ammonium-chloride 
potassium  bicarbonate  (ACK)  lysis  buffer.  Cells  were  pre-enriched  for  CD4,  CD8  or 
CD25  via  staining  with  the  respective  biotinylated  antibodies  followed  by  anti-biotin 
microbead (Miltenyi Biotec) labeling and magnetic separation in an automated carrier 
(AutoMACS,  Miltenyi  Biotec).  Upon  enrichment,  cells  were  stained  with  fluorescent 
antibodies and incubated for at least 20 minutes at 4°C. Cell subpopulations were then 
sorted  on  an  FACS  ARIA  II  or  III  cell  sorters  (BD  Biosciences).  For  analysis,  cell 
populations were acquired on LSR II, LSR Fortessa or Canto II flow cytometers. For 
intracellular  staining,  cells  were  first  stained  with  surface  antibodies  followed  by 
fixation / permeabilization (Foxp3 Fix/perm buffer set, eBiosciences) and intracellular 
staining. Antibodies used in these experiments are listed in the appendix section (10.1 
List of antibodies used for flow cytometry and FACS). 
 
Isolation of RNA and reverse transcription followed by qPCR 
Sorted cell populations were lysed and RNA was isolated using the RNeasy Mini Kit 
(Quiagen). Synthesis of cDNA was performed with SuperScript Reverse Transcriptase 
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II and oligo(dT) primers (both Life Technologies) according to manufacturer’s 
instructions. Real-time PCR was performed using a ViiA7 instrument (Life 
Technologies)  and  Power  SYBR  green  master  mix  or  Taqman  master  mix  (both 
Applied Biosystems). Gene expression values were normalized to housekeeping genes 
(Hprt or Gapdh). Both SYBR primer sequences and Taqman order numbers are listed in 
the appendix section. 
 
Purification and bisulfite conversion of genomic DNA 
Sorted  cell  populations  were  resuspended  in  PBS  and  genomic  DNA  was  purified 
according to manufacturers guidelines using the DNEasy Blood and Tissue kit 
(Quiagen). DNA purity and concentration was measured with a NanoDrop ® photometer. 
DNA concentration was adjusted to 2000 ng DNA, if applicable. Bisulfite-conversion 
was  performed  using  the  EpiTect  Bisulfite  Conversion  Kit  (Quiagen)  and  converted 
DNA (BS-DNA) was used immediately after purification or stored at -20°C. 
 
Computation and testing of BS-DNA primers 
Foxp3 genomic DNA was in-silico bisulfite-converted using the Bisulfite Primer Seeker 
software (http://www.zymoresearch.com/tools/bisulfite-primer-seeker). Primer 
sequences were calculated based on manufacturers recommendations. Primer pairs were 
tested  on  BS-converted  genomic  DNA  to  determine  optimal  annealing  temperature 
range  and  cycle  number  for  each  specific  reaction.  Once  parameters  were  optimized, 
adaptor sequences for 454 sequencing and barcodes to distinguish individual reactions 
were  attached  to  each  primer  pair  sequence  and  re-synthesized.    Based  on  optimal 
annealing  temperature  and  PCR  cycle  number,  primers  were  used  to  generate  PCR 
amplicons  from  bisulfite-converted  DNA  for  each  cell  type  tested.  An  overview  of 
primers  used  for  our  sequencing  experiments  is  listed  in  the  appendix  (10.3  List  of 
bisuflite primers used for 454 pyrosequencing).  
 
BS-DNA PCR and 454 pyrosequencing 
The complete workflow for the epigenetic analysis of selected regions is illustrated in 
Figure  8.  Once  genomic  DNA  had  been  bisulfite-converted,  PCR  reactions  with  BS-
specific primers were performed. PCR amplicons were separated from primer dimers on 
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1%-2%  agarose  gels  and  visualized  using  ethidium  bromide.  Specific  bands  were 
excised under UV light exposure and DNA amplicons were purified using a Quick Gel 
Extraction  Kit  (Life  Technologies).  Equimolar  amounts  of  amplicons  were  combined 
and processed on a GS Junior Sequencer (Roche). Sequence reads were aligned to the 
BS-converted mouse genome and methylation levels were visualized in heat maps.  
 
Figure 8: Workflow for the epigenetic analysis of selected CG-rich regions in cells. 
First,  primary  cells  are  isolated  using  FACS  and  genomic  DNA  (gDNA)  is  extracted.  Then, 
gDNA is converted via the sodium bisulfite reaction, where methylated CG dinculeotides are 
protected and unmethylated cysteine residues are converted into thymidine. Once conversion is 
complete, a PCR reaction with bisulfite-DNA specific primers containing barcodes and adapter 
sequences  is  performed.  PCR  amplicons  are  extracted  and  purified  for  454  pyrosequencing. 
Data  are  mapped  against  the in-silico  bisulfite-converted  mouse  genome  and  CG  methylation 
status is calculated.   
6 Materials and Methods 
  56 
6.2  Transcriptional  and  epigenetic  control  of  tissue-specific 
Treg cells 
Mice 
Animals  were  housed  under  specific  pathogen-free  conditions  at  the  DKFZ,  and  the 
governmental committee for animal experimentation approved all animal experiments. 
In these experiments, we used wild type B/6 mice or Foxp3 GFP, DTR, CD90.1 , Foxp3GFP, DTR, 
CD45.1 B/6 mice or Foxp3YFP, Cre  B/6 mice. All animals were male. 
 
Isolation of T cells from various tissues 
We isolated T cells from gonadal fat, skin, liver, and inguinal lymph nodes. For lymph 
nodes,  single-cell  suspensions  were  established  and  red  blood  cells  were  lysed.  Cells 
were  stained  with  antibodies  for  FACS-based  purification.  Gonadal  fat  tissue  was 
mechanically dissected following a digestion with buffers containing collagenase II (1 
mg/mL), BSA (20 mg/mL) and DNAse (20 µg / mL). Skin tissue was digested using a 
buffer containing collagenase IV (4 mg/mL), FCS (2% vol/vol), and DNAse (10 µg / 
mL). Liver tissue cells were isolated with a collagenase II (1 mg/mL), BSA (5 mg/mL), 
and  DNAse  (20  µg/mL)  containing  digestion  buffer  followed  by  a  Ficoll/hypaque 
gradient  centrifugation  step.  Digestions  were  performed  at  37°C  in  a  slow-shaking 
water bath for 30 minutes to 45 minutes. Afterwards, cells were filtered and stained for 
FACS-based isolation of target cells. Antibodies and reagent suppliers are listed in the 
appendix section. 
 
Fluorescence-activated cell sorting and gDNA / RNA isolation 
Stained cells were pre-sorted with moderate purity settings on an ARIA II or III cell-
sorting  machine  (4-way  sort,  “enrich  mode”)  into  FACS  buffer.  Then,  cells  were  re-
acquired and sorted again with high purity settings (4-way sort, “4-way purity mode”) 
directly  into  lysis  buffer.  Aliquots  were  sorted  into  FACS  buffer  for  post-sort  purity 
controls. Genomic DNA was isolated using a gDNA Microprep Kit (Zymo Research) 
and concentrations were measured with a Qubit® fluorometer. Average DNA 
concentration  was  39.5  ng  per  sample.  RNA  was  isolated  with  the  RNEasy  mini  kit 
(Quiagen)  and  concentration  was  determined  with  a  2100  Bioanalyzer  instrument 
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(Agilent  technologies).  The  average  RNA  integrity  number  was  8.5,  and  the  average 
RNA concentration per sample was 3.1 ng.  
Tagmentation-based whole genome bisulfite sequencing (TWGBS) 
We  used  a  protocol  adapted  from 173,  based  on  the  original  tagmentation  protocol 
described in 119 with top oligo 1 Tn5mC-Apt1 
(TcGTcGGcAGcGTcAGATGTGTATAAGAGAcAG ), top oligo 2 Tn5mC-Apt2 
(GTcTcGTGGGcTcGGAGATGTGTATAAGAGAcAG ), and complementary oligo 
Tn5mErev (5’-[phos] CTGTCTCTTATACACATCT-3’ ). Next, oligonucleotides were pre-
annealed in a final volume of 40µL and 50µM concentration with a PCR (95°C 3min, 
70°C 3 min, 70°C – 26°C 30sec, 45 cycles). Load adapters were then diluted to 10 µM 
in  glycerol-H2O.  Transposome  assembly  was  performed  with  12  µL  of  load  adapters 
and 10 µL Ez-Tn5 transposase (Epicentre EZI011RK) for 30 minutes at RT. Then, 10 
ng of genomic DNA were combined with Tris-MgAc-DMF buffer and 5pg 
unmethylated λ DNA, followed by heat treatment (55°C for 8 min). After that, DNA 
was purified with AmPure bead system (Agilent technologies) followed by gap repair 
with Bst DNA polymerase (NEB M0275S) and 5mC-dNTP mix (Zymo D1030) for 20 
min  at  65°C.  After  gap  repair,  samples  were  again  purified  with  the  AmPure  bead 
system.  Samples  were  bisulfite-converted  with  the  EZ  DNA  methylation  kit  (Zymo 
D5001) according to manufacturer’s instructions. Following complete conversion, 
PCRs were performed to attach barcodes and adapters for high throughput sequencing 
with bisulfite-converted DNA, Kapa 2G Robust HotStart ReadyMix (Kapa Biosystems 
KK5515), SYBRGreen® reagent (Life Technologies), a Tn5mCP1 primer 
(AATGATACGGCGACCACCGAGATCTACACTCGTCGGCAGCGTC ) and barcoded 
Tn5mC reverse primer (CAAGCAGAAGACGGCATACGAGAT (-BARCODE-) 
GTCTCGTGGGCTCGG )  with  barcodes  either GACTGATA , AGGCAGAA, GCTACGCT, 
CGAGGCTG  to assemble four libraries. PCR was stopped at six or more fluorescence 
units, followed by purification of PCR products with the AmPure bead system. Sample 
DNA concentration and size distribution was measured, where DNA concentrations and 
molarity  were  similar  between  different  replicates  of  one  cell  type  and  different  cell 
types and size distributions were homogenously between 270bp and 700bp, with a peak 
at 350bp-380bp. We prepared equimolar library pools of 10nM concentration and 30µL 
volume for sequencing. Sequencing was performed with Illumina HiSeq 2000 v3 Paired 
End 100bp runs according to manufacturer’s recommendations for bisulfite sequencing.  
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RNA-Sequencing 
cDNA  was  generated  and  amplified  using  0.8  ng  of  total  RNA  and  SMARTer  Ultra 
Low Input RNA for Illumina Sequencing - HV (Clontech Laboratories, Inc.) according 
to  the  manufacturer’s  protocol.  Then,  sequencing  libraries  were  prepared  using  the 
NEBNEXT ChIP-Seq Library Prep Master Mix Set for Illumina (New England Biolabs 
E6240) according to the manufacturer's instructions with the following modifications: 
The adapter-ligated double-stranded cDNA (10µl) was amplified using NEBNext 
Multiplex  Oligos  for  Illumina  (New  England  Biolabs  E7335  and  E7500,  25  µM 
primers), NEBNext High-Fidelity 2x PCR Master Mix (New England Biolabs M0541) 
and 15 cycles of PCR. The final libraries were validated using Agilent 2100 
Bioanalyzer (Agilent Technologies) and Qubit flourometer (Invitrogen), normalized and 
pooled in equimolar ratios. 50bp single-read sequencing was performed on the Illumina 
HiSeq 2000 v4 according to the manufacturer’s protocol.  
 
Mapping of whole-genome bisulfite sequencing data 
The  TWGBS  data  were  processed  as  described  in 119:  The  hg19  reference  genome 
(37d5) was transformed in silico for both the top strand (C to T) and bottom strand (G 
to A) using MethylCtools 174. Before alignment, adaptor sequences were trimmed using 
SeqPrep (https://github.com/jstjohn/SeqPrep). The first read in each read pair was then 
C-to-T  converted  and  the  2nd  read  in  the  pair  was  G-to-A  converted.  The  converted 
reads were aligned to a combined reference of the transformed top (C to T) and bottom 
(G to A) strands using BWA (bwa-0.6.2-tpx) with default parameters, yet, disabling the 
quality threshold for read trimming (-q) of 20 and the Smith-Waterman for the 
unmapped mate (-s). After alignment, reads were converted back to the original states, 
and  reads  mapped  to  the  antisense  strand  of  the  respective  reference  were  removed. 
Duplicate reads were removed, and the complexity determined using Picard 
MarkDuplicates (http://picard.sourceforge.net/). Reads with alignment scores less than 1 
were filtered before subsequent analysis. Total genome coverage was calculated using 
the total number of bases aligned from uniquely mapped reads over the total number of 
mappable bases in the genome. 
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Methylation calling 
At  each  cytosine  position,  reads  that  maintain  the  cytosine  status  were  considered 
methylated,  and  the  reads  that  have  cytosine  converted  to  thymine  were  considered 
unmethylated. Only bases with Phred-scaled quality score of ≥20 were considered. In 
addition, the 5 bp at the two ends of the reads were excluded from methylation calling 
according  to  M-bias  plot  quality  control.  For  TWGBS  libraries,  the  first  9  bp  of  the 
second read and the last 9 bp before the adaptor of the first read were excluded from 
methylation calling.  
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6.3 Transcription-factor based control of the Foxp3 gene 
Mice / cell lines 
Animals  were  housed  under  specific  pathogen-free  conditions  at  the  DKFZ,  and  the 
governmental committee for animal experimentation approved all animal experiments. 
In these experiments, we used wild type B/6 mice or Foxp3 GFP, DTR, CD45.1  B/6 mice 171. 
For cell lines, we used a human embryonic kidney cell line (ATCC ® CRL-1573™), a 
murine  EL4  T-cell  line  (ATCC ®  TIB-39™),  and  a  human  Jurkat  JE6.1  T-cell  line 
(ATCC ® TIB-152™). Cells were incubated at standard TC conditions (37°C, 5% CO2) 
in complete medium and were regularly tested for mycoplasma infection and 
contamination with other cell types. 
 
Isolation of nuclear protein 
Nuclear protein was isolated from EL4 T cells with the NXtract isolation kit (Sigma), 
and protein concentration was measured using a BCA kit (Thermo). Upon isolation of 
nuclear protein, a selective enrichment of nuclear protein of 5.5 fold compared to the 
cytosolic  fraction  was  achieved  (data  not  shown).  Furthermore,  we  observed  a  good 
enrichment for nucleus-associated proteins based on gene ontology of detected peptides 
(Figure 9C). About 40 mg of nuclear protein were used for each replicate.   
 
Preparation of Foxp3 Fra1, Fra2, and Fra3 probes 
Short  Foxp3-promoter  fragments  were  produced  from  a  Full  Foxp3  promoter  vector 
with a biotinylated forward primer and standard reverse primers. PCR conditions for the 
production of biotinylated PCR primers were optimized to reduce a contamination with 
unbound biotinylated PCR primers (see Figure 9). PCR products were purified using a 
quick PCR purification kit (Life Technologies). To measure successful biotinylation of 
the  probe,  the  PCR  product  and  its  individual  primers  were  plotted  onto  a  PVDF 
membrane  and  UV  cross-linked.  Biotinylation  was  detected  with  an  anti-biotin  HRP 
and chromogenic detection substrate in a Western-Blot visualization unit.   
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Figure 9: Preparation of probes and nuclear protein for the inverted ChIP. 
We determined optimal annealing temperature and concentration of template plasmid DNA and 
primers for the generation of 500 bp oligonucleotide probes (A). We used the same parameters 
for the generation of all three probes (Foxp3-Fra1, Foxp3-Fra2, Foxp3-Fra3). The membrane 
in the lower right quadrant shows the selective biotinylation of the forward primer as well as the 
biotinylation of the final PCR product. In B, we show the purification of several milligrams of 
nuclear protein from the EL4 T cell line, which is highly enriched for DNA binding factors and 
RNA processing factors as well as RNA-Protein complexes, as shown in C. 
 
Inverted Chromatin IP 
The inverted Chromatin IP procedure is visualized in Figure 10. First, carefully washed 
streptavidin beads were linked individually to Foxp3-Fra1 probes, Foxp3-Fra 2 probes, 
or Foxp3-Fra 3 probes for 3 hours at RT. Then, free bead binding sites were blocked 
and beads were washed again. Nuclear protein was pre-incubated with unlabeled beads 
to  remove  non-specific  bead-binding  proteins.  The  cleared  nuclear  protein  was  then 
added to each probe-labeled bead and incubated on a rotating wheel for 3 hours at 4°C. 
6 Materials and Methods 
  62 
After  incubation,  beads  were  washed  to  remove  unbound  protein  and  bead-bound 
sequence-specific proteins were eluted. Protein was trypsin-digested and peptides were 
labeled with stable isotopes by dimethylation of N-termini and lysines. Samples were 
then combined and reduced by isoelectric focusing. Finally, samples were subjected to 
nanoLN-MS/MS analysis, which allows the quantitative detection of peptides that were 
originally bound to specific probe-labeled beads.  
 
 
Figure 10: Overview of inverted ChIP procedure. 
First, beads are labeled with the respective biotinylated oligonucleotide probes. Then, nuclear 
protein from murine EL4 T cells is added for a three-hour in-vitro binding reaction. Next, beads 
are  purified  via  magnetic  enrichment  and  unbound  protein  is  washed  off.  Finally,  protein  is 
released from the beads, purified and fractionated for mass spectrometry-based analysis. 
 
Real-time PCR to check expression levels of candidate proteins 
First,  we  synthesized  and  tested  Sybr  primers  for  both  mouse  and  human  candidate 
proteins  with  the  aid  of  a  public  database  (http://pga.mgh.harvard.edu/primerbank/). 
Primer  efficiency  and  melting  curve  characteristics  were  analyzed,  with  efficiencies 
between 80% and 120% and single melting curves as criteria. We then isolated RNA 
from cell lines, FACS-sorted primary Treg and Tconv cells or plasmid-transfected 293 
cells with the RNeasy mini kit. RNA was concentration-adjusted and reversely 
transcribed  using  Reverse  Transcriptase  II  and  oligo(dT)  primers  (Life  Technologies) 
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according to manufacturers standards. Real-time PCR was performed with Sybr Master 
Mix  (Applied  Biosystems)  and  Sybr  primers.  Sybr  primer  sequences  are  listed  in  the 
appendix.  
 
Cloning  of  candidate  genes  and  evaluation  of  proper  expression  for  downstream 
reporter assays 
First, we generated PCR products containing intron-free coding DNA for each 
candidate  protein,  either  from  mouse  splenic  cDNA  or  commercially  available  vector 
clones. PCR products were ligated into pENTR/D-TOPO ® vectors (Life Technologies) 
and sequenced for proper gene orientation and exclusion of mutations. Once complete, 
pENTR®  vectors  were  used  to  shuttle  coding  DNA  into  destination  vectors  such  as 
pDEST26® for eukaryotic overexpression and pMSCV-CD90.1 ® for viral transduction 
of  T  cells  with  LR  clonase  II  enzyme  (Life  Technologies).  Again,  vectors  were 
sequence-verified  to  exclude  mutations.  To  exclude  vector  mix-ups  and  demonstrate 
eukaryotic  expression,  we  transfected  HEK  293  cells  with  each  pDEST®  eukaryotic 
production vector and isolated RNA 48hrs post transfection followed by reverse 
transcription and Real-time PCR. To check for protein expression, we re-shuttled some 
pENTR®-based genes into FLAG ®-tagged pDEST ® eukaryotic production vectors and 
performed Western-Blot based detection of FLAG ®-tagged protein with an anti-FLAG ® 
antibody. Size and band intensity was used to identify the transgene of interest. Finally, 
we  validated  vector  DNA  integrity  on  agarose  gels  to  ensure  vector  stability  and 
concentration for downstream analyses.  
 
Molecular cloning of short Foxp3 promoter luciferase vectors 
We  used  a  full  Foxp3  promoter  luciferase  vector  as  a  template  to  create  short  Foxp3 
promoter  Fragment  1,  Fragment  2  and  Fragment  3  PCR  products  with  gene-specific 
primers  including  restriction-enzyme  binding  sites:  Foxp3  Fra  1  (ForP  with  XhoI 
CTAGCTCGAGACTGCTAGAGGGGGATCAGC  and RevP with Sbf1 
GATCCCTGCAGGGCAGGCTTCAGATCCCTTCT ), Foxp3 Fra 2 (ForP with XhoI 
CTAGCTCGAGCTGCCATGTGAATGGGAAG  and RevP with Sbf1 
GATCCCTGCAGGCCTGGGCCGCTATGTGTAT ) and Foxp3 Fra 3 (ForP with XhoI 
CTAGCTCGAGCCAGGGTCCTAGTCCTGTCA and RevP with Sbf1 
GATCCCTGCAGGGTTGGCTTCAGGAAAACTGG ).  The  Full  Foxp3  promoter  vector  was 
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then  digested  with  XhoI  and  Sbf1  restriction  enzymes  to  remove  the  Foxp3  promoter 
sequence, size-separated and isolated from an agarose gel, and treated with phosphatase 
to prevent re-ligation. Next, the individual small fragments 1,2, or 3 were ligated into 
the  empty  vector.  The  Foxp3  Fra1,  Fra2,  and  Fra3-pGL3  vectors  were  sequenced  to 
confirm  proper  orientation  of  the  small  Foxp3  fragments  into  the  luciferase  reporter 
vector pGL3.  
 
Luciferase-based reporter assays in HEK 293 cells 
First,  we  optimized  the  dual  luciferase  reporter  system  for  cell  seeding  numbers, 
incubation time, linearity of the luciferase system, and transfection efficiencies. In our 
optimized protocol, we seeded 50,000 HEK 293 cells into a 96-well flat bottom plate on 
day 1. After overnight cell attachment, we added 125 ng each of three vectors: first, the 
β-galactosidase (β-gal) transfection normalization vector; second, a luciferase reporter 
vector, either the Full, Fra1, Fra2, or Fra3 Foxp3 promoter vector; third, we added the 
transgene of interested in an eukaryotic production vector. A total of 375 ng of plasmid 
DNA  were  transfected  into  each  well.  For  transfection,  we  used  the  Lipofectamine® 
transfection system (Life Technologies) according to manufacturer’s recommendation. 
In short, the DNA-water mix containing all three vectors was mixed with a 
Lipofectamine®-medium  suspension  and  incubated  for  5  minutes  at  RT  for  liposome 
formation. Then, the liposomal mix was added to the cell culture and incubated for 24 
hours. 50% of medium was exchanged followed by an additional 24 hours of 
incubation. 48 hours after transfection, cell culture medium was aspirated and cells were 
lysed with respective lysis buffer from a Dual Light luciferase kit (Thermo Fisher). 75 
µL of supernatant were transferred to a black 96-well plate and 12.5 µL of buffer A was 
added.  We  then  automatically  injected  50  µL  of  Buffer  B  plus  X-GAL  substrate  and 
measured luciferase signals for the pGL3 luciferase vector on a luminometer (Berthold). 
After sixty minutes, another 50 µL of Accelerator-II solution were injected and the b-
galactosidase signal was measured.  
 
Normalization of luciferase values 
To  check  for  transfection  efficiency  differences,  we  averaged  β-gal  light  intensity 
values across all transfected wells of a 96-well plate. We then divided the β-gal readings 
of each individual well by the average β-gal intensity to determine a relative 
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transfection efficiency reading. The measured luciferase values were then corrected for 
transfection  differences  by  normalization  with  the  respective β-gal  ratio  for  each 
individual well.  
Transfection efficiency A1 != Individual read β-gal  A1
Average β-gal  across 96w plate
 
Normalized luciferase A1!= Individual read luciferase  A1Transfection efficiency A1  
 
Calculation of specific binding 
To test for unspecific binding effects to elements on the pGL3 luciferase vector other 
than the integrated Foxp3 promoter, we measured all our candidate proteins against a 
control-pGL3 vector, which does not contain any relevant promoter sequence before the 
luciferase ORF. We then cross-compared the normalized luciferase values for the Full 
Foxp3 promoter vector as well as Fra1, Fra2 and Fra3 Foxp3 promoter vectors against 
the control pGL3 vector to determine sequence-specific up-or downregulation of gene 
expression. These values are depicted in graphs in Figure 27. To now check whether 
any of our candidate proteins significantly up-or downregulate Foxp3 promoter activity, 
we compared normalized luciferase expression values between cells co-transfected with 
GFP, a non-nuclear protein without transcription factor activity, and cells co-transfected 
with a candidate Foxp3-promoter binding protein.  
Sequence-specific binding!=! Norm. luciferase value for Foxp3-luciferase vector A2
Norm. luciferase value for control-luciferase vector A1 
Significance level for protein X!= T.Test (Specific binding GF P vs. Specific binding X) 
 
Luciferase-based reporter assays in TCR-stimulated Jurkat cells 
Analogously to the screenings described above, we used a three-vector system to check 
the effects of our candidate proteins in Jurkat T cells: The first vector was a luciferase 
reporter  vector  containing  the  Full  Foxp3  promoter  sequence  (5000  ng  per  test);  the 
second vector was a eukaryotic production vector carrying the candidate gene (5000 ng 
per test); third, we used a Renilla-based normalization vector (500 ng per test). Before 
electroporation, Jurkat T cells were counted and adjusted to 2x106 cells per 
electroporation.  Cells  were  washed  with  OptiMEM  medium  and  a  mix  of  all  three 
plasmids was added to each Jurkat cell preparation. Cells were transferred to 
electroporation cuvettes (Biorad) and electroporated with 125 V of electric current and 
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Mammalian  11  –  Jurkat  settings  with  a  Biorad  electroporation  machine.  Afterwards, 
cells  were  transferred  into  pre-warmed  six-well  plates  with  1500  µL  of  complete 
medium.  24  hours  after  incubation,  electroporated  cells  were  either  stimulated  with 
PMA  (100  ng/µL)  and  Ionomycin  (1000  ng/µL)  or  left  untreated.  20  hours  after 
stimulation, cells were washed and resuspended in 330 µL 1X lysis buffer (Promega) 
and lysed for 15 minutes at RT. Lysate was transferred to black 96-well plates, with 120 
µL of luciferase measurements and 30 µL for Renilla measurements. Luciferase 
substrate and Renilla substrate were freshly prepared (details see Appendix) and 100 µL 
were injected followed by 10s reading time on a luminometer (Berthold).  
 
Calculation of specific binding for the Jurkat T cell screening 
Similar to our transfection efficiency calculation for the HEK293-cell based screenings, 
we first averaged the Renilla transfection control values across all Renilla-transfected 
and non-stimulated samples. We then divided the individual Renilla read per well by the 
average reading to yield a measure of electroporation efficiency for each well. It should 
be  noted  that  we  used  electroporation  efficiencies  of  unstimulated  wells  to  normalize 
PMA/Ionomycin-treated samples, since PMA specifically induces activity on the 
Renilla vector and thereby causes false-positive results also in the luciferase channel.   
Electroporation efficiency A1 !=! Individual read! Renilla  A1
Average! Renilla  across experiment  
Normalized luciferase A1 =! Individual read! luciferase  A1
Electroporation efficiency A1
 
 
Next,  we  calculated  normalized  luciferase  values  for  wells  carrying  the  Full  Foxp3 
pGL3 luciferase vector plus a selected transgene and calculated the relative induction 
compared to non-stimulated controls. These values were combined across four 
independent experiments and used to check for significant downregulators in 
comparison to GFP controls.  
Rel. Induction (protein X)!=! Normalized luciferase of stimulated well protein X
Normalized luciferase of unstimulated well protein X
 
Significance level for protein X!= T.Test (Rel. Induction GF P vs. Rel. Induction X) 
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Viral transduction of candidate genes into primary induced Treg cells 
Retrovirus  in  the  pMSCV-CD90.1®  system  can  be  manufactured  in  PhxEco  cells,  a 
pCL-Eco  (packaging  plasmid)  carrying  variant  of  HEK  293  cells.  Therefore,  PhxEco 
cells were seeded on a gelatin matrix at 400,000 cells per well in a six well plate 24 
hours before lipofection. To produce liposomal particles containing the viral transgene, 
we co-incubated 3000ng of vector DNA and 1000ng of additional pCL-Eco packaging 
plasmid with 7.5 µL of TransIT-293 ® transfection reagent (Mirus) for 15-30 minutes at 
RT.  Liposomes  were  added  to  PhxEco-carrying  six-well  plates  and  incubated  for  an 
additional 48 hours. In parallel, T-cells were isolated from spleen and lymph nodes via 
AutoMACS-based negative selection (depletion of CD8, CD19, CD25, CD11b, CD11c, 
CD49b positive cells) and TCR-stimulated with plate-bound CD3 and CD28 
monoclonal antibodies (CD3 @ 0.1 µg/mL and CD28 @ 1.0 µg/mL) on a 96-well flat 
bottom  plate.  We  also  added  50  ng/mL  TGF-β  to  T-cell  cultures  to  induce  Foxp3 
expression. Two days after cell seeding, we added viral supernatant carrying pMSCV ® 
retrovirus with the transgenes of interest. Viral supernatant was supplemented with IL-2 
(20  U/mL),  TGF-β  (50  ng/mL)  and  polybrene  (4  µL/mL).  T  cells  were  spun  for  90 
minutes at 32°C and 2000 rpm followed by five hours of incubation at 37°C. 
Afterwards, viral supernatant was removed and cells were incubated with fresh medium 
supplemented  with  IL-2  and  TGF-β  for  another  72  hours.  Then,  cells  were  harvested 
and  surface-stained  with  CD4,  CD90.1  and  a  live/dead  exclusion  dye,  followed  by 
fixation and intracellular staining for Foxp3 protein expression. Cells were analyzed on 
a Canto II flow cytometer, and transduction efficiency was tested using GFP controls 
and overall CD90.1 transgene expression levels.   
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6.4 Rbpj and its function for Treg cell homeostasis 
Mice / cell lines 
Animals  were  housed  under  specific  pathogen-free  conditions  at  the  DKFZ,  and  the 
governmental committee for animal experimentation approved all animal experiments. 
In these experiments, we used wild type B/6 mice or Foxp3 GFP-DTR-CD90.1 or Foxp3 GFP-
DTR-CD45.1 B/6 mice 171. Rbpj floxed mice 175 were crossed to Foxp3 YFPCre mice to generate 
Treg-specific  Rbpj  knockout  mice  (Foxp3CreRbpjΔ/Δ).  NICDLSL  mice  were  crossed  to 
Foxp3YFPCre  mice  to  generate  Treg-specific  NICD  knock-in  mice  (Foxp3CreNICDLSL). 
NotcheGFP reporter mice were housed at the Weizmann Institute of Science and 
described in 176. 
 
Isolation of Treg cells from various tissues 
We isolated Treg cells from fat, skin, colon, lung, liver, and different lymph nodes as 
well as spleen and thymus. For lymph nodes and spleen, single-cell suspensions were 
established  and  red  blood  cells  were  lysed.  Cells  were  stained  with  antibodies  and 
purified using FACS. For thymus samples, cells were first depleted of double-positive 
and CD8-single positive thymocytes by staining with CD8 biotinylated mAb and anti-
biotin beads followed by AutoMACS-based depletion. Gonadal fat tissue was 
mechanically dissected following a digestion with buffers containing collagenase II (1 
mg/mL),  BSA  (20  mg/mL)  and  DNAse  (20  µg  /  mL).  Skin  and  colon  tissue  was 
digested using a buffer containing collagenase IV (4 mg/mL), FCS (2% vol/vol), and 
DNAse (10 µg / mL). Liver tissue cells were isolated with collagenase II (1 mg/mL), 
BSA  (5  mg/mL),  and  DNAse  (20  µg/mL)  containing  digestion  buffer  followed  by  a 
Ficoll/hypaque  gradient  centrifugation  step.  Lung  tissue  was  digested  in  a  buffer 
containing collagenase IV (2 mg/mL), BSA (0.5% w/vol), and DNAse (20 µg / mL). 
Digestions were performed at 37°C in a slow-shaking waterbath for 30 minutes to 45 
minutes. Afterwards, cells were filtered and stained for FACS-based isolation of target 
cells. 
 
Flow cytometry, FACS and cell counting (plus Annexin-V and Caspase-3) 
For flow cytometric evaluation of surface proteins or cell isolation via FACS, surface 
staining with monoclonal antibodies was performed at 4°C for 20 minutes followed by 
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immediate  analysis.  For  intracellular  staining,  cells  were  first  surface-stained  for  20 
minutes at 4°C followed by fixation, permeabilization and intracellular staining with the 
Foxp3  Fix/perm  buffer  set  (eBiosciences)  according  to  manufacturer’s  instructions. 
Annexin-V staining and active Caspase-3 staining was performed according to 
manufacturer’s instructions (Biolegend, Abcam). Flow cytometric analysis was 
performed  using  BD  LSRII,  LSR  Fortessa,  or  BD  Canto  II  flow  cytometers  with 
AccuCheck® counting beads (Life Technologies). Cell sorting was performed using BD 
FACS ARIA II or III cell sorting machines (BD Biosciences).  
 
Isolation of RNA and reverse transcription followed by qPCR 
Sorted  cell  populations  were  lysed  and  RNA  was  isolated  using  the  RNeasy  mini  kit 
(Quiagen). cDNA synthesis was performed with SuperScript reverse transcriptase (Life 
Technologies)  and  oligo(dT)  primers  according  to  manufacturer’s  instructions.  qPCR 
analysis  was  performed  using  a  ViiA7  instruments  (Life  Technologies)  and  either 
Power  SYBR  green  master  mix  (Life  Technologies)  or  Taqman  master  mix  (Life 
Technologies). Gene expression values were normalized to housekeeping genes (Hprt or 
Gapdh).  Both  SYBR  primer  sequences  and  Taqman  order  numbers  are  listed  in  the 
appendix section. 
 
Western Blot for Rbpj 
We isolated 500,000 CD4posCD25posFoxp3YFP-pos Treg cells and 500,000 
CD4posCD25negFoxp3YFPneg  Tconv  cells  from  Foxp3 CreRbpjΔ/Δ  and  Foxp3Cre animals. 
Cells were lysed in RIPA buffer with protease inhibitors and supplemented with loading 
buffer  for  SDS-PAGE.  125,000  cells  were  separated  on  a  gradient  acrylamide  gel 
(Biorad).  Proteins  were  blotted  onto  a  PVDF  membrane  and  blocked  with  5%  milk-
PBST for one hour at RT, followed by incubation with primary anti-Rbpj mAb (Cell 
signaling, clone D10A4) overnight at a 1:3000 dilution. After washing, the membrane 
was stained with an anti-rabbit HRP conjugated secondary mAb at 1:10000 for one hour 
at RT. Membrane was washed and specific binding was detected using a chromogenic 
substrate and a Western Blot detection unit.  
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In-vitro Treg suppression assay 
First,  we  isolated  CD90.1-congenically  labeled  CD4-positive  T-responder  cells  and 
MHCII-positive  antigen-presenting  cells  from  spleen  and  liver  of  Foxp3GFP-DTR-CD90.1 
animals.  CD90.1pos  T-responder  cells  were  labeled  with  CFSE  (final  concentration  1 
µM, Life Technologies) for 15 minutes at RT followed by stringent washings steps. We 
incubated 100,000 MHCII-positive APCs with 50,000 CFSE-labeled T-responder cells 
in a 96-well U-bottom plate. To stimulate T-responder cell division, we added 2µg/mL 
soluble CD3 mAb to each well for TCR crosslinking through APCs. Next, we isolated 
CD4posCD25posFoxp3YFPpos Treg cells and CD4 posCD25negFoxp3YFPneg Tconv cells from 
sick Foxp3 CreRbpjΔ/Δ and Foxp3 Cre mice. Treg and Tconv cells were titrated and added 
to each well for a 4:1, 2:1, 1:1, 1:2, 1:4, 1:8, 1:16 and 1:0 Treg or Tconv to T-responder 
cell ratio. Cells were incubated for 5 days at 37°C (144 hours) followed by re-staining 
for flow cytometric analysis and measurement on a flow cytometer. T-responder cells 
were identified by CD90.1 expression, whereas Foxp3 CreRbpjΔ/Δ and Foxp3 Cre animals 
express  CD90.2  and  MHCIIpos  APCs  express  neither.  Cell  division  was  identified  by 
active CFSE dilution of CD90.1pos T-responder cells.  
 
Epigenetic analysis of the TSDR 
To  analyze  specific  demethylation  of  Treg-specific  demethylated  region,  we  isolated 
Treg and Tconv cells from sick Foxp3 CreRbpjΔ/Δ and Foxp3 Cre control mice via FACS. 
We purified genomic DNA with the DNA Blood and Tissue Kit (Quiagen) followed by 
sodium-bisulfite  conversion  (Epitect  BS  conversion  kit)  according  to  manufacturer’s 
protocol. Barcode-labeled amplicons from BS-DNA were generated with TSDR-
specific BS primers (see appendix). Equimolar amounts of amplicons were combined 
and processed on a GS junior sequencer (Roche). Sequence reads were aligned to a BS-
converted mouse genome and methylation levels were visualized in heat maps.  
 
TCR sequencing 
We  isolated  spleen  as  well  as  inguinal,  axial,  brachial,  and  cervical  LN  from  sick 
Foxp3CreRbpjΔ/Δ  and  Foxp3Cre  animals.  We  pre-purified  Treg  cells  via  CD25-positive 
selection via magnetic bead enrichment (Miltenyi Biotec) and isolated 
CD4posCD25posFoxp3pos  Treg  cells  from  via  FACS.  Genomic  DNA  was  isolated  with 
the DNEasy Blood and Tissue Kit followed by nanodrop ®-based gDNA concentration 
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adjustment. 500 ng of gDNA were submitted for immunoSEQ® TCR-β Survey 
Sequencing (Adaptive Biotechnologies) followed by bioinformatic analysis. 
 
Intracellular cytokine secretion assay 
Whole  spleen  was  isolated  from  sick  Foxp3CreRbpjΔ/Δ  and  Foxp3Cre animals  and  red 
blood cells were lysed. Splenocytes were resuspended in fresh complete medium and 
treated  with  1X  PMA/Ionomycin  stimulation  cocktail  plus  transport  inhibitors  or  just 
transport  inhibitors  (eBiosciences).  Cells  were  incubated  for  eight  hours  at  37°C, 
followed  by  surface  antibody  staining  for  20  minutes  at  4°C.  Cells  were  then  fixed, 
permeabilized, and stained intracellularly with the Foxp3 Fix/perm buffer set 
(eBiosciences)  and  anti-cytokine  antibodies.  Cells  were  analyzed  on  a  LSR  II  flow 
cytometer.  
 
Ig subtype ELISA 
Peripheral  blood  serum  was  isolated  from  sick  Foxp3CreRbpjΔ/Δ  and  Foxp3Cre control 
animals  via  intracardial  puncture.  Blood  was  allowed  to  clot  for  30  minutes  at  RT, 
followed  by  centrifugation  (20,000xg  for  15  minutes)  and  removal  of  blood  serum. 
Blood serum was titrated for Ig subtypes with an ELISA against mouse IgG1, IgG2a, 
IgG2b, IgG3, IgE and IgM. 
 
Autoantibody screening with RAG2 KO organ protein via Western Blot 
We isolated organs of the gastro-intestinal tract (stomach, small intestine, large 
intestine),  lymphatic  system  (lymph  nodes),  endocrine  system  (pancreas),  brain,  eye, 
spleen, salivary gland, liver, heart, lung, and testis from a RAG2 -/- animal. Protein was 
extracted using ProteoJet lysis buffer with protease inhibitors for 10 minutes at RT and 
orbital  shaking  (1000  rpm).  Lysate  was  cleared  for  15  minutes  at  16,000xg  and 
supernatant was measured for protein content with BCA (Pierce). 20 µg of protein were 
loaded onto a gradient acrylamide gel (Biorad) and separated using SDS-PAGE. 
Proteins  were  transferred  onto  a  PVDF  membrane  and  blocked  with  5%  Milk-PBS-
Tween.  Membranes  were  cut  into  strips  and  incubated  individually  with  peripheral 
blood serum in 5% Milk overnight (1:500 serum concentration). Membrane strips were 
washed and incubated with an HRP-conjugated donkey-anti mouse IgG mAb (1:3000 in 
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5% milk-PBST) for one hour at RT. Membrane strips were washed, re-assembled and 
measured with a chromogenic detection kit and a Western Blot detection unit. 
 
Gene expression microarray 
We isolated 50,000 CD4posCD25posFoxp3YFPpos Treg and 50,000 
CD4posCD25negFoxp3YFPneg Tconv cells from sick Foxp3 CreRbpjΔ/Δ and Foxp3Cre animals 
using FACS ARIA II or III cell sorters. Furthermore, we isolated CD4 posCD25posFoxp3-
NICDYFPposFoxp3GFPpos  Treg  and  50,000  CD4posCD25posFoxp3-NICDYFPnegFoxp3GFPpos 
Treg cells from Foxp3 CreNotchLSL mice using FACS ARIA II or III cell sorters. RNA 
was extracted using the RNEasy Plus Micro Kit (Qiagen) followed by amplification and 
hybridization  of  material  to  the  MouseWG-6  v2.0  Expression  BeadChip  (Illumina) 
through  the  DKFZ  Genomics  and  Proteomics  Core  Facility.  Microarray  data  will  be 
deposited at the Gene Expression Omnibus (GEO). 
 
Chromatin-IP with Rbpj  
Chromatin-IP  experiments  were  performed  with  an  anti-Rbpj  monoclonal  antibody 
(Cell  Signaling,  clone  D10A4,  concentration  25  µg  /  mL)  at  a  1:50  dilution  with  the 
Magnify ChIP system (Lie Technologies). We used three to four biological replicates of 
CD4posCD25posFoxp3YFPpos Treg cells from Foxp3Cre animals, 
CD4posCD25posFoxp3YFPpos Treg cells from Foxp3CreRbpjΔ/Δ animals, and 
CD4posCD25negFoxp3YFPneg  Tconv  cells  from  Foxp3 Cre  animals.  Chromatin  IP  was 
performed according to manufacturers recommendations. Bead-bound DNA was eluted 
in  100µL  elution  buffer  and  used  for  Real-time  PCR  based  measurements  with  Sybr 
primers specific for Hes1, Dtx1, and IL7R putative RBPJ binding sites (see appendix). 
Real-time PCR measurements were performed using the Sybr Master Mix and a Viia 7 
RT-PCR  system  (Life  Technologies).  Results  were  normalized  to  input  controls,  and 
Rbpj-specific binding at different loci was identified by calculation of binding in Rbpj-
proficient Treg cells vs. binding in Rpbj-deficient Treg cells. 
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7 Results 
7.1 Epigenetic control of the Foxp3 gene in Treg cells 
Identification of CG hotspots for analysis 
First,  we  downloaded  the  mouse  and  human  genetic  code  for  the  Foxp3  gene  and  its 
promoter  region  from  public  databases  (human:  FOXP3  CCDS14323,  mouse:  Foxp3 
CCDS29965).  We  then  compared  the  conservation  between  both  sequences  on  a 
nucleotide-per-nucleotide level and computed a histogram shown in Figure 11 
(http://genome.lbl.gov/vista/mvista/submit.shtml).  Using  this  histogram,  we  overlaid 
mouse Foxp3 intron and exon information and identified highly conserved regions such 
as the conserved non-coding sequences (CNS1-3), the promoter (PRO) and a putative 
upstream enhancer (ENH). Along this line, we used the mouse Foxp3 genetic code and 
calculated the number of CG dinucleotides per 100 bases. We plotted the CG density in 
another histogram to identify 6 regions that are enriched for CG dinucleotides. Some of 
these regions also show a high degree of conservation (region 1, 2, 4, and 6). These six 
CG hotspots were used for a detailed downstream CG dinucleotide methylation 
analysis. Their specific location is described in Table 1. 
 
Figure 11: Conservation of the Foxp3 gene and identification of CG hotspots. 
The upper histogram shows the conservation between mouse and human genetic code for the 
Foxp3 gene. Relative positions of Foxp3 gene introns and exons are superimposed on top. The 
lower histogram depicts the average CG dinucleotide distribution across the whole Foxp3 gene. 
Six distinct CG-rich regions can be identified and will be analyzed throughout this chapter. 
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R Area Start TSS Start Stop Length AUC 
R1 Enhancer -2000 7,577,676 7,578,176 500 800 
R2 Promoter -300 7,579,376 7,579,876 500 800 
R3 Promoter/Intron +400 7,580,076 7,580,776 700 1300 
R4 TSDR +4,000 7,583,676 7,584,376 700 1400 
R5 Exon 8 +11,400 7,591,076 7,591,776 700 800 
R6 Exon 11 +13,100 7,592,776 7,593,176 400 1100 
Table 1: Precise description of Foxp3 CG-rich regions, their location relative to TSS 
(7,579,676) or precise genomic location, specific length and area under the curve. 
 
Epigenetic  analysis  reveals  distinct  methylation  of  several  regions  of  the  Foxp3 
promoter 
Next,  we  prepared  primers  for  each  specific  region  1-6  and  synthesized  them  with 
specific  barcodes  and  adaptor  sequences.  To  identify  the  methylation  pattern  among 
Treg  cells,  Tconv  cells  and  CD8  T  cells,  we  FACS-purified  each  cell  type  from  pre-
enriched  cell  preparations  and  measured  the  methylation  pattern  (Figure  12).  We 
observed  that  region  1,  which  is  a  potential  upstream  enhancer  of  the  Foxp3  gene, 
carries a partial demethylated phenotype only in Treg cells. Region 2, which is the core 
Foxp3 promoter, was mostly demethylated in all cell types, indicating a rather 
transcription-factor based control of this gene area. In contrast to this, region 3, which is 
just  downstream  of  the  core  promoter  in  the  first  intron,  has  a  distinct  demethylation 
phenotype. This phenotype is comparable to region 4, which is the already published 
TSDR. These results suggest a not yet appreciated, potentially regulatory region (R3) 
adjacent to the Foxp3 gene promoter.  
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Figure 12: Analysis of Foxp3 promoter R 1-4 in Treg, Tconv, and CD8 T cells. 
The dot plots in A show the sorting strategy for CD25 pre-enriched samples from mouse spleen 
and  lymph  nodes.  In  B,  we  show  post-sort  quality  control  and  purity  measurements  of  Treg 
cells, CD8 T cells and Tconv cells. An overview of the CG-rich regions is shown in C. The plot 
in D guides along the interpretation for sequencing data: each column represents an individual 
CG dinucleotide, whereas each row represents an individual read. The total number of reads is 
written  left-hand  of  the  graph.  A  yellow  color  indicates  unmethylated  CG  dinucleotides, 
whereas  blue  color  shows  methylation.  In  E,  we  show  the  differential  methylation  pattern  of 
Treg, Tconv, and CD8 T cells for R1, R2, R3 and R4. 
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The epigenetic imprint of Treg cells is established during thymic development 
To  identify  the  precise  developmental  step  at  which  Foxp3  gene  methylation  at  our 
target regions occurs, we isolated thymic T-cell precursors (double negative 
thymocytes), early Treg precursors cells (cytokine – and TCR-dependent Treg precursor 
cells),  late  Treg  precursor  cells  (cytokine-dependent  Treg  precursor  cells)  as  well  as 
mature Foxp3GFP positive thymic Treg cells as shown in Figure 13 29. The epigenetic 
analysis  revealed  that  region  1  is  heavily  methylated  in  all  Treg  precursor  cells  and 
becomes  partially  demethylated  only  in  thymic  Foxp3pos  Treg  cells.  The  promoter-
adjacent region 3 as well as the TSDR R4 is methylated just until Foxp3 is expressed in 
thymic Treg cells. Our results suggest that the demethylation on the Foxp3 locus occurs 
immediately before Foxp3 expression, and suggests a role of epigenetic imprinting in 
stabilizing and modulating the expression strength of Foxp3. Interestingly, the exonic 
regions R5 and R6 (situated in exon 8 and 11) conserve their highly methylated pattern, 
indicating that these regions have no impact on Foxp3 gene expression or its strength, 
but rather promote genetic stability and integrity. 
 
The Treg-specific methylation pattern is stable in circulating mature Treg cells 
Since we already investigated the imprinting of the Treg-specific methylation pattern in 
thymic Treg cell induction, we now wanted to compare it to both circulating Treg cells 
and  iTreg  cells.  To  do  so,  we  isolated  either  naive  or  antigen-experienced  Treg  and 
Tconv cells from spleen and lymph nodes from mice. Furthermore, we induced iTreg 
cells from Tconv cells via in-vitro activation and cytokine treatment. We investigated 
all cell types for their epigenetic phenotype and plotted the data in Figure 14. We could 
show  that,  first,  in-vitro  induced  Treg  cells,  albeit  Foxp3GFP  positive,  carry  no  Treg-
specific  demethylation  pattern  at  both  R3  and  R4  loci.  The  missing  demethylation  of 
R4-TSDR and its implications for the long-term stability of in-vitro induced Treg cells 
has been discussed already 126. Importantly, the specific demethylation of R3 and R4 is 
stable  in  circulating  Treg  cells,  independent  of  antigen  experience.  We  also  observed 
the  partial  demethylation  of  R1  only  in  Treg  cells,  but  not  in  Tconv  cells  or  induced 
Treg populations. The exonic regions R5 and R6 were again methylated in all cell types. 
Based on this dataset, we can draw the conclusion that region 3, which is established 
during  thymic  Treg  development,  remains  demethylated  once  Treg  cells  leave  their 
birthplace and travel the body. Antigen experience does not alter this epigenetic imprint. 
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Figure 13: Investigation of Foxp3 gene methylation in developing Treg cells. 
We isolated T cell subpopulations from the thymus, and show the gating strategy in A. Post-sort 
controls  show  purity  and  surface  phenotype  of  DN1  (CD4 negCD8negCD25negCD44pos),  early 
Treg  precursor  cells  (CD4 posTCRβposCD69posCD25negFoxp3GFPneg),  late  Treg  precursor  cells 
(CD4posTCRβposCD69negCD25posFoxp3GFPneg), and mature thymic Treg cells 
(CD4posTCRβposCD69negCD25posFoxp3GFPpos). The methylation pattern is shown in B. 
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Figure 14: Investigation of Foxp3 gene methylation in mature T cells. 
Cells  were  isolated  from  spleen  and  lymph  nodes.  Cells  were  then  separated  into  memory 
(antigen-experienced)  and  naive  T  cells  based  on  their  CD44  expression  (A).  The  dot  plots 
show  the  post-sort  purity  control  for  memory  and  naive  Treg  and  Tconv  as  well  as  in-vitro 
induced Treg cells (iTreg). The methylation pattern of each group is shown in B. 
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The Treg-specific methylation pattern is independent of Foxp3 expression strength 
Since  selective  CG  methylation  can  not  only  modulate  gene  expression  in  a  binary 
manner,  but  also  level  the  gene  expression  strength,  we  isolated  Foxp3 GFP  high-, 
medium-,  and  low  expressing  Treg  cells  populations.  Furthermore,  we  also  isolated 
CD25-negative Foxp3-positive Treg cells as well as Tconv cells from spleen and lymph 
nodes (Figure 15). We compared Foxp3 GFP expression intensity with Foxp3 and CD25 
(Il2ra) mRNA levels and identified a positive correlation between Foxp3 GFP signals and 
Foxp3 mRNA, and interestingly also for Foxp3 GFP signals and Il2ra mRNA. Zheng and 
co-workers have identified the molecular link between Foxp3 protein and CD25 
expression as a Foxp3-dependent regulation of Il2ra levels, which fits our results 177. 
Also,  Foxp3posCD25neg  Treg  cells  had  very  low  levels  of  Foxp3  mRNA,  albeit  still 
higher  than  Tconv  cells.  If  we  now  compare  the  specific  methylation  signature  of  all 
five cell types, we can observe that region 1, which is a potential upstream enhancer, is 
methylated  in  Tconv  cells  and  partially  demethylated  in  high  –  medium  –  and  low- 
Foxp3  expressing  Treg  cells.  This  rules  out  a  possible  function  of  this  region  in 
manipulating Foxp3 expression strength. Interestingly, it shows higher methylation in 
Foxp3posCD25-negative Treg cells, indicating that it might be involved in or regulated 
by IL-2 cytokine signaling pathways. We also compared region 3, a new Treg-specific 
demethylation  region,  amongst  all  cell  types.  To  increase  resolution,  we  probed  the 
region with two amplicons and analyzed it separately. Our data indicate that region 3 
clearly follows the pattern of region 4, again demonstrating its Treg-specific epigenetic 
imprint. Interestingly, both region 3 and 4 show the same demethylation pattern in high- 
medium-  and  low-  Foxp3  expressing  Treg  cells.  One  can  infer  from  this  dataset  that 
TSDR methylation does not regulate Foxp3 expression strength, but only stabilizes its 
expression in a binary (on/off) manner. Furthermore, it is independent of signals derived 
from the IL-2 receptor (CD25), at least once Treg cells have matured in the thymus. 
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Figure 15: Influence of Foxp3 gene methylation on Foxp3 protein expression. 
Cells were isolated from spleen and lymph nodes and sorted based on their expression strength 
of  Foxp3  (A).  We  isolated  CD4 posCD25posFoxp3GFPhigh,  CD4 posCD25posFoxp3GFPmedium,  and 
CD4posCD25posFoxp3GFPlow Treg cells. Furthermore, we sorted CD4 posCD25negFoxp3GFPpos Treg 
cells as well as CD4 posCD25negFoxp3GFPneg Tconv cells. Post sort purity is shown in B, with a 
correlation  between  sort  purity  and  Foxp3  and  Il2ra  mRNA  expression  shown  in  C.  The 
methylation results are shown in D. 
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DNA-methyltransferase hypomorphic mice have phenotypically intact Treg cells 
In  order  to  analyze  the  importance  of  our  Treg  methylation  patterns  at  the  Foxp3 
promoter,  we  took  advantage  of  a  mouse  carrying  only  the  most  basic  methylation 
pattern due to is near-complete loss of the DNA-methyl transferase enzyme 1 (Dnmt1). 
Since a complete knockdown of this important maintenance and de-novo methyl 
transferase  in  mouse  and  human  cells  is  embryonically  lethal,  a  Dnmt1  hypomorphic 
allele (Dnmt1 chip) has been used to create a Dnmt1-hypomorphic mouse strain 172. We 
analyzed  the  T-cell  compartment  in  splenocyte  preparations  from  these  mice  (Figure 
16). We identified CD4 and CD8 T cells in the periphery, although at a lower frequency 
than in wild type controls. Foxp3 pos Treg cell percentage in the CD4 T cell populations 
was  reduced  to  about  50%  of  normal  (30%  in  WT  vs.  15%  in  Dnmt1  hypomorphic 
mouse spleens). This also translates into a decrease in absolute Treg cell numbers in the 
spleen. In contrast to this, Tconv cell numbers were not drastically reduced, especially 
in comparison with the heavily constricted B cell compartment in the spleen. In addition 
to cell frequencies, we also measured lineage-defining protein expression in Treg cells 
from  WT  controls  and  Dnmt1chip  mice.  We  could  not  detect  any  abnormalities  in  the 
expression of CTLA-4, Nrp1, Helios or GITR, as well as Foxp3 protein. Since it has not 
been reported that Dnmt1 chip mice develop autoimmune disease, protective function of 
the  Treg  lineage  can  be  inferred  since  potentially  self-reactive  Tconv  cells  should  be 
present in normal frequency. Last, we were also interested in the methylation levels of 
Treg  vs.  Tconv  cells  in  this  particular  mouse.  Therefore,  we  isolated  both  cell  types 
from splenic preparations and measured the methylation phenotype as shown in Figure 
17.  Interestingly,  the  methylation  patterns  of  region  3  and  4  are  conserved  also  in 
animals  with  hypomorphic  DNA  methyltransferase  1  activity.  One  can  appreciate  the 
gradual loss of methylation for region 5 and 6, which in turn should not affect Foxp3 
gene expression. Also, the putative enhancer region 1 retains the differential 
methylation  pattern.  Taken  together,  these  data  indicate  that  methylation  of  Region  3 
and 4 is necessary for Tconv cells to prevent an epigenetic opening of the Foxp3 locus, 
and its differential methylation is maintained even in a Dnmt1 hypomorphic situation.  
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Figure 16: Analysis of the Treg cell compartment in Dnmt1-hypomorphic mice. 
First, we investigated splenocytes from Dnmt1-hypomorphic mice for the presence of any Treg 
cell species. Representative gates are shown in A, with a quantification of Treg percentages (B) 
and absolute numbers (C). In D, we compared the expression of key Treg lineage proteins via 
flow cytometry. The histograms are representative of duplicate experiments from individually 
shipped cell samples. 
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Figure 17: Foxp3 gene methylation in Dnmt1-hypomorphic mice. 
We isolated Treg and Tconv cells from the spleens of Dnmt1 hypomorphic mice (A). No purity-
based  differences  have  been  observed  between  T  cell  populations  isolated  from  wild  type  or 
Dnmt1-hypomorphic mice (B). Since we had no Foxp3 GFP marker in these animals, we used the 
surface marker CD25 to stratify Treg and Tconv cells. The methylation pattern for WT Tconv 
cells and Treg / Tconv cells from Dnmt1 chip mice is shown in C.  
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The differential methylation of the Foxp3 gene by whole-genome sequencing 
In the following section, we describe the whole-genome sequencing based methylation 
analysis of Treg and Tconv cells from lymph nodes along with tissue-isolated Treg cells 
from  fat,  skin  and  liver.  To  obtain  these  data,  we  collaborated  with  the  division  of 
Epigenetics and Cancer Risk Factors at the DKFZ Heidelberg. Quality aspects of our 
dataset in terms of CG dinucleotide coverage across the whole genome, homogeneity 
amongst samples, and mapping efficiencies are described in the following section. We 
used this dataset to analyze the Foxp3 gene and its CG-rich regions, as shown in Figure 
18. We were able to confirm our amplicon-based data, showing that regions 3 and 4 are 
Treg-specific demethlated regions. Furthermore, we also confirmed the 
hypermethylated state of regions 5 and 6. We also observed the partially demethylated 
phenotype  of  region  1,  which  remains  conserved  also  in  tissue-specific  Treg  cells. 
Finally, region 2, which is the core Foxp3 promoter, is demethylated in all cell types 
tested, which was shown already with amplicon-based methylation analysis. 
Furthermore, we plotted the whole Foxp3 gene along with its preceding gene Ppp1r3f 
(Protein Phosphatase1, Regulatory Subunit 3F) in 3’ and the untranslated region (UTR) 
of the Foxp3 5’ end (Figure 19). The Ppp1r3f gene, coding for the glycogen-binding 
protein  R3F,  which  in  turn  binds  the  glycogen  target  protein  phosphatase  1  (PP1),  is 
involved  in  the  regulation  of  glycogen  metabolism.  It  can  modulate  the  activity  of 
glycogen  synthase  and  glycogen  phosphorylase,  key  enzymes  in  glucose  metabolism 
178.  It  can  be  assumed  that  this  gene  is  expressed  in  many  different  cells,  and  not 
regulated in a tissue-specific manner. Interestingly, the complete promoter and Exon 1 
of the Ppp1r3f gene are demethylated in all cell types. Since this gene is located on the 
reverse  strand,  its  promoter  and  the  Foxp3  promoter  are  linked.  If  we  move  further 
towards the extended Foxp3 promoter, a differential methylation pattern between Treg 
cells and Tconv cells can be appreciated – this probably marks the end of the Ppp1r3f 
gene promoter. As mentioned earlier, the core Foxp3 promoter with 9 CG dinucleotides 
is completely demethylated in all cell types, just like the promoter of the Ppp1r3f gene. 
Once we move across the transcription start site, the intronic region containing CNS1 
and CNS2 regions is, again, differentially methylated between Tconv and Treg cells of 
all tissues. Importantly, this Treg-specific demethylated regions covers the whole Foxp3 
first  intron,  and  not  just  the  areas  of  high  CG  density  such  as  Region  3  or  Region  4 
(TSDR/CNS2). In contrast to this, the differential methylation pattern is complete gone 
after exon 1,  showing a fully demethylated phenotype for about 10 CG dinucleotides 
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(like at the promoter). Importantly, this is also the approximate location of the CNS3 
region. Once this short demethylated stretch is passed, the remaining exons and the 5’ 
UTR are highly methylated in all cell types. 
In summary, we detect a Treg-specific demethylation only at the first intron, covering 
our regions 3 and 4, and at an upstream enhancer of the Foxp3 promoter, our region 1. 
The  promoter  itself  and  Foxp3  exons  are  unanimously  methylated  or  de-methylated, 
independent of Foxp3 expression activity. 
 
 
Figure 18: Foxp3 gene methylation in tissue-resident Treg cells. 
We isolated Treg and Tconv cells from lymph nodes, along with Treg cells from fat, liver, and 
skin. Genomic DNA was bisulfite-converted and analyzed with tagmentation-based next-
generation sequencing, as described previously. Yellow color indicates demethylation, and blue 
color indicates methylated CG dinucleotides. 
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Figure 19: Overview of whole Foxp3 gene methylation on single-nucleotide level. 
Plotted  are  single-CpG  nucleotide  methylation  data  for  Tconv  and  Treg  cells  from  different 
tissues.  The  uppermost  heatmap  shows  the  CG  methylation  status  for  the  whole  Foxp3  gene 
plus  its  5’  neighboring  gene  Ppp1r3f  and  the  Foxp3  3’  UTR  (created  with  Gene  Pattern 
Software). To be able to decipher the methylation status in more detail, we split the gene into 
three regions, shown separately below (1, 2, 3). The Foxp3 gene intron and exons are annotated 
on top of the heatmaps, and the numbers indicate the genomic position of the CG dinculeotides. 
In  B,  we  plot  the  Foxp3  promoter  and  the  first  4  exons  of  the  Foxp3  gene  with  methylation 
plotter software ( 179), and we overlaid the approximate localizations for the CNS 1-2-3 regions 
and the core Foxp3 promoter. Colors or grey values indicate percent methylation as shown in 
the legends.   
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7.2  Transcriptional  and  epigenetic  control  of  tissue-specific 
Treg cells 
FACS-sorting of populations with high purity 
First, we validated protocols to isolate tissue-resident T cells meeting our standards for 
viability and post-sort purity. Therefore, we tested and optimized different collagenase-
based treatments of tissues to liberate intact immune cells. Afterwards, cells were pre-
filtered  and  pre-enriched  via  FACS,  followed  by  a  second  high-purity  sort  (polishing 
step).  Pre-sort  tissue  T-cell  numbers  and  post-sort  quality  control  are  exemplified  in 
Figure 20. As appreciated in literature and discussed in the introduction to this thesis, 
Treg cells from different tissues also account for a different percentage of T cells. In our 
case,  Treg  cells  accounted  for  more  than  30%  of  CD4pos  T  cells  in  fat  and  skin,  and 
about  13%  in  lymph  nodes.  In  liver  tissue,  Treg  cells  account  for  only  3.9%  of  all 
CD4pos T cells on average. After double sorting, we obtained post-sort purities of 90% 
or more for all tissues. Since collagenase-treated T cells lose their expression of sort-
relevant  markers  such  as  CD25  and  CD4  over  time  during  the  sorting  procedure,  the 
end-gate purity without these shifting populations would be even higher. Taken 
together, one can conclude that we were able to isolate functionally intact, pure Treg 
and Tconv populations from the described target organs. Upon isolation of RNA and 
DNA, and measurement of the respective concentrations, we were able to determine a 
linear  cell  number  –  yield  relationship  for  DNA,  but  not  for  RNA  (Figure  21). 
Importantly, we observed high homogeneity between samples for methylomics run data 
(C) with almost equal total read numbers, GC content and duplication rate. For RNA-
sequencing data, reads and duplication levels were also comparable between samples, 
highlighting  the  successful  normalization  of  input  genetic  material  before  PCR-based 
amplification. 
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Figure 20: Isolation of tissue-specific T cell populations via FACS. 
We isolated T cells from inguinal lymph nodes (LN), gonadal fat, liver, and skin. Anatomical 
details of tissue isolation are shown in Part A. Part B shows representative dot plots indicating 
CD25posFoxp3GFPpos Treg and CD25negFoxp3GFPneg Tconv frequency of intact 
CD3posCD45posCD8negCD4pos T cells. Percentages below the dot plots indicate average Treg and 
Tconv cell frequencies and standard deviation between different experiments. Part C highlights 
the  post-sorting  purity  calculations  with  representative  dot  plots  and  average  values  across 
experiments. 
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Figure 21: Quality control of DNA/RNA isolations and NGS run data. 
The table in part A describes the total number of cells sorted for each cell type per biological 
replicate  and  the  average  genomic  DNA  (gDNA)  concentration  per  replicate.  This  dataset  is 
plotted  again  on  the  right  hand  side  to  highlight  the  linear  relation  between  cell  number  and 
DNA yield. In parallel, we plotted average RNA concentration and cell numbers for our RNA 
isolation  experiments  in  part  B.  Finally,  we  plot  average  read  number,  GC  content  and 
duplication  rate  for  methylomics  NGS  data  (part  C)  and  transcriptomics  NGS  data  (part  D). 
Each group represents three biological replicates with several technical replicates. 
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Library complexity reveals the whole-genome coverage of methylation data 
Reads  recovered  from  whole-genome  sequencing  of  bisulfite-converted  DNA  were 
mapped to a mouse reference genome. Based on mapping efficiency (“how many reads 
can be aligned to the genome”) and pairing efficiency (“pairing of forward and reverse 
reads”),  the  overall  library  complexity  was  determined  (Figure  22).  It  describes  all 
reads  that  can  finally  be  used  to  determine  the  methylation  status  of  single  CG 
dinucleotides  over  the  whole  genome.  As  already  indicated  by  our  next-generation 
sequencing  run  data,  we  achieved  a  homogenous  complexity  across  all  samples  with 
only  minor  variations  in  read  number.  The  read  numbers  eventually  translate  into 
coverage, which can be calculated for each individual chromosome, and describes how 
often  individual  reads  cover  every  single  nucleotide.  Homogenously  distributed  over 
chromosome 1 through 19, we achieved about 3.5 reads per single CG dinucleotide per 
biological  replicate.  Since  three  replicates  will  be  combined  to  determine  differential 
methylation  patterns,  a  median  coverage  of  10  or  more  is  expected  per  group.  The 
coverage of individual CG dinucleotide depends on the genomic context of its location 
and therefore varies for every single CG dinucleotide. Importantly, the coverage for the 
X allosome is only about half of the one for autosomes. Since we exclusively used male 
animals for this study, the reduction of coverage in the X chromosome was expected. 
Interestingly, the Y chromosome coverage is very poor (0.22 reads per CG 
dinucleotide).  This  problem  is  known  to  the  field  and  based  on  the  high  content  of 
repetitive DNA sequences, which translates into small, unmappable reads. 
 
Tissue-resident Treg cells have lower whole-genome methylation levels 
When comparing the methylation of all CGs on individual chromosomes, an interesting 
tissue-specific phenomenon can be appreciated. First, Treg and Tconv cells from lymph 
nodes do not differ in overall CG methylation levels, despite already-described Treg-
specific methylation at Foxp3-Intron 1 and others (Figure 19). In contrast to this, Treg 
cells from liver, fat, and skin have different whole-genome methylation levels, 
indicating tissue-specific adaptation by epigenetic events. Importantly, control λ DNA 
and  mitochondrial  DNA  do  not  display  this  tissue-specific  methylation  difference, 
ruling out PCR bias or input DNA variation as a source for this difference. Next, it will 
be interesting to analyze these differences on a per-gene basis with the aim to identify 
potential epigenetic hotspots of Treg tissue adaptation (work in progress). 
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Figure 22: Mapping, coverage and whole-genome methylation status. 
In  A,  we  show  mapping  and  pairing  efficiency  of  adapter-trimmed  reads  to  the  hg19  mouse 
reference genome. Based on the mapped reads, the library complexity with all mappable reads 
can  be  determined  (B).  These  reads  were  used  to  compute  the  coverage  of  every  single  CG 
nucleotide on a per-chromosome-basis for all four libraries in autosomes (Chromosome 1-19) 
and allosomes (X and Y chromosome). In C, we calculated the average CG methylation across 
all  chromosomes  and  compared  it  to  methylation  level  of  mitochondrial  DNA  and  λ  DNA. 
Statistical evaluation was performed with two-way ANOVA (*** = p<0.0001, ns = p>0.05).  
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7.3 Transcription-factor based control of the Foxp3 gene 
The Foxp3 promoter is highly conserved between species 
In  our  epigenetic  study  of  the  Foxp3  locus,  we  compared  the  conservation  between 
mouse and human Foxp3 genetic code. The histogram in Figure 23 shows the 
conservation  in  percent  with  a  superimposed  Foxp3  gene  structure.  We  can  interpret 
that the Foxp3 gene promoter, at least in its very proximal 1000 bp, is highly conserved 
between  mouse  and  human.  This  indicates  transcription-factor  binding  sites  to  be 
present in this area, as already reviewed in the introduction. Furthermore, our epigenetic 
analysis summarized in Chapter 5 showed that this particular part of the Foxp3 gene is 
demethylated  in  regulatory  and  non-regulatory  cell  types,  which  could  indicate  that 
potential repressive factors occupy this area in Foxp3-negative cell types. To identify 
putative binding partners, we performed the inverted  ChIP  as  described  in  Figure  10 
and the methods section. 
 
Figure 23: Overview of Foxp3 species conservation and inverted ChIP procedure. 
The histogram in A highlights the conservation between mouse and human genetic code for the 
Foxp3 gene. Highly conserved sequences are colored in red. The relative position of the Foxp3 
gene introns and exons are overlaid on top, and the specific probes used for the inverted ChIP 
are shown below.  
 
A specific array of factors bind the Foxp3 gene promoter 
We performed the inverted ChIP and evaluated specific protein binding to each 
fragment (Figure 24). First, we cross-compared binding of each factor to each 
individual  Foxp3  probe:  for  example,  the  candidate  factor  Zinc  finger  protein  574 
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(Znf574) binds strongly to Foxp3-promoter fragment 2 since its relative binding to this 
fragment is much higher than its binding to Fra 1 (Fra2/1) or to Fra3 (Fra2/3). This can 
also be visualized in dot plots showing the relative binding or in a heatmap generated 
from selected candidate proteins and shown in Figure 24. In an effort to decrease the 
number of candidates, we applied filters based on published gene ontology (GO) terms 
for candidates identified in this experiment. First, we disregarded candidates with less 
than 3-fold differential binding between fragments. Next, we used a p-value threshold 
of  p<0.05  to  identify  candidates  with  statistically  sound  binding  patterns.  Finally,  we 
used  the  GO  terms  DNA-binding  or  RNA-binding  to  filter  our  candidate  proteins,  of 
which seven were reported transcription factors for the very proximal Foxp3 promoter 
1, five for the Foxp3 promoter fragment 2, and three for the most distal probe Foxp3 
promoter fragment 3. 
 
Candidate proteins are overexpressed in human, but not murine, Tconv cells 
To evaluate differential gene expression of our candidate proteins, we cultivated several 
human and mouse cell lines. For the mouse system, we used EL4 (ATCC ® TIB-39™) 
and  RMA  cells  that  are  commonly  referred  to  as  T-lymphoma  cell  lines 180.  Besides 
these, we also FACS-isolated primary Treg (CD25posFoxp3GFPpos) and Tconv 
(CD25negFoxp3GFPneg) cells from Foxp3GFP mice. In the human system, we also isolated 
primary Treg (CD25pos) and Tconv (CD25neg) cells from healthy human donors. For cell 
lines, we used Jurkat T cells (ATCC ® TIB-152™), an acute T leukemia cell line, as well 
as CCRF-CEM (ATCC ® CCL-119™) and BE-13 as additional leukemic cell lines 181. 
We then isolated RNA and prepared cDNA libraries for each cell type. We tested the 
expression levels of our candidate proteins via qPCR, and plotted the results in Figure 
25. We observed that many of our candidate factors are overexpressed in human Tconv 
cells compared to primary Treg cells and leukemic cell lines. In the mouse system, we 
observed that some factors are also overexpressed in Tconv cells, but most factors are 
upregulated in both Treg and Tconv cells compared to cell lines. Importantly, none of 
the factors are strongly upregulated in EL4 T cells - this makes non-physiological tumor 
cell-line  based  overexpression  of  proteins  as  a  source  for  binding  patterns  in  the 
inverted  ChIP  unlikely.  If  we  now  search  for  our  candidate  proteins  in  a  differential 
mouse  Treg  /  Tconv  proteome  (derived  from 182),  we  cannot  identify  any  bias  in  the 
expression pattern between mouse Treg and Tconv, validating our qPCR data. 
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Figure 24: Results of the inverted ChIP with Foxp3-promoter Fra1, 2, 3 probes. 
The left-hand dot plots in part A illustrate averaged relative binding of all detected proteins to 
Fra1, Fra2, or Fra3. Some selected candidates are highlighted. The p-value vs. relative binding 
plot  on  the  right  hand  side  adds  the  statistical  evaluation  of  binding  partners  with  a  p-value 
calculation across all detected peptides from two replicates. To identify candidates, we filtered 
the candidate list with parameters shown in C. The heat map in B shows fragment-specific and 
significant  binding  partners  via  an  unsupervised  hierarchical  clustering.    Protein  interaction 
analysis of several candidates in D shows an interrelated network of transcription factors. 
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Figure 25: Gene expression analysis of target proteins in primary cells. 
For  our  selected  candidates,  we  tested  their  gene  expression  profile  in  primary  Treg  cells, 
primary Tconv cells and several cell lines in mouse and human background (A). To assess the 
differential expression profile of the Foxp3-binding candidates in murine Treg and Tconv cells 
on a protein level, we utilized the primary Treg/Tconv proteome data from M. Barra et al. 182 
and  mapped  it  to  our  dataset.  We  used  candidate  proteins  with  selective  binding  to  only  one 
fragment with a fold change of at least 2. Out of 153 proteins specifically binding to Fra1, we 
were able to map 129 to the Treg/Tconv proteome (Fra2: 25 out of 40, Fra3: 72 out of 98). We 
then overlaid the candidate proteins for each fragment onto the differential proteome in part B 
and highlighted some candidate proteins. On top of each graph, we indicate the total number of 
proteins  up-or  downregulated  in  Treg  vs.  Tconv  cells,  as  well  as  the  number  of  candidate 
proteins up-or downregulated in the Treg/Tconv proteome dataset. 
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Stable expression of our candidate proteins in cell culture systems 
The table in Figure 26 provides an overview of genes cloned into the pDEST26 ® and 
pMSCV-CD90.1®  expression  system.  To  avoid  vector  mix-ups  and  prove  plasmid 
integrity,  we  transfected  293  cells  with  each  plasmid,  followed  by  RNA  isolation, 
cDNA synthesis and gene expression measurement by qPCR. When we overexpressed a 
specific transgene, for example encoding the Rpa1 gene, and analyzed the gene 
expression profile against all our candidate proteins, we only detected a high increase in 
mRNA for Rpa1, but not for others. This was the case for all genes observed except the 
Ssbp1 transgene, which seems to also induce Rfx1 mRNA. This could indicate cross-
regulation of both proteins. Before performing extended in-vitro luciferase screens, we 
also tested transgene expression and protein production with FLAG ®-tagged expression 
vectors  (Figure  26C).  We  were  able  to  show  that  transgenes  in  pDEST26®  and  viral 
vectors are expressed and its protein products run at the specified molecular weight. 
 
Most candidate proteins downregulate Foxp3 gene expression or have no effect 
We  tested  our  candidate  proteins  in  HEK  293  cells  transfected  with  a  full  Foxp3 
promoter  luciferase  vector.  We  also  cloned  small  Foxp3  promoter  luciferase  vectors 
containing  Fra1,  Fra2  and  Fra3  Foxp3  promoter  elements  (Figure  27A).  Then,  we 
tested a positive control, the Nr4a1 gene, and its effects on Foxp3 expression (Figure 
27B).  As  published,  Nr4a1  specifically  induces  luciferase  gene  expression  at  the  Full 
Foxp3 promoter, but not at the basic (control) pGL3 vector or the Fra1-Foxp3 promoter 
vector. Nr4a1 is reported to bind the Foxp3 gene promoter, but probably not the most 
proximal promoter. Furthermore, we validated GFP as a control since it does not induce 
gene expression at any of our vectors. With these controls in place, we tested all our 
candidate proteins against the Full Foxp3 promoter vector as well as each Fra1, Fra2, or 
Fra3 vector individually. The normalized data for the Full Foxp3 promoter are shown in 
Figure  27C.  We  were  able  to  show  that  some  candidates  specifically  downmodulate 
Foxp3  gene  expression.  When  observing  only  one  specific  gene,  Zinc  finger  protein 
574,  a  sequence-specific  regulatory  behavior  can  be  identified:  whereas  the  protein 
downmodulates expression on the Full Foxp3 promoter, it does not bind the Foxp3 Fra1 
promoter. Its weak binding to this region had also been predicted by our MS data. But 
since binding is predicted to Fra2, as well as to Fra3 with a lower intensity, we also see 
downregulation at these specific loci. 
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Figure 26: Molecular cloning of candidate genes and gene expression controls. 
First, we cloned target gene cDNA into a pENTR ® vector system. The annealing temperature 
(TA), origin of the PCR product (mouse cDNA or order from Thermo Open Biosystems), and 
size of the destination vector are shown in table A. In B, we compared the selective transgene 
expression  in  HEK293  cells  that  were  transfected  with  the  respective  eukaryotic  production 
vector. Afterwards, we isolated RNA and measured gene expression via qPCR. In C, we utilized 
FLAG®-tagged  vectors  and  overexpressed  our  candidate  genes  in  HEK293  cells.  After  lysis, 
proteins were separated via SDS-PAGE and blotted followed by staining with an anti-FLAG ® 
antibody. We finally compared DNA integrity and concentration of each expression plasmid in 
graph D, where non-linearized intact vectors run at a higher DNA marker size than predicted. 
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Figure 27: Luciferase-based evaluation of candidate proteins in HEK 293 cells. 
We  used  a  Foxp3  promoter  luciferase  vector  to  clone  small  constructs  containing  the  Foxp3 
promoter Fra1, Fra2, or Fra3 (A). As a positive control, we tested Nr4a1 against the Full Foxp3 
luciferase  vector  and  the  promotorless  pGL3  luciferase  basic  vector  (B).  In  C,  we  tested  all 
candidate  proteins  against  the  Full  Foxp3  promoter  vector.  Data  are  representative  of  four  or 
more independent experiments with two biological/technical replicates each. Statistical 
evaluation was performed using a two-tailed non-parametric Mann-Whitney t test against GFP 
controls.  This  experimental  setup  was  utilized  also  for  Fra1,  Fra2  and  Fra3  short  luciferase 
vectors  (D).  If  the  average  normalized  luciferase  expression  was  more  than  GFP,  candidates 
were classified as upregulators. If the average luciferase expression was less than GFP, 
candidates  were  considered  downregulators.  In  E,  we  show  Zinc  finger  protein  574  and  its 
normalized expression values across all four Foxp3 luciferase fragments tested with this assay. 
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Some candidates downregulate T-cell receptor induced Foxp3 promoter activity 
Since  we  established  that  our  candidates  are  mostly  gene-repressing  factors,  we  were 
interested in testing them in a T-cell line under TCR-stimulation conditions. Therefore, 
we introduced a system where Jurkat T cells were electroporated with the Full Foxp3-
luciferase  vector  followed  by  T-cell  receptor  stimulation  with  PMA  and  Ionomycin 
(Figure  28A,  B).  We  observed  that  TCR  stimulation  causes  a  10-fold  increase  in 
luciferase activity of the Foxp3 promoter as compared to TCR-stimulated Jurkat T cells 
tested with a promoterless luciferase plasmid. Next, we tested all our factors against the 
Full  Foxp3  luciferase  vector  to  determine  whether  some  of  those  can  downmodulate 
TCR-induced Foxp3 promoter gene activity (Figure 28 D). Some candidates did indeed 
downregulate  luciferase  activity,  and  these  effects  were  not  seen  with  the  control 
luciferase vector (Figure 28 C). This dataset shows that some of our factors have the 
ability to downmodulate PMA/Ionomycin-stimulated Foxp3 promoter activity. 
 
Testing of candidate proteins in primary in-vitro induced Treg cells 
Since  our  cell-culture  derived  testing  methods  showed  promising  Foxp3  promoter 
inhibitory activity, we now wanted to test our factors in primary T cells. Therefore, we 
re-cloned all vectors into pMSCV-CD90.1 ® viral expression vectors and manufactured 
virus  in  PhxEco  cells,  a  variant  of  HEK293  cells.  Then,  we  isolated  primary  mouse 
Tconv  cells  and  cultivated  them  under  CD3/28  stimulation  and  TGF-β  conditions  to 
induce Foxp3 (iTreg cells). Then, we transduced these cells with retrovirus carrying the 
candidate genes and measured Foxp3 protein expression after 4 days (Figure 29). To 
evaluate our dataset, we compared Foxp3 expression in non-transduced T cells (CD90.1 
negative) and candidate-gene transduced T cells (CD90.1-positive). When transducing a 
control vector (which does not carry any transgene), no differences in Foxp3 expression 
were observed, as expected. When transducing T-cells with Foxp3-pMSCV ®-CD90.1, 
retrovirally-transduced cells had almost twice as much Foxp3 expression compared to 
non-transduced cells in the same well. Once we tested all our candidate factors in this 
system, we could not detect any significant downmodulation of Foxp3 gene expression, 
neither  in  percentage  nor  median  fluorescence  intensity  (MFI)  values.  This  could 
indicate that our factors operate in a TGF-β pathway-independent manner; especially, 
since Foxp3 gene expression is initiated via binding of TGF-β response elements to the 
CNS1, but not to the Foxp3 gene promoter. 
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Figure 28: Luciferase-based testing of candidate proteins in Jurkat cells. 
To test the effects of our candidate proteins on TCR-stimulated Foxp3 gene induction, we used 
Jurkat T cells and electroporated them with a uciferase reporter plasmid, a candidate gene and a 
Renilla normalization vector. Cells were then either stimulated for 24h with PMA and 
Ionomycin  or  left  unstimulated.  Luciferase  intensities  were  measured  afterwards  (schematic 
shown in A). The assay-specific increase in Foxp3-pGL3 luciferase activity is shown in B. In C, 
we show data across five independent experiments with the pGL3 basic vector. Once the basic 
vector  is  replaced  with  the  Full  Foxp3  luciferase  vector,  down  –  or  upregulation  of  Foxp3 
induction by electroporated vectors can be measured (D). Values above the bar graphs indicate 
average increase in Luc activity upon stimulation, compared to non-stimulated cells. Statistical 
analysis was performed using a non-parametric two-tailed Mann-Whitney t test against the GFP 
control. 
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Figure 29: Viral overexpression of candidate proteins in induced Treg cells. 
We transduced primary iTreg cells with murine stem cell virus (MSCV) produced in PhxEco 
cells. As controls, we used a control vector without transgene (A) or a GFP-pMSCV ® vector. 
We gated on CD90.1-positive (virus-transduced) and CD90.1-negative (non-transduced) iTreg 
cells and quantified Foxp3 expression levels. As a positive control, we used a Foxp3-
pMSCV®vector (B). With this experimental layout, we transduced all factors into iTreg cells (C, 
D)  and  quantified  Foxp3  protein  expression  across  four  independent  experiments.  Data  for 
relative viral Foxp3 induction are shown in the bar graph, with statistical evaluation performed 
by Mann-Whitney t testing. 
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7.4 Rbpj and its function for Treg cell homeostasis 
Rbpj is upregulated in Treg cells on protein and RNA level  
We  analyzed  the  RNA  expression  of  Rbpj  in  CD4posCD25posFoxp3GFPpos  Treg  cells 
versus CD4posCD25negFoxp3GFPneg Tconv cells from various tissues such as axial lymph 
node  (LN),  brachial  LN,  cervical  LN,  inguinal  LN,  mesenteric  LN,  spleen,  thymus, 
colon, skin, fat, and liver from Foxp3GFP animals (Figure 30). We observed an 
upregulation  of  Rbpj  mRNA  in  Treg  cells  from  most  tissues.  Furthermore,  we  also 
evaluated the expression of Rbpj in a proteomic dataset previously generated in our lab 
182. We identified RBPJ to be upregulated 1.5 fold in Treg cells with high confidence 
(p=0.056). 
 
 
Figure 30: Rbpj expression levels in Treg and Tconv. 
We investigated the expression strength of Rbpj in Treg vs. Tconv cells on protein and RNA 
level.  The  differential  Treg/Tconv  proteome  dataset  was  derived  from  M.  Barra  et  al. 182, 
whereas  qPCR  data  were  generated  from  FACS-isolated  primary  T  cells.  Part  C  shows  the 
upregulation of Rbpj in Treg cells from various tissues. The data are representative of three or 
more biological replicates, and statistical significance was determined using the non-parametric 
Mann-Whitney t test with *p<0.05, **p<0.01, and ***p<0.001. 
 
7 Results 
  103 
Notch Signaling is not active in steady state Treg cells 
Following  the  observation  that  Rbpj  is  upregulated  in  Treg  cells,  we  investigated  the 
activity  of  the  Notch  signaling  pathway  in  steady-state  Treg  cells  from  a  NotcheGFP 
reporter mouse in Figure 31. In this mouse, an Rbpj response element with four Rbpj 
binding sites and a minimal VS-40 promoter is linked to an eGFP reporter. As soon as 
Notch-receptor cross-linking releases the Notch intracellular domain, it can bind Rbpj at 
the reporter vector and induce GFP expression 176. 
We stained peripheral Treg and Tconv cells from spleen and lymph nodes as well as 
thymic double-negative stage 1-4 thymocytes and measured eGFP intensities. In 
accordance with the literature, Notch signaling was induced following the DN1 stage, 
being highest at the DN2 and DN3 stages and declining again following the DN4 stage. 
In peripheral T cells, we detected virtually no Notch eGFP reporter activity in both Treg 
and  Tconv  cells.  Furthermore,  we  stained  for  the  expression  of  the  Notch1  receptor. 
Again, only DN2 and DN3 thymocytes express high levels of Notch1, whereas mature 
Treg and Tconv cells did not express this receptor under steady-state conditions. The 
Notch1R flow cytometry data were supported by mRNA expression profiling for DN 
thymocytes and peripheral T cells. 
 
Breeding of Foxp3Cre mice with Rbpjfloxed mice specifically eliminates Rbpj in Tregs  
Next,  we  wanted  to  investigate  the  effects  of  an  Rbpj-specific  deletion  in  Treg  cells. 
Therefore, we crossed our Foxp3 YFP-Cre mice with Rbpj floxed mice (see Figure 32). We 
expected a specific deletion between exon 6 and 7, making Rbpj functionally defective. 
In fact, we observed a clear deletion of Rbpj (Exon 6-7) on genomic DNA level from 
FACS-isolated Treg cells, but not Tconv cells, in Foxp3CreRbpjΔ/Δ animals. We 
validated  this  Treg-specific  deletion  also  on  RNA  level,  where  no  differences  were 
observed for Exon 1 Rbpj mRNA, but for Exon 6-7 Rbpj mRNA. Finally, we stained 
FACS-isolated Treg and Tconv cells from Foxp3 CreRbpjΔ/Δ and Foxp3 Cre animals with 
an anti-Rbpj mAb in a Western Blot (Figure 32D). It became obvious that Rbpj protein 
is specifically and exclusively deleted in Foxp3 CreRbpjΔ/Δ Treg cells, but not in Tconv 
cells from these mice. 
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Figure 31: Notch receptor expression and Notch signaling in steady-state Tregs. 
The dot plots in A show representative examples for Notch receptor 1 expression in Treg cells 
from  spleen  and  lymph  nodes  as  well  as  thymus-resident  DN2/3  thymocytes.  The  bar  graphs 
show average expression levels for at least four biological replicates on protein and RNA level. 
In part B, we investigated thymus-derived DN populations and splenic T cell populations for the 
activity of Notch-eGFP in a Notch eGFP reporter mouse. The dot plots show gating strategy and 
eGFP reporter signal intensity for each subpopulation. The bar graph is a representation of the 
analysis  of  four  biological  replicates.  Statistical  significance  was  determined  using  one-way 
ANOVA with Bonferroni post-test (*p<0.05, **p<0.01, and ***p<0.001). 
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Figure 32: Treg-specific Rbpj deletion in Foxp3 CreRbpjΔ/Δ mice. 
Part A illustrates the genomic location of loxp sites in the Rbpj gene. For graph B, we FACS-
isolated Treg and Tconv from Foxp3 CreRbpjΔ/Δ mice and measured the presence of exon 6-7 on 
genomic DNA level via PCR. In C, measured Rbpj RNA expression with exon 1 and exon 6-7 
specific  Taqman  probes  in  Treg  and  Tconv  cells  via  qPCR  (C).  Finally,  we  measured  Rbpj 
protein in Treg and Tconv cells from Foxp3 CreRbpjΔ/Δ and Foxp3 Cre mice via Western Blot (part 
D).  Bar  graphs  depict  band  intensity  as  measured  via  ImageJ  software  and  normalized  to 
background  membrane/plot  staining.  Statistical  significance  was  determined  using  unpaired  t 
tests from three or four biological replicates (*p<0.05, **p<0.01, and ***p<0.001). 
7 Results 
  106 
Some Foxp3CreRbpjΔ/Δ mice spontaneously develop lymphadenopathies and 
inflammation 
Upon  careful  investigation  of  our  breeding,  we  detected  signs  of  skin  irritation  in 
Foxp3CreRbpjΔ/Δ mice. We observed skin abnormalities, indicating skin inflammation, as 
well as abnormalities on digits and tails reminiscent of psoriatic lesions. Some animals 
showed  bloody  lesions  on  ear  and  snout,  probably  due  to  extensive  scratching.  Once 
animals  showed  signs  of  skin  irritation,  we  sacrificed  them  and  analyzed  them  using 
gross pathology and flow cytometry. First, we observed lymphadenopathy of all easily 
accessible lymph nodes (axillary, brachial, cervical, inguinal) except mesenteric lymph 
nodes, which were protected from overt lymphadenopathy (Figure 33). Furthermore, an 
evident  splenomegaly  with  more  than  twofold  increase  in  organ  weight  (age-matched 
WT  controls:  spleen  111.4  ±  8.57  SEM  vs.  KO:  spleen  278.0  ±  12.4  SEM,  p-value 
<0.0001) as well as hepatomegaly with about 1.5 fold increase in weight (age-matched 
WT controls: liver 1263 ± 125.8 SEM vs. KO: spleen 1874 ± 31.72 SEM, p-value = 
0.0026)  was  observed.  No  weight  changes  were  observed  for  kidneys  (WT:  kidneys 
382.0 ± 17.7 SEM vs. KO: kidneys 335.7 ± 24.2 SEM, p-value = 0.1864), heart (WT: 
heart 154.0 ± 19.6 SEM vs. KO: heart 148.6 ± 14.5 SEM, p-value = 0.8246) or overall 
mouse  weight.  Disease  symptoms  as  described  above  presented  from  5  weeks  of  age 
until 23 weeks of age, and breeding was usually discontinued beyond that time point. 
About 50% of Foxp3 CreRbpjΔ/Δ animals had no obvious disease at 23 weeks of age, this 
and  the  fact  that  we  observed  a  widespread  onset  of  disease  (between  5-23  weeks  of 
age) indicates that individual factors can modify the onset or progression. 
Next, we studied Treg cell frequency and absolute Treg numbers in Foxp3 CreRbpjΔ/Δ vs. 
Foxp3Cre animals. We observed a strong increase in Treg frequency in spleen and lymph 
nodes,  from  about  15%  of  CD4  T  cells  in  control  animals  to  30%  and  more  in  sick 
Foxp3CreRbpjΔ/Δ animals (Figure 33C). Additionally, the absolute numbers of Treg cells 
increased  about  tenfold  in  individual  tissues,  as  depicted  in  Figure  33D.  We  can 
conclude  that  the  selective  RPBJ  knockout  in  Treg  cells  causes  pathological  disease 
symptoms  reminiscent  of  autoimmune  disease,  with  a  strong  increase  in  Treg  cell 
frequency and absolute tissue numbers. 
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Figure 33: Consequences of Treg-specific Rbpj deletion in Foxp3 CreRbpjΔ/Δ mice. 
The  picture  in  A  shows  representative  examples  of  splenomegaly  and  lymphadenopathy  in 
Foxp3Cre and sick Foxp3CreRbpjΔ/Δ animals with evident pathological symptoms. These 
symptoms were observed in all sick Foxp3 CreRbpjΔ/Δ animals shown throughout this paper. In B, 
we  show  the  onset  of  disease  of  Foxp3CreRbpjΔ/Δ  and  control  animals  for  the  duration  of  23 
weeks after animal birth. We do not show Foxp3 CreRbpjΔ/Δ animals that did not develop disease 
until  23  weeks  of  age,  which  accounts  to  about  50%  of  all  animals  with  Treg-specific  Rbpj 
deficiency.  Parts  C  and  D  show  Treg  cell  frequency  in  sick  Foxp3CreRbpjΔ/Δ  animals  versus 
Foxp3Cre controls. Each circle represents a single animal, and significance was determined using 
the Mann-Whitney t test (*p<0.05, **p<0.01, and ***p<0.001). Cell count measurements were 
performed in multiple experiments over an extended period of time. 
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Development of a 12-color flow cytometry panel to evaluate Foxp3CreRbpjΔ/Δ mice 
To investigate the systemic effects of Rbpj deletion in Treg cells, we established a 12-
color/16-parameter flow cytometry panel as shown in Figure 34. It utilizes the 
fluorescent parameters GFP/YFP, PE, PE-Cy7, PerCP-Cy5.5, APC, APC-Cy7, BV 421, 
e506, BV 605, BV 711, BUV 395 and BUV 737 along with scatter parameters (FSC-H 
and  FSC-W  as  well  as  SSC-H  and  SSC-W).  We  were  able  to  evaluate  the  absolute 
number  (with  counting  beads)  and  relative  frequencies  of  CD4posCD25posFoxp3YFPpos 
Treg cells, CD4 posCD25negFoxp3YFPneg Tconv cells, CD8 pos cytotoxic T cells, CD19 pos 
B-cells, NK1.1pos NK cells, and CD11b pos and Ly6C pos subpopulations of myeloid cells 
in  one  staining.  Furthermore,  we  included  CD44  and  CD62L  as  markers  for  memory 
phenotype on T and B cells. 
 
Treg  cells  from  Foxp3CreRbpjΔ/Δ  animals  express  Foxp3,  Helios,  GITR,  CTLA-4, 
and Nrp-1 
Since previous literature suggested that Treg cells deficient in Rbpj overexpress Treg-
specific proteins such as Helios or Nrp-1, we were interested in the characterization of 
these Treg cells via flow cytometry. Therefore, we double-stained Treg cells and Tconv 
cells  from  various  lymph  nodes  and  spleen  of  sick  Foxp3 CreRbpjΔ/Δ  and  Foxp3Cre 
animals  for  Foxp3  and  other  key  Treg  markers  (Figure  35).  First,  we  analyzed  the 
expression  of  Helios,  a  marker  of  thymic-derived  Treg  cells,  in  Treg  and  Tconv 
populations.  No  significant  differences  in  Rbpj-deficient  Treg  cells  were  observed. 
Next,  we  measured  the  expression  of  GITR.  Interestingly,  Tconv  cells  from  sick 
Foxp3CreRbpjΔ/Δ mice had slightly increased GITR levels, indicating active signaling via 
the TCR and heightened T-cell activation status 52. Also, Rbpj-deficient Treg cells seem 
to  have  slightly  elevated  GITR  levels.  Staining  for  intracellular  CTLA-4  revealed 
increased expression levels in Treg cells from axial and brachial lymph nodes in sick 
Foxp3CreRbpjΔ/Δ,  but  no  other  lymphoid  tissues.  Expression  of  Nrp-1  and  CD86  was 
unaffected by the Treg-specific Rbpj deletion. Taken together, our data suggest that key 
proteins  implicated  in  Treg  suppressive  capacity  and  Treg  lineage  identification  are 
either expressed equally or increased in Treg cells from Foxp3 CreRbpjΔ/Δ mice. The pro-
inflammatory  environment  in  sick  Foxp3CreRbpjΔ/Δ  mice  could  cause  some  of  those 
effects. In general, our data don’t suggest that RBPJ-deficient Treg cells lose 
characteristic Treg markers, but maintain their Treg signature.  
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Figure 34: Overview of extended immunophenotyping panel and gating strategy. 
We here show our 12-color/16-parameter flow cytometry panel used for the immunophenotypic 
evaluation in this study. Part A shows our gating strategy for cell counting of B cells, CD8 T 
cells,  Treg  cells,  Tconv  cells,  NK  cells,  and  myeloid-lineage  cells.  The  upper  rectangle  is  a 
representative example of a staining with wild type animal splenocytes followed by a staining 
with  splenocytes  from  a  sick  Foxp3 CreRbpjΔ/Δ  animal  with  apparent  signs  of  pathology.  In 
section  B,  we  show  the  expression  of  memory  markers  /  activation  markers  on  Treg  cells, 
Tconv cells, CD8 T cells, B cells and NK cells. A statistical validation follows in later figures.  
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Figure 35: Expression of key Treg proteins in RBPJ KO vs. WT Treg / Tconv cells. 
We stained for key Treg surface and intracellular proteins. We compared the presence of these 
specific markers in Treg cells as well as their absence in Tconv cells from sick Foxp3 CreRbpjΔ/Δ 
and Foxp3 Cre animals. In part A, we stained for the intracellular protein Helios, in B for the cell 
surface molecule GITR, in C for the cell surface receptor CTLA-4, in D for Neuropillin-1, and 
in E for CD86. Statistical significance was determined using unpaired t tests from three to eight 
biological replicates measured in separate experiments (*p<0.05, **p<0.01, and ***p<0.001). 
Due to separate measurements with individual machine settings, evaluation of median 
fluorescence intensity for individual protein stainings is not feasible.  
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Treg  cells  from  Foxp3 CreRbpjΔ/Δ mice  are  suppressive  and  demethylated  at  the 
CNS2 
To determine whether Treg cells from sick Foxp3 CreRbpjΔ/Δ mice lose their suppressive 
capacity  and  thereby  promote  the  pro-inflammatory  environment  observed  in  these 
animals,  we  performed  an  in-vitro  suppression  assay  with  congenically  labeled  T-
responder cells and MHCII-positive APCs (Figure 36). Our data demonstrate that both 
Treg cells from Foxp3CreRbpjΔ/Δ and Foxp3Cre animals were suppressive in-vitro. 
Furthermore,  we  analyzed  the  methylation  of  the  CNS2  /  TSDR  region,  which  is 
important for Treg cell lineage stability 36, 127, 183. No differences were detected between 
Rbpj-deficient  and  -proficient  Treg  cells,  both  displaying  strong  demethylation  at  the 
TSDR locus. Tconv cells were hypermethylated at this site, as expected. 
 
Treg cells from Foxp3 CreRbpjΔ/Δ mice are clonally diverse 
To rule out single-clone expansion or malignant transformation of Rbpj-deficient Treg 
cells, we isolated genomic DNA from Treg cells of sick Foxp3 CreRbpjΔ/Δ and Foxp3 Cre 
animals. DNA was subjected to T-cell receptor sequencing and identification of TCR-β 
chains.  In  total,  we  identified  27718  ±  4689  (KO)  vs.  39460  ±  6306  (WT)  uniquely 
rearranged  loci,  indicating  a  modest  decrease  in  clonality  in  Treg  cells  from  sick 
Foxp3CreRbpjΔ/Δ  mice  (p=0.065)  This  translates  also  in  changed  productive  clonality 
with  0.1300  ±  0.0176  (KO)  vs.  0.0506  ±  0.0091  (WT,  p<0.01),  indicating  that  Treg 
samples from sick Foxp3 CreRbpjΔ/Δ mice have slightly more pre-dominant clones. Our 
summary in Figure 36C shows the most abundant clones for J01 and J02 chains, with 
only  minor  differences  observed  between  Treg  cells  from  sick  Foxp3CreRbpjΔ/Δ  and 
Foxp3Cre animals. From this, we can conclude that Treg cells from sick Foxp3 CreRbpjΔ/Δ 
animals  retain  their  polyclonal  TCR  repertoire,  ruling  out  malignant  conversion  or 
single-clone expansion as reason for the increased Treg frequency. 
 
Treg cells from Foxp3 CreRbpjΔ/Δ mice do not produce pro-inflammatory cytokines 
We stimulated Treg cells from sick Foxp3CreRbpjΔ/Δ and Foxp3Cre animals with 
PMA/Ionomycin and measured  intracellular expression of pro-inflammatory (IFN-γ, IL-
2, TNF-α) and anti-inflammatory (IL-10) cytokines. Again, no differences were 
observed between Rbpj-deficient and -proficient Treg cells, indicating that the deletion 
of Rbpj in Treg cells does not mediate a pro-inflammatory conversion of this cell type. 
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Figure 36: Comparison of Treg footprint and function in Rbpj-deficient Treg cells. 
We performed an in-vitro suppression assay (A) with Treg cells from sick Foxp3 CreRbpjΔ/Δ (left) 
and Foxp3 Cre (right) mice. In B, we measured CG methylation at the TSDR in the Foxp3 gene 
promoter.  The  bar  graphs  are  representative  of  three  biological  replicates.  Furthermore,  we 
assessed clonal diversity via TCR sequencing of Treg cells (C). The graph represents the clonal 
variety of J01 and J02 chains, respectively. In part D, Treg cells were isolated and incubated 
with or without PMA/Ionomycin in the presence of transport inhibitors. Intracellular cytokine 
expression was measured by flow cytometry. The bar graphs represent four biological replicates 
in two separate experiments. Statistical testing was performed with an unpaired student’s t test 
with ns p>0.05 and ***p<0.001.  
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The selective deletion of RBPJ in Treg cells decreases cell death by apoptosis 
Animals with a Treg-specific Rbpj deficiency display increased Treg cell number and 
frequency in spleen and lymph nodes. Since these cells do not express more Nrp-1 or 
Helios,  we  can  rule  out  peripheral  conversion  of  Tconv  into  Treg  as  source  of  the 
largely  increased  Treg  cell  compartment.  Since  increased  proliferation  or  reduced 
apoptosis  of  RbpjΔ/Δ  Treg  cells  could  be  responsible  for  elevated  cell  numbers,  we 
stained for Caspase-3 expression in Treg and Tconv cells from healthy, but advanced-
age Foxp3CreRbpjΔ/Δ, sick Foxp3CreRbpjΔ/Δ animals, and Foxp3Cre controls. We observed 
a  strong  decrease  in  Caspase-3  expression,  which  correlated  with  an  increase  in  Treg 
frequency  on  a  per-animal  basis  (Figure  37  A-B-C).  To  validate  these  data,  we 
measured Annexin-V expression on Treg cells from sick Foxp3 CreRbpjΔ/Δ mice (Figure 
37 D-E). Based on Hoechst cell cycle measurements, we did not detect any differences 
between WT and KO Treg cells for their cycling behavior (part G) in sick animals, but a 
strongly significant increase in KI-67 expression indicates recent cell divisions (part F). 
 
B cells increase in number, get activated and produce autoimmune antibodies 
Using our extended 12-color immunofluorescence panel described earlier, we 
investigated the number and activation status of B cells in sick Foxp3 CreRbpjΔ/Δ animals 
vs. controls (Figure 38). First, we stained for the expression of L-selectin (CD62L), a 
protein usually expressed on naive T cells and required to extravasate into secondary 
lymphoid  tissues.  Interestingly,  we  could  observe  a  significant  decrease  of  L-selectin 
expression on B cells from lymph nodes and spleen, indicating activation and 
differentiation into a memory/effector-like phenotype. Also, the overall B-cell number 
was  steadily  increased  in  lymphoid  tissues.  Next,  we  analyzed  levels  of  Ig  subtype 
antibodies in the peripheral blood serum of sick Foxp3 CreRbpjΔ/Δ and control mice. We 
observed  a  strong  increase  in  IgG1  and  IgE  antibody  secretion,  while  IgG3  was 
downregulated,  indicating  a  class  switch  as  classically  induced  by  IL-4  treatment 1. 
Finally, we measured the quality of peripheral blood serum to bind SDS-PAGE 
separated  gross  protein  isolates  from  various  organs  of  RAG2  KO  animals.  Our  data 
indicate  that,  at  least  for  some  organs,  autoimmune  antibodies  are  present  in  the 
peripheral blood serum of sick Foxp3CreRbpjΔ/Δ animals, again indicating B-cell 
activation and maturation.  
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Figure  37:  Analysis  of  apoptosis  and  cell  cycle  in  T  cells  from  Foxp3CreRbpjΔ/Δ 
mice. 
Graph A shows representative dot plots for Caspase-3 expression in Treg and Tconv cells from 
sick Foxp3CreRbpjΔ/Δ vs. Foxp3 Cre cells. In part B, we analyzed the Caspase-3 expression in Treg 
cells  from  old,  but  healthy  Foxp3 CreRbpjΔ/Δ  mice  (age  >  18  weeks)  and  compared  to  age-
matched wild type controls. In parallel, we measured the percentage of Treg cells among CD4 pos 
T cells and correlated the Caspase-3 downregulation to an increase in Treg percentage (C). For 
further  validation,  we  also  stained  Annexin-V  on  Treg  cells  from  sick  Foxp3 CreRbpjΔ/Δ  vs. 
Foxp3Cre controls (D and E). Finally, we investigated the cell cycle status of Treg cells (G) and 
their expression intensity for KI-67 (F). Dot plots are representative of at least three biological 
replicates. Statistical testing was performed with an unpaired student’s t test with ns p>0.05 and 
*p<0.05, **p<0.01, and ***p<0.001. 
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Figure 38: B cell tissue frequency and antibody secretion in Foxp3CreRbpjΔ/Δ mice. 
First, we investigated the downregulation of CD62L on B cells from sick Foxp3 CreRbpjΔ/Δ vs. 
Foxp3Cre mice isolated from spleen and lymph nodes (representative dot plots in A). In B, we 
quantified  the  absolute  number  of  B  cells  in  various  tissues  including  the  axial  lymph  node, 
brachial LN, cervical LN, inguinal LN, mesenteric LN and spleen. The lower graph depicts the 
increase of memory-type B cells (CD62 low) in the respective tissues. The visualized data are 
representative of at least seven biological replicates and at least five independent experiments. 
In  C,  we  measured  the  concentration  of  Ig  subtypes  in  peripheral  blood  serum  of  seven  sick 
Foxp3CreRbpjΔ/Δ mice and respective WT controls with ELISA. Blood serum was also used in D 
to assess autoantibody presence against specific tissues isolated from RAG KO mice in Western 
Blots. Statistical significance was determined using the Mann-Whitney t test (*p<0.05, 
**p<0.01, and ***p<0.001). 
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CD4pos  Tconv  cells  express  memory  markers,  increase  in  tissue  frequency  and 
produce cytokines 
Since B cells showed strong signs of activation and effector function, we stained for the 
expression of CD44 and CD62L on Tconv cells from sick Foxp3 CreRbpjΔ/Δ vs. Foxp3Cre 
mice  (Figure  39).  We  observed  a  significant  downregulation  of  L-selectin  on  Tconv 
cells from sick mice, along with an upregulation of CD44. This is a strong indicator of 
antigen-experience  and  maturation  of  naive  T  cells  into  effector  T  cells 184.  A  strong 
upregulation of CD44 was also observed in Treg cells, again indicating a pro-
inflammatory environment leading to activation of both effector T cells and regulatory 
T cells. When investigating tissue numbers of Tconv cells, a steady increase in lymph 
node  and  spleen  tissues  was  observed,  indicating  effector  T  cell  proliferation  and 
activation.  Finally,  we  measured  the  expression  of  pro-inflammatory  cytokines  by 
Tconv cells upon PMA/Ionomycin stimulation. Not surprisingly, we found that Tconv 
cells  from  sick  Foxp3CreRbpjΔ/Δ  mice  produce  significantly  more  IL-2,  IL-4  (data  not 
shown),  IL-10,  and  IFN-γ  than  their  wild  type  control  counterparts.  Taken  together, 
these data indicate strong activation of Tconv cells and a likely differentiation into T H 
effector subsets. 
 
CD8pos T cells, myeloid-derived cells and NK cells respond to the pro-
inflammatory environment 
In Figure 40, we show strongly increased numbers of CD8 pos cytotoxic T cells in sick 
Foxp3CreRbpjΔ/Δ  mice  (A).  Furthermore,  CD8 pos  cytotoxic  T  cells  in  these  animals 
express  CD44,  a  marker  of  antigen  experience,  at  a  very  high  percentage.  It  can  be 
inferred  that  CD8pos  T  cells,  just  like  Treg,  Tconv  and  B  cells,  develop  into  effector 
cells  in  the  pro-inflammatory  environment  generated  in  sick Foxp3CreRbpjΔ/Δ  animals. 
Also,  myeloid-origin  cells  respond  to  this  environment  (B).  We  can  detect  a  steady 
increase of CD11bposLy6Cpos myeloid cells (granulocytes and monocytes) into 
lymphoid tissues. Being usually a rather scarce population, they now account for up to 
20%  of  CD3negNK1.1neg  cells.  Finally,  we  also  measured  NK  cell  numbers  and  their 
activation  status  by  CD25  expression  (C).  A  modest,  but  significant  increase  in  NK 
cells numbers in sick Foxp3 CreRbpjΔ/Δ mice was detected, and they express more CD25, 
which  indicates  that  the  innate  immune  system  responds  to  the  pro-inflammatory 
environment in these mice as well. 
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Figure 39: Tconv cell number, memory marker expression and cytokine secretion. 
In A, we show representative dot plots illustrating the downregulation of CD62L and 
upregulation of CD44 on Treg and Tconv cells from sick Foxp3 CreRbpjΔ/Δ mice. The bar graphs 
are representing at least seven biological replicates in at least five separate experiments. From 
the same dataset, we calculated the absolute number of Tconv cells in various lymphoid tissues 
in  B.  Finally,  we  stimulated  Tconv  cells  with  PMA/Ionomycin  and  checked  their  cytokine 
secretion  profile  in  C.  Statistical  significance  was  determined  using  the  Mann-Whitney  t  test 
(*p<0.05, **p<0.01, and ***p<0.001).  
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Figure 40: CD8 T cell, CD11b posLy6Cpos myeloid cell and NK cell analysis. 
We  measured  the  absolute  tissue  frequency  of  CD8 pos  T  cells  in  sick  Foxp3 CreRbpjΔ/Δ  vs. 
Foxp3Cre animals (A), and quantified the expression of CD44 as a marker of antigen exposure. 
In B, we identified CD11bposLy6cpos myeloid cells and quantified their increase in both 
percentage and absolute numbers in several tissues. Finally, we investigated NK-cell numbers in 
C, and quantified their activation status via CD25 staining as shown in the dot plots. Bar graphs 
represent at least 7 biological replicates assayed in three or more individual experiments, with 
significance elucidation by Mann-Whitney t testing (*p<0.05, **p<0.01, and ***p<0.001). 
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Pathological evaluation of different tissues reveals skin inflammation 
We  evaluated  tissue  architecture  and  signs  of  autoimmune  infiltrations  in  specimens 
from sick Foxp3 CreRbpjΔ/Δ and Foxp3 Cre mice via Haematoxylin and Eosin staining of 
formalin-fixed  tissues  (Figure  41).  In  collaboration  with  a  pathologist,  we  examined 
specimens from the lymphatic system (axial, brachial, cervical, inguinal lymph nodes; 
spleen), the cardiovascular system (heart), respiratory system (lung), digestive system 
(small  intestine,  large  intestine,  stomach),  endocrine  system  (pancreas,  adrenal  gland, 
salivary gland, kidneys), nervous system (brain, eyes) as well as liver. Furthermore, we 
embedded skin pieces with obvious inflammation, such as snout, ears or patches of skin, 
and  compared  them  with  non-inflamed  tissues.  While  this  in-depth  analysis  is  still 
ongoing,  a  general  conclusion  is  that  most  organs  did  not  show  signs  of  lymphocyte 
infiltration.  The  liver,  despite  being  increased  in  weight  about  1.5  fold,  had  some 
cellular  infiltrates,  but  would  not  classify  as  inflamed  (hepatitis).  Lymph  nodes  and 
spleen were greatly enlarged, but maintained their tissue architecture. We are currently 
staining for B cells to evaluate the germinal center architecture more closely. The only 
obvious  site  of  inflammation  was  skin,  where  infiltrates  were  present,  and  overall 
tissues architecture was severely compromised. While most organs are untouched, skin 
is heavily affected and might enhance systemic disease by the re-circulation of cells via 
the lymph system. We also tested peripheral blood of these mice via standard clinical 
small panel testing (data not shown). 
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Figure  41:  Pathological  evaluation  of  organs  and  tissues  from  Foxp3 CreRbpjΔ/Δ 
mice. 
We isolated organs from sick Foxp3 CreRbpjΔ/Δ and Foxp3 Cre mice and stored them in formalin. 
Tissues were then embedded, cut, and H&E stainings were performed. Photographs were taken 
with a Zeiss AxioPlan microscope. Tissue morphology and architecture was evaluated optically. 
A: Small intestine; B: Large intestine; C: Stomach; D: Kidneys; E: Lungs; F: Salivary Gland; G: 
Spleen; H: Cervical LN; I: Skin, with patches of normal (left) and inflamed skin (right) from the 
same animal; J: Liver, with two images from different samples of the same genetic background. 
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Treg cells from sick Foxp3 CreRbpjΔ/Δ mice display a specific gene signature 
We  isolated  Treg  and  Tconv  cells  from  healthy  young  Foxp3CreRbpjΔ/Δ  and  Foxp3Cre 
age-matched  controls  and  subjected  them  to  gene  expression  profiling  (Figure  42A). 
We  observed  only  one  gene,  Deltex-1,  to  be  significantly  downregulated  in  Rbpj-
deficient  Treg  cells.  Since  the  Illumina  bead  chip  array  used  for  gene  expression 
profiling does not contain a probe for Rbpj, its loss cannot be shown in this plot. The 
strong  downregulation  of  Dtx-1  was  confirmed  by  qPCR  (data  not  shown,  p<0.001). 
When comparing Rbpj-deficient or –proficient Treg cells to respective Tconv cells, the 
typical Treg-specific signature with upregulation of Foxp3 and Nrp1 and 
downregulation  of  Pde3b  can  be  appreciated.  In  contrast  to  this,  Dtx-1  is  specifically 
downregulated  in  RBPJ-deficient  Treg  cells,  but  not  Tconv  cells.  In  Figure  42B,  we 
now compared the gene expression profile of Treg cells isolated from sick 
Foxp3CreRbpjΔ/Δ animals versus healthy heterozygous control animals. Now, a distinct 
signature can be identified. While Dtx-1 remains downregulated, more factors such as 
Bcl-2, CD86 or CCR7 follow this trend. Furthermore, several proteins are upregulated, 
such  as  the  IL7R,  KLRG-1  or  ITGAE.  Since  sick  Foxp3CreRbpjΔ/Δ  mice  display  an 
inflamed environment with lymphadenopathy and splenomegaly, we can infer that parts 
of the specific Treg signature are based on their elevated activation status. This is also 
true for gene expression in Tconv cells, where we now detect several factors to be up – 
or downregulated in sick vs. healthy mice. To evaluate whether the discrete signature 
identified  in  Treg  cells  from  sick  Foxp3CreRbpjΔ/Δ  mice  is  already  present  in  young 
healthy  Foxp3CreRbpjΔ/Δ  mice,  we  overlaid  upregulated  genes  of  the  Foxp3CreRbpjΔ/Δ 
sick  Treg  signature  with  the  gene  expression  data  of  young  healthy  animal  Rbpj-
deficient  Treg  cells.  We  observed  that  a  significant  proportion  of  genes  were  already 
upregulated  in  Treg  cells  from  otherwise  healthy  Foxp3CreRbpjΔ/Δ  animals,  indicating 
that  the  signature  and  its  molecular  consequences  are  already  prepared,  but  have  not 
caused pathological effects yet. The same observation has been made for genes 
specifically downregulated in Treg cells from sick Foxp3 CreRbpjΔ/Δ mice. In Figure 43, 
we confirm part of the Rbpj-deficient Treg signature via flow cytometry. Furthermore, 
we show top 40 up – and downregulated genes in an unsupervised hierarchical 
clustering. 
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Figure 42: Gene expression comparison of T cells from Foxp3 CreRbpjΔ/Δ mice. 
Treg and Tconv cells were isolated from spleen using FACS and subjected to gene expression 
profiling with Illumina Bead Chip technology. In A, we compared gene expression profiles of 
Treg and Tconv cells isolated from healthy Foxp3 CreRbpjΔ/Δ and Foxp3 Cre animals of young age 
(age  <  6  weeks).  In  B,  we  cross-compare  Treg  cells  from  advanced-age  sick Foxp3CreRbpjΔ/Δ 
mice (age > 12 weeks) and young healthy Foxp3 Cre mice (age < 6 weeks). Each plot represents 
averaged  gene  expression  data  from  three  biological  replicates  (age  <  6  weeks)  or  four 
biological  replicates  (Foxp3CreRbpjΔ/Δ  sick  mice  >  12  weeks),  with  p-values  calculated  with  a 
two-tailed  student’s  t  test.  Numbers  indicate  genes  with  >2  or  <0.5  fold  average  differential 
expression and p<0.05. Next, we overlaid upregulated genes (part C, left side) and 
downregulated genes (part C, right side) in Treg cells from Foxp3 CreRbpjΔ/Δ sick mice onto the 
gene signature of young healthy Foxp3 CreRbpjΔ/Δ mice. Numbers indicate the number of genes 
that are up-or downregulated in the young animal Treg signature, respectively, and p-values are 
based on chi-square testing. 
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Figure 43: Analysis and verification of the Rbpj-specific Treg gene signature. 
Graph A shows a p-value vs. gene expression comparison between Treg cells from advanced-
age sick Foxp3 CreRbpjΔ/Δ mice (>12 weeks of age) and healthy Foxp3 Cre mice (6 weeks of age). 
In  B,  we  used  the  top  40  up-  and  downregulated  genes  (without  p-value  correction)  and 
subjected them to unsupervised hierarchical clustering. Red indicates high expression strength. 
In C, we confirmed gene expression data from A and B via flow cytometry. Treg and Tconv 
cells  from  spleens  of  sick  Foxp3CreRbpjΔ/Δ  mice  and  Foxp3Cre  controls  were  stained  for  IL7R 
expression.  The  bar  graphs  represent  at  least  4  (thymus)  or  6  (spleen)  replicates  in  several 
separate experiments. Statistical testing in A and C was performed with a two-tailed unpaired 
students t test (*p<0.05, **p<0.01, and ***p<0.001). 
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Treg and Tconv cells from sick Foxp3 CreRbpjΔ/Δ mice are TH1, TH2, and TH17 prone 
We used the microarray data from Treg and Tconv cells isolated from sick 
Foxp3CreRbpjΔ/Δ and Foxp3Cre cells and calculated over – and under expressed genes, as 
described  earlier  (23948  downregulated,  22288  upregulated).  We  then  overlaid  this 
signature  with  genes  specifically  upregulated  in  TH1,  TH2,  and  TH17  differentiated  T 
cells.  Gene  expression  data  for  cytokine-induced  T H1,  TH2,  and  T H17  cells  were 
published earlier. Then, we calculated genes specifically upregulated in the respective 
T-cell  subset,  which  yielded  between  200  and  400  T-subset  specific  genes.  Next,  we 
looked  for  T-subset  specific  upregulated  genes  in  our  microarray  data.  Results  are 
shown in Figure 44. Interestingly, we identified that most T H-subset upregulated genes 
are  also  upregulated  in  Treg  cells  from  Foxp3CreRbpjΔ/Δ mice  (77%  for  TH1,  69%  for 
TH2, and 75% for T H17) compared to Treg cells from Foxp3 Cre mice. Furthermore, this 
lineage skewing is also present in Tconv cells from sick Foxp3 CreRbpjΔ/Δ mice. To make 
sure that our dataset is not biased, we generated Foxp3CreNICDLSL mice, which 
constantly  express  the  Notch  intracellular  domain,  and  checked  the  gene  signature  in 
healthy young mice (6 weeks) against Foxp3 Cre mouse Treg cells. We then overlaid the 
TH1, TH2, and TH17 specific genes and evaluated bias. Since these mice are healthy, and 
did  not  display  signs  of  autoimmunity  or  T-cell  activation,  no  TH  bias  was  observed: 
TH1-, 2-, or 17- upregulated genes were distributed equally, with 50% for T H1, 56% for 
TH2, and 53% for T H17. Statistical evaluation by χ 2 testing still displays a significant 
difference,  what  is  based  on  the  strong  upregulation  of  genes  in  Treg  cells  from 
Foxp3CreNICDLSL mice compared to Foxp3Cre mice (17105 downregulated, 28986 
upregulated). The signature overlays indicate that our T H-subset bias is specific for the 
pro-inflammatory scenario in sick Foxp3 CreRbpjΔ/Δ mice. Furthermore, we also stained 
for GATA-3 and T-bet, lineage-defining transcription factors for both T H1 (T-bet) and 
TH2  (GATA-3)  subsets,  in  Treg,  Tconv  and  CD8  T  cells  from  sick  Foxp3CreRbpjΔ/Δ 
mice. Interestingly, all three T cell types show enriched expression in these factors. This 
observation runs in concert with previous data, where we showed that Tconv cells from 
these mice more readily produce IL-10 and IFN-γ, but also IL-4. Taken together, our 
observations indicate that, in sick Foxp3CreRbpjΔ/Δ mice, autoimmune pathology evolves 
not  only  due  to  the  expansion  of  one  specific  TH  subset,  but  rather  by  a  systemic, 
unbiased expansion of pro-inflammatory T cells. 
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Figure 44: Analysis of TH1, TH2, and TH17 lineage-defining gene expression. 
Graph  A  shows  a  gene  expression  comparison  between  Treg  cells  from  advanced-age  sick 
Foxp3CreRbpjΔ/Δ mice and healthy Foxp3 Cre heterozygous mice, as shown already in Figure 42 . 
Here,  we  overlaid  it  with  genes  specifically  upregulated  in  TH1  (left),  TH2  (middle)  or  TH17 
(right) differentiated cells. Numbers indicate how many TH-subset regulated genes are 
upregulated  also  in  Treg  cells  from  sick  Foxp3CreRbpjΔ/Δ  mice  (red)  or  not  (blue).  In  B,  we 
repeated  this  approach  with  the  Tconv  cell  signature  from  sick  Foxp3CreRbpjΔ/Δ  and  Foxp3Cre 
mice, and in C we performed this comparison with Treg gene signatures from Foxp3 CreNICDLSL 
and Foxp3 Cre mice. In D and E, we stained for key T H1 and T H2 proteins in Treg, Tconv and 
CD8 T cells from sick Foxp3 CreRbpjΔ/Δ mice and Foxp3 Cre mice. 
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The IL7R links KLRG-1 expression and proliferation of Rbpj-deficient Treg cells 
In our gene expression profiling, we detected KLRG-1 to be overexpressed in RBPJ-
deficient Treg cells isolated from sick Foxp3 CreRbpjΔ/Δ mice. Therefore, we performed 
flow  cytometric  staining  for  this  marker,  along  with  the  IL7R  (Figure  45).  Our  data 
clearly  indicate  that  the  IL7Rhigh  expressing  Treg  cells  are  also  positive  for  KLRG-1, 
which could indicate that this population is indeed responsible for the massive cellular 
expansion of Treg cells observed in these mice. Co-staining for IL7R and KI-67, which 
shows that only IL7R high Treg cells drive the massive proliferation in Foxp3 CreRbpjΔ/Δ 
animals, supports this notion. KI-67 is present during all active cell cycle phases (G1, S, 
G2,  mitosis),  but  is  completely  absent  in  resting  cells 185.  Therefore,  we  sought  to 
determine the molecular link between IL7R expression and Treg cell numbers in Figure 
46.  First,  we  measured  IL7R  expression  in  T-conventional  cells  of  young  healthy 
Foxp3CreRbpjΔ/Δ  and  Foxp3Cre  animals,  older  healthy  Foxp3 CreRbpjΔ/Δ  and  Foxp3Cre 
animals,  and  sick  Foxp3CreRbpjΔ/Δ  animals  with  age-matched  Foxp3Cre  controls.  We 
observed no difference in IL7R expression in Tconv cells. We also evaluated 
CD25posFoxp3YFPpos Treg cells from all three groups for their IL7R expression. 
Interestingly, an about two-fold increase in IL7R high Treg cell frequency can already be 
observed in otherwise healthy Foxp3CreRbpjΔ/Δ animals. Furthermore, in sick 
Foxp3CreRbpjΔ/Δ animals, more than 80% of Treg cells display the IL7R at high levels. 
When we correlated the frequency of IL7R high expressing Treg cells with the frequency 
of Treg cells of CD4 T cells in all three groups of Foxp3 CreRbpjΔ/Δ animals, we observe 
a reasonably good correlation between IL7R expression and increase in Treg frequency 
(Figure 46C, R 2 = 0.6543). Therefore, we now sought to investigate the molecular link 
between  the  absence  of  Rbpj  in  Treg  cells  from  Foxp3 CreRbpjΔ/Δ  animals  and  the 
expression of the IL7R. As already mentioned in the introduction, binding of Rbpj to 
the IL7R-promoter has been investigated already. To proof this binding, we performed 
Chromatin IP experiments with an anti-Rbpj antibody followed by real-time PCR based 
detection  putative  Rbpj  binding  sites  on  the  IL7R  gene  (Figure  46D).  Therefore,  we 
measured putative IL7R binding-site DNA in Rbpj-antibody based 
immunoprecipitations with Rbpj-deficient Treg cells (control) and wildtype Treg cells. 
We then calculated the relative binding of Rbpj to the respective fragment in Treg cells 
from  Foxp3Cre  mice  vs.  Treg  cells  from  Foxp3CreRbpjΔ/Δ  mice.  To  this  end,  we  could 
show that Rbpj indeed binds the IL7R gene, probably downmodulating its activity in the 
absence of active Notch signaling. 
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Figure 45: Correlation between IL7R, KLRG-1 and KI-67 expression. 
We  stained  splenic  Treg  and  Tconv  cells  from  sick  Foxp3 CreRbpjΔ/Δ  and  Foxp3Cre  mice  for 
expression of CD127 (IL7R), KLRG-1 and KI-67. In A, we show representative dot plots for 
KLRG-1  expression  vs.  CD127  expression.  The  histograms  depict  expression  of  KLRG-1  in 
pre-gated  IL7Rhigh  and  IL7Rlow  Treg  and  Tconv  cells  from  six  sick Foxp3CreRbpjΔ/Δ  and  eight 
Foxp3Cre  controls.  In  B,  we  evaluate  the  expression  of  KI-67  vs.  CD127.  The  bar  graphs 
represent 4 or more biological replicates in several separate experiments. Statistical testing in 
was  performed  using  a  two-tailed  unpaired  students  t  test,  with  *p<0.05,  **p<0.01,  and 
***p<0.001. 
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Figure 46: Molecular link between Treg cell proliferation and IL7R expression.  
In  A,  we  plot  IL7R  expression  in  Treg  and  Tconv  from  young  healthy  Foxp3CreRbpjΔ/Δ  and 
Foxp3Cre, advanced-age healthy Foxp3 CreRbpjΔ/Δ and Foxp3 Cre mice or sick Foxp3 CreRbpjΔ/Δ and 
age-matched Foxp3 Cre mice. Statistical evaluation was performed using a two-tailed student’s t 
test.  The  IL7R  expression  data  were  correlated  with  Treg  frequency  in  part  B,  and  a  linear 
regression fitting has been performed. R Square and significance values have been calculated 
using  Prism  software.    In  C,  we  show  the  RBPJ  binding  motif  and  its  forward  and  reverse 
orientation in the IL7R gene. In D, we show results of a Chromatin IP with an anti-Rbpj mAb 
and Rbpj-deficient Treg cells as well as wild type Treg cells. We plot mean relative binding of 
wild type Treg over Rbpj-deficient Treg cells for binding sites described in C. 
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8 Discussion 
Whole-genome and amplicon-based sequencing reveals differential methylation of 
the Foxp3 gene 
In this thesis, we first investigated the molecular control of Foxp3, the master regulator 
of Treg cells, on an epigenetic level. We asked several questions dealing with the CpG 
methylation  status  of  the  Foxp3  gene,  and  addressed  those  with  our  amplicon-  and 
whole genome-based approaches. First, we wanted to evaluate whether the 
TSDR/CNS2  is  the  only  region  with  a  Treg-specific  demethylation  pattern.  Our  data 
clearly indicate that there is at least one additional Treg-specific demethylated region, 
just downstream of the Foxp3 promoter (Region 3). We confirmed that this region is 
demethylated specifically once thymic Treg cells express Foxp3, but not in thymic Treg 
cell precursors. Furthermore, its demethylation pattern is stable in antigen-experienced 
Treg cells, and independent of the Foxp3 protein expression strength as measured with 
our Foxp3GFP reporter model. Interestingly, our whole-genome sequencing dataset not 
only  confirms  the  selective  demethylation  of  region  3  and  its  blueprint,  the  TSDR 
(Region  4),  in  Treg  cells,  but  also  the  extent  of  this  region  –  indeed,  the  whole  first 
Foxp3  intron  carries  a  Treg-specific  demethylated  phenotype,  which  has  not  been 
detected by previous MeDIP-based sequencing approaches 44. In contrast to this, it was 
surprising to find the 5’ neighboring gene of Foxp3, Ppp1r3f, completely demethylated 
at both its promoter and the first exon. Deeper bioinformatical analysis will reveal the 
complexity  of  the  epigenetic  regulation  of  such  genes  in  combination  with  gene 
expression profiling. 
Another  important  question  was  the  analysis  of  the  methylation  status  of  the  Foxp3 
promoter and its exons in Treg cells. Our data indicate a dichotomy between both areas: 
the  promoter  is  demethylated  not  only  in  Treg  cells,  but  also  Foxp3  non-expressing 
Tconv  cells  and  CD8pos  T  cells.  This  indicates  that  the  promoter  per  se  is  open  for 
binding  by  the  transcriptional  machinery  once  proper  Foxp3-inducing  transcription 
factors are presented, as discussed in the following paragraph. Furthermore, additional 
epigenetic  mechanisms  such  as  histone  modifications  and  nucleosome  positioning 
might  add  another  layer  of  epigenetic  control  of  the  promoter  region.  A  study  by 
Ohkura  and  co-workers  investigated  histone  modifications  at  the  Foxp3  Treg-specific 
demethylated  region,  and  identified  a  euchromatic  histone  marker  (H3K4me3)  at  this 
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region, keeping it in a transcriptionally permissive state 44. Unfortunately, the promoter 
was  not  analyzed  in  this  study.  The  authors  also  looked  at  highly  methylated  Foxp3 
exons (here: exon 11). They were shown to be both methylated at their CG 
dinucleotides  and  to  lack  H3K4me3  trimethlyation  at  the  histones,  indicating  a  non-
permissive  state  for  gene  expression  induction.  Again  validating  our  amplicon-based 
data with the whole-genome analysis, we identified that almost all exonic regions of the 
Foxp3 gene are highly methylated: The Treg-specific demethylation pattern is not only 
absent  in  exon  6  and  8  (region  5  and  6),  but  most  of  the  protein-coding  exons  and 
introns of Foxp3. As discussed in the introduction, more than 95% of CG dinucleotides 
in  non-regulatory  sequences  are  methylated  to  increase  genetic  stability 106;  we  can 
detect the same for Foxp3 coding regions. This highlights the importance of 
demethylational events in the Foxp3 promoter and intron 1. 
When is the Treg-specific demethylation pattern established? Our results indicate that 
T-cell receptor based signals, inducing the cytokine-dependent (late) Treg precursor, are 
not immediately involved in the demethylation events. Once late Treg precursor cells 
receive stimulation by common γ-chain cytokines, Foxp3 expression and Treg-specific 
demethylation  is  induced.  This  would  indicate  that  both  programs  are  initiated  in 
parallel,  and  that  demethylation  at  specific  regions  is  not  a  pre-requisite  for  Foxp3 
induction,  but  a  means  of  stabilizing  gene  expression  once  initiated.  This  is  also 
confirmed  by  our  findings  that  Foxp3  expression  levels  (Foxp3  high-medium-low  as 
measured by the Foxp3GFP reporter) have no influence on epigenetic marks in the Foxp3 
gene.  Therefore,  the  methylation  patterns  might  act  as  a  binary  switches,  stabilizing 
Foxp3 expression when on (=demethylated) or leading to a progressive loss of Foxp3 
expression  when  off  (=methylated).  This  can  be  confirmed  by  looking  at  in-vitro 
induced  Treg  cells  (iTreg),  which  gradually  lose  Foxp3  expression  once  TCR  and 
cytokine stimuli are removed 125. These iTreg cells have no selective demethylation at 
intron 1. Furthermore, when the CNS2/TSDR region was selectively deleted in mice, 
loss of Foxp3 gene expression in Treg cells over time occurred, again validating the role 
of epigenetic modification in specific regions of Foxp3 for its long-lasting and stable 
expression in Treg cells 153. Sakaguchi and co-workers dissected the establishment of 
the Treg-specific methylation program and Foxp3 gene induction with various genetic 
models on a whole-genome scale 44: They found that TCR-stimulation induces a Treg 
cell-specific  CpG  hypomethylation  pattern,  which  is  independent  of  Foxp3  induction. 
Furthermore,  they  showed  that  this  pattern  is,  once  established  in  the  thymus,  also 
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present in the periphery, even in the absence of Foxp3 protein expression. Finally, the 
authors discovered that this epigenetic framework is necessary to complement the Treg-
specific gene signature and to promote lineage stability, finally leading to full 
suppressive capacity. In line with this, the Treg-specific demethylation framework has 
been shown to regulate many key Treg genes independently of Foxp3 activity. 
Examples include CD25 (Il2ra), CTLA-4 (Ctla4), GITR (Tnfrsf18), or Eos (Lkzf4). 
Finally, we looked at the T-cell compartment in Dnmt1-hypomorphic (Dnmt1 chip) mice. 
We detected a decreased Treg frequency to about 50% of normal. This runs in concert 
with findings from the specific knockout of the TSDR in mice, where Treg cell numbers 
decrease with increasing age of the animals, but not in young mice 153. Since Dnmt1 chip 
mice  already  have  particular  defects  in  the  generation  of  precursor  cells  in  the  bone 
marrow, with a particular shift in the myeloid / lymphoid lineage decision, care has to 
be  taken  when  comparing  cell  numbers  in  this  mouse  with  its  wild  type  littermates. 
Upon  the  investigation  of  the  epigenetic  imprinting  of  the  Foxp3  gene  in  circulating 
Treg cells from Dnmt1chip mice, we saw that they maintained their specific 
demethylation  pattern,  and,  more  importantly,  conventional  T  cells  also  remained 
methylated at the Treg-specific demethylated regions. This indicates that this epigenetic 
mark is important even in a Dnmt1-hypomorphic scenario. We also analyzed markers 
for peripherally induced Treg cells, like Helios or Nrp-1, on Treg cells from Dnmt1 chip 
and  WT  mice.  Since  we  observed  no  significant  differences,  increased  peripheral 
conversion of Tconv cells is very unlikely – this supports the above-mentioned 
observation that Tconv cells from this mouse have methylated Treg-specific regions 3 
and 4, protecting them from unintended Foxp3 induction. 
Taken together, we not only identified a new Treg-specific demethylated region in this 
study,  but  we  also  extended  this  region  to  cover  the  whole  Foxp3  Intron  1.  We 
investigated  its  induction  during  Treg  development  and  confirmed  its  stability  in 
circulating Treg cells. We showed that the Treg-specific demethylation is also present in 
Dnmt1chip mice. Lastly, we could show that this demethylation pattern is independent of 
tissue localization of Treg cells. In terms of tissue-specific adaptation, we were able to 
isolate  Treg  cells  from  four  different  tissues  (fat,  liver,  skin,  lymph  node)  with  high 
viability  and  purity.  We  subjected  them  to  whole-genome  bisulfite  sequencing  and 
mapped  the  data  to  the  mouse  genome.  We  identified  the  methylation  pattern  of  the 
Foxp3 gene in these tissue-derived Treg cell populations and compared it to our patterns 
observed from splenic and lymph node Treg vs. Tconv cells. We did not observe any 
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tissue-specific  differences  in  the  Treg-specific  demethylation  of  intron  1,  the  Foxp3 
promoter, or upstream and downstream gene elements. This indicates that Treg-specific 
demethylation is a reliable and stable marker also for tissue-adapted Treg cells. 
Furthermore,  we  already  prepared  RNA  sequencing  libraries  to  link  whole-genome 
methylation  data  to  gene  expression  profiles.  Our  next-generation  run  data  indicate 
homogenous  sequencing  and  data  acquisition,  which  should  result  in  a  high  quality 
dataset.  Furthermore,  we  can  already  detect  quite  profound  differences  in  the  whole-
genome  methylation  level  between  Treg  cells  from  different  tissues,  indicating  that 
tissue adaptation might indeed be mediated by epigenetic events. Therefore, it will be 
most  interesting  to  study  differentially  methylated  regions  in  more  detail,  and  to  link 
differentially methylated promoter sites or gene regions to the respective gene 
expression profile. 
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Specific proteins bind the Foxp3 gene promoter and downmodulate its activity 
Since  epigenetics  is  only  one  arm  of  transcriptional  control,  we  surveyed  the  Foxp3 
gene promoter for transcription factor binding activity as well. We used a quite novel 
unbiased proteomic approach to decipher the molecular complex binding to the Foxp3 
gene promoter. Since we used Foxp3 non-expressing EL4 T cells for our study, it was 
feasible that we would detect potential Foxp3 repressing transcription factors. In order 
to  detect  Foxp3  inducing  factors,  we  initially  though  to  repeat  this  procedure  with 
Foxp3-induced EL4 T cells as well. Unfortunately, we were not able to induce Foxp3 
protein expression by TCR-stimulation and TGF-β treatment in these cells to an extent 
and number suitable for inverted ChIP analysis. 
When  performing  this  procedure  with  nuclear  proteins  isolated  from  EL4  T  cells,  we 
identified several thousand proteins binding to either the very proximal Foxp3 promoter 
(“Fra1) or its more distal parts (“Fra2”, “Fra3”). To exclude unspecific protein binding 
to the bead system, we used stringent criteria to select candidates for luciferase-based 
validation: First, we disregarded proteins binding to two or more fragments; if proteins 
bound  to  all  three  fragments,  it  was  very  likely  that  these  proteins  were  ligated  to 
biotinylation sites or the bead itself. If proteins bound two regions, they might act co-
operatively  across  our  assay  junction.  These  would  be  disregarded  in  our  selection 
process and classify as false-negatives. Second, we investigated whether our candidate 
proteins had been detected across both biological replicates and with a certain peptide 
recovery  rate,  which  forms  the  basis  of  the  p-value  calculation.  Furthermore,  a  false-
discovery  rate  adjustment  was  performed  to  reduce  the  probability  of  false-positive 
results.  Third,  we  analyzed  whether  our  candidate  proteins  are  expressed  in  T  cells, 
which was the case for most of our factors. Finally, more technical aspects during the 
molecular  cloning  procedure  (cDNA  length,  availability  of  commercially  available 
ORFs) narrowed the list of candidates to its final touch. On this list, we identified and 
cloned out following putative Foxp3-promoter binding partners: 
To  the  very  proximal  Foxp3  Fra1  promoter  sequence,  we  identified:  THAP  Domain 
Containing  11  (Thap11),  a  transcriptional  repressor  important  during  embryogenesis 
and  maintenance  of  pluripotency;  Single-Stranded  DNA-Binding  Proteins  1  and  2 
(Ssbp1  and  Ssbp2),  which  are  involved  in  the  regulation  of  genomic  stability  in  the 
nucleus; Replication Protein 1 (Rpa1), playing a role for DNA replication and cellular 
DNA damage response; Poly(RC) Binding Protein 1 and 2 (Pcbp1 and Pcbp2), which 
are both multifunctional genes involved in RNA binding and co-activation of pro-virus 
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RNA replication; Heterogeneous Nuclear Ribonucleoproteins (Hnrnpk, Hnrnpd, 
Hnrnpab) that bind pre-mRNA and influence its processing; a Y Box Binding Protein 1 
(Ybx1),    which  has  been  reported  to  modulate  the  interaction  between  mRNA  and 
transcription  factors  at  gene  promoters,  therefore  being  a  transcriptional  regulator; 
Splicing Factor 1 (Sf1), reported as putative transcription repressor which is required for 
spliceosome  assembly;  and  a  Small  Nuclear  RNA  Activating  Complex  1  (Snapc1), 
important for transcription of RNA-polymerase II and III nuclear RNA genes. 
We identified 5 binding partners to the more proximal Foxp3 promoter Fra 2: three Zinc 
finger  proteins  Znf574,  Znf691,  and  Znf692,  where  involvement  in  transcriptional 
regulation is predicted, but no more detailed functions are known; Nuclear 
Transcription Factor Y α (Nfya), which forms a complex with B and C subunits to bind 
DNA  with  high  affinity,  thereby  regulating  its  expression;  Regulatory  Factor  X  1 
(Rfx1), transcriptional activator binding target DNA as monomer or heterodimer with 
other Rfx family members, essential for MHC II gene expression. 
Following binding partners were identified at the most distal Foxp3 promoter fragment 
3:  Myb-like,  SWIRM  and  MPN  Domains  1  (Mysm1),  a  metalloprotease  that  actively 
de-represses  epigenetically  silenced  genes  (H2A  histone  modification)  and  thereby 
promotes  initiation  and  elongation  steps  for  gene  induction;  TGF-β  induced  Factor 
Homeobox 2 (Tgif2), a transcriptional repressor recruiting epigenetic silencing 
mechanisms  to  TGF-β  responsive  genes.  It  might  interact  with  Smad  proteins  and 
recruits histone deacetylase proteins; Transcription Factor CP2 (Tfcp2), reported to bind 
various cellular promoters and regulating the transcriptional switch; N(α)-
Acetyltransferase 38, NatC Auxiliary Subunit (Naa38), a protein involved in the 
acetylation of methionine residues (all gene ontology information from genecards.com, 
186). 
In the introduction, we summarized, in a very detailed manner, the pathways involved 
in Foxp3 gene expression control. Interestingly, we did not detect obvious factors in our 
short  list  of  the  TCR/CD28  signaling  pathway,  the  PI3K/Akt  pathway  or  the  NFκB 
pathway  with  our  procedure.  Only  one  protein  (Tgif2),  involved  in  silencing  TGF-β 
responsive  genes,  was  identified  in  our  screen  as  a  part  of  the  TGF-β  axis.  When 
analyzing  the  GO  terms  for  our  candidate  proteins  carefully,  one  can  appreciate  that 
these proteins fall into three categories: First, some proteins identified with our 
procedure  are  reported  to  repress  gene  transcription,  therefore  taking  part  in  gene 
silencing.  Since  we  know  that  the  Foxp3  promoter  is  demethylated  in  Foxp3  non-
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expressing Tconv cells, the presence of a gene-silencing complex at the Foxp3 promoter 
in these cells would be feasible. Second, we identified factors for DNA replication and 
repair/genomic stability. These could be maintenance factors, binding to DNA without 
inducing  gene  expression.  Third,  we  found  factors  that  bind  RNA  or  aid  in  RNA 
processing and splicing. These proteins are probably standing by to produce pre-mRNA 
as soon as activating factors are present, being part of a pre-assembled DNA-dependent 
RNA processing machinery. 
In order to confirm the repressive function of some of those factors, we cloned them 
into  eukaryotic  expression  vectors  and  tested  them  in  a  Foxp3-promoter  luciferase 
system. As expected, some factors significantly downmodulated gene expression once 
over expressed in 293 cells, whereas no factors strongly upregulated gene expression. 
Furthermore,  we  tested  all  factors  against  small  500  bp  Foxp3  promoter  luciferase 
vectors. Here, we also detected more downregulating effects of our candidate factors. 
Since  293  cells  are  derived  from  embryonic  kidney,  we  now  wanted  to  test  our 
candidates in a T-cell based system. Therefore, we used Jurkat T cells, stimulated with 
PMA  and  Ionomycin  to  induce  Foxp3  gene  expression  at  the  full  Foxp3  promoter 
luciferase vector. Again, some candidates were able to significantly downmodulate gene 
expression. There was no overlap in the downregulating activity of factors in 293 cells 
and Jurkat T cells. This can be explained by the test system differences: in 293 cells, 
endogenous  Foxp3  promoter  activity  (“leakage”)  was  downmodulated,  whereas  in 
Jurkat  T  cells,  TCR-stimulation  inducing  Foxp3  promoter  activity  was  decreased. 
Finally,  we  tested  our  factors  in  TCR  –  and  TGF-β  stimulated  primary  mouse  iTreg 
cells.  In  this  scenario,  no  factor  was  able  to  overrule  this  potent  stimulus.  Since  we 
already know that TGF- β pathway components signal along the CNS1 region, but not 
the  Foxp3  promoter,  our  promoter  binding  partners  might  be  unable  to  dampen  this 
stimulation. Furthermore, from these results, one could infer a rather recessive mode of 
action  for  our  factors:  once  no  TCR  –  or  TGF-β  based  signals  are  present,  they  can 
occupy  the  Foxp3  promoter  and  either  actively  downmodulate  expression  or  block 
access of transcription-inducing complexes. Once TCR and TGF-β pathway signals are 
active, the suppressive effect can be overruled. Since our partners were identified based 
on their binding patterns to the Foxp3 promoter, and not the CNS1-3 regions, one can 
also  infer  that  gene-inducing  signals  at  these  sites  further  overrule  Foxp3-promoter 
based repression. 
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Finally,  we  compared  the  gene  expression  profile  of  our  candidate  factors  in  Foxp3-
expressing and non-expressing T cells as well as Foxp3-negative cell lines. It was quite 
surprising to find differences between mouse and human T cells: whereas our candidate 
Foxp3-promoter binding factors are over expressed in human Tconv cells, no 
differences in expression on protein or RNA level can be detected in the mouse system. 
Since Foxp3 gene expression can be transiently induced in human T cells by activation, 
which  normally  does  not  occur  in  murine  T  cells,  this  system  difference  might  be 
explained by the special circumstances in both species: murine Tconv cells resist Foxp3 
induction when activated by cognate antigen. But in humans, Tconv cells can 
upregulate  Foxp3  in  the  presence  of  pro-inflammatory  stimuli  without  becoming  a 
regulatory T cell, losing Foxp3 gene expression again once stimulation ceases. 
Therefore,  in  the  human  system,  TCR  engagement  by  antigen  can  induce  Foxp3  to  a 
certain extent. Since our factors are only upregulated in the human system, one could 
infer that the general “leakiness” of the Foxp3-regulating system in human Tconv cells 
is compensated in part by our candidate factors. In the mouse system, where Foxp3 is 
more tightly regulated, these factors can still repress gene expression at the promoter, 
but don’t require such strong upregulation. 
Additionally, with all candidate factors expressed in EL4 and Jurkat T cells, these cells 
generally  resist  strong  means  of  Foxp3  induction:  we  were  not  able  to  induce  Foxp3 
mRNA or protein in Jurkat or EL4 cells by TGF-β treatment in combination with TCR-
stimulation by CD3/CD28 microbeads or plate-bound CD3/CD28 (data not shown). 
To summarize, we detected putative Foxp3 promoter binding proteins in this study. We 
confirmed  the  gene-repressive  nature  of  some  of  our  candidate  factors,  and  analyzed 
their expression signature amongst different cell types. To finally prove their function to 
downmodulate Foxp3 promoter activity, a Crispr/Caspase based deletion of candidate 
proteins in a T-cell line in-vitro or the T-cell specific knockout in-vivo could validate 
our dataset. 
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Rbpj is a Notch-independent regulator of Treg cell homeostasis and function 
Foxp3  is  the  master  transcription  factor  in  Treg  cells,  and  has  been  identified  by  its 
specific overexpression in these cells. Another protein, Rbpj, is overexpressed in Treg 
cells as well, albeit at a much lower Treg/Tconv ratio. Our Notch reporter studies and 
Notch receptor expression analysis revealed that Notch signaling is not active in steady-
state Treg cells. So why is Rbpj upregulated in these cells? 
Since RBPJ without Notch signaling can act as a profound repressor of transcription, we 
wanted to study the specific role of Rbpj in Treg cells. Therefore, we performed a Treg-
specific deletion of this protein. In young animals, the deletion had no further 
consequences, as gene expression analysis of Treg cells from six-week old 
Foxp3CreRbpjΔ/Δ and Foxp3 Cre animals confirmed: only two genes, Rbpj and Dtx1, were 
downregulated  on  a  larger  scale,  with  quite  a  few  genes  differentially  regulated  on  a 
smaller  scale.  Once  animals  aged  beyond  10  weeks,  and  probably  received  certain 
environmental triggers, strong lymphoproliferation with skin pathology, splenomegaly 
and lymphadenopathy had been observed. Not only Treg cells, which of course were the 
only cells to experience the loss of Rbpj, increased strongly in absolute numbers (about 
10fold), but also conventional T cells, B cells, myeloid cells, and NK cells. Pathological 
examination  revealed  that  lymph  nodes  and  spleen,  albeit  being  several  times  bigger 
than normal, retained their tissue architecture and compartmentalization. This resembles 
studies where Nr4a transcription factors, which are normally required for proper Foxp3 
induction  at  the  promoter,  had  been  deleted.  Treg  cells  became  less  suppressive  and 
accelerated  the  conversion  of  T  cells  into  TH2  or  TFH  effector  cells,  causing  strong 
lymphoproliferation and autoimmunity 145, 187. In contrast to this, Treg cells deficient in 
Rbpj  still  express  Treg-lineage  defining  proteins  such  as  Foxp3,  CD25,  CTLA-4, 
Helios, Nrp-1, and others. Furthermore, gene expression analysis of Treg cells from sick 
Foxp3CreRbpjΔ/Δ  revealed  that  the  Treg-specific  gene  signature  was  intact.  This  was 
confirmed by in-vitro experiments, where Rbpj-deficient Treg cells were still 
suppressive  in  a  CFSE-based  in-vitro  suppression  assay  and  did  not  produce  pro-
inflammatory  cytokines  such  as  IFN-γ  or  IL-2  upon  PMA/Ionomycin  stimulation. 
Finally,  they  showed  normal  demethylation  at  the  CNS2/TSDR  region,  indicating 
strong  and  persistent  Foxp3  expression  in  these  cells.  In  addition  to  this,  massive 
parallel sequencing of the T-cell receptors in Treg cells from sick Foxp3 CreRbpjΔ/Δ and 
Foxp3Cre revealed no substantial differences in TCR repertoire, indicating that neither 
clonal  outgrowth  nor  malignant  conversion  accounted  for  the  strong  increase  in  Treg 
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cell numbers. Additionally, thymic Treg numbers were not different in sick 
Foxp3CreRbpjΔ/Δ  and  Foxp3Cre  mice,  ruling  out  increased  thymic  output  as  source  of 
increased Treg cell frequency. So why are there so many Treg cells? 
Since  we  did  not  detect  significant  differences  in  the  expression  of  Neuropillin-1  or 
Helios,  which  usually  indicate  peripheral  conversion  of  Tconv  into  Treg  cells,  the 
strong increase in the Treg compartment could be based on either strong proliferation or 
decreased apoptosis, or both. Therefore, we next determined expression levels of active 
Caspase-3: significantly less Treg cells expressed active Caspase-3, a sign of imminent 
apoptosis, in Foxp3CreRbpjΔ/Δ animals, as compared to Foxp3 Cre animals. No differences 
were  detected  in  Tconv  cells.  Furthermore,  stainings  for  KI-67  revealed  that  Rbpj-
deficient  Treg  cells  had  a  much  more  profound  history  of  proliferation,  although 
analysis  of  cell  cycle  via  DNA  staining  did  not  reveal  any  more  cycling  during  late-
stage disease. Since both lymph nodes and spleen were increased dramatically at this 
point, and we ruled out malignant conversion as a means of cellular proliferation, we 
can  expect  that  programs  controlling  cellular  growth  by  nutrient  deprivation  or  by 
measuring the size of the respective niche are still active and prevent runaway 
proliferation as seen with malignant cell lines or primary tumor cells. 
But  why  do  other  cells,  such  as  B  cells,  NK  cells,  and  Tconv  cells,  also  increase  in 
numbers? To determine the activation status of these immune cells, we stained for L-
selectin,  CD25  and  CD44.  Tconv  cells,  B  cells,  CD8  T  cells,  and  NK  cells  showed 
significant signs of activation, indicating mobilization against self-tissues in this mouse. 
Furthermore, we identified autoantibodies via Western Blot and identified an IL-4 (or 
TH2)  characteristic  Ig-subtype  class  switch  in  peripheral  blood  serum.  Therefore,  we 
overlaid  Foxp3CreRbpjΔ/Δ  Treg-  or  Tconv  upregulated  genes  with  upregulated  genes 
identified in T H1, TH2, and T H17 gene expression data 129: indeed, elements of all three 
pro-inflammatory effector cell types were also upregulated in both Treg and Tconv cells 
from  the  Foxp3CreRbpjΔ/Δ  mouse,  indicating  that  Rbpj-deficient  Treg  cells  lost  their 
ability  to  control  TH  subset  differentiation  in-vivo.  In  contrast  to  this,  the  signature 
observed in Foxp3 CreNICDLSL mice did not show a bias towards either one of the T H 
subsets.  The  upregulation  of  both  TH1  and  TH2  signature  in  Tconv  cells  from  sick 
Foxp3CreRbpjΔ/Δ mice was confirmed by intracellular cytokine stainings, where IFN-γ, 
IL-2, IL-10, and IL-4 were increased. In addition to this, intracellular proteins staining 
revealed an increase in the expression of both GATA-3 and T-bet, again indicating that 
both arms of TH subsets were expanded in this mouse. 
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Next, we carefully analyzed our gene expression data and the signature present in sick 
Foxp3CreRbpjΔ/Δ  animals.  We  observed  that  the  cell  surface  receptor  for  interleukin  7 
(IL7R), which is ubiquitously expressed in Tconv cells and CD8 T cells, but not Treg 
cells,  is  suddenly  upregulated  also  on  Rbpj-deficient  Treg  cells.  Looking  at  gene 
expression data from young, healthy Foxp3 CreRbpjΔ/Δ animals, we saw that loss of Rbpj, 
early on, translates into increased IL7R expression. Next, we observed that the 
overexpression  of  the  IL7R  is  tightly  linked  to  increased  Treg  cell  numbers,  with 
increased proliferation (based on KI-67 and KLRG-1) and decreased apoptosis in these 
cells. Therefore, we concluded that Rbpj might regulate expression of the IL7R, and the 
Treg-specific  Rbpj  deletion  induces  a  strong  cytokine  stimulation  of  this  cell  type, 
leading to enhanced proliferation. 
Furthermore,  our  gene  expression  microarray  showed  the  early-on  downregulation  of 
Dtx-1, a factor driving T-cell anergy and resistance towards TCR engagement 188. This 
might,  in  combination  with  the  overexpression  of  the  IL7R,  release  the  brakes  for 
increased Treg cell proliferation. Therefore, we investigated the molecular link between 
Rbpj and the IL7R by Chromatin IP (ChIP), and validated its specific binding there. To 
further validate this molecular link, we are now planning overexpression studies in T-
cell  lines  and  several  in-vitro  experimental  procedures  such  as  luciferase-based  gene 
promoter activity screens with both Rbpj and Dtx1 transgenes. We are also testing an 
Rbpj-Chromatin-IP  in  primary  Treg  cells  followed  by  next-generation  sequencing.  A 
Rbpj-ChIP-sequencing  approach  has  already  been  undertaken  in  a  2013  study  with 
mammalian myogenic cells in the context of stimulated Notch signaling via the 
exposure to Dll1 ligand 189. The authors reported that Rbpj bound 158 gene areas upon 
Dll1 binding, 78 of which were within or near genes. A common Rbpj binding motif, 
(CC)GTGGGAA, was identified to be present in about 80% of putative binding sites. 
Furthermore, the study showed that Rbpj binds 63 sites independent of Notch activity, 
indicating that it might be involved in Notch-independent gene regulation. Once cells 
were stimulated, 128 genes were induced, while the Rbpj-NICD complexes repressed 
175  genes.  The  authors  correlated  the  putative  Rbpj  binding  sites  to  gene  expression 
profiles  and  determined  that,  of  the  genomic  regions  constantly  associated  with  Rbpj 
and therefore independent of Notch signaling, only one gene was subsequently 
upregulated upon Dll1 ligand stimulation. This strongly indicates that Rbpj has a Notch-
independent  role  in  the  regulation  of  genes;  it  is  thought  that  Rbpj  acts  as  a  general 
repressor of gene transcription. If NICD translocates to the nucleus upon active Notch 
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signaling, it can displace repressors and induce gene transcription in concert with Rbpj, 
or  repress  gene  transcription,  respectively.  Importantly,  for  Notch-regulated  genes,  a 
simple deletion of Rbpj did not upregulate their expression, indicating that it does not 
actively repress at those sites or relies on co-factors for gene induction. In contrast to 
this, Rbpj deletion released suppression at Notch-independent sites, indicating that Rbpj 
can act as a Notch-independent suppressor of gene translation. If we are able to confirm 
the role of Rbpj as a repressor of IL7R expression in the absence of NOTCH signaling, 
and  possibly  also  Dtx-1  expression,  we  can  link  molecular  deletion  of  Rbpj  and  its 
effects on Treg cell proliferation and homeostasis. 
Since we discussed the role of Rbpj in Treg cells and correlated it with our data, we 
now  want  to  take  a  step  back  and  review  the  role  of  Notch  signaling,  dependent  or 
independent of Rbpj, for Treg cell homeostasis. Notch-ligand expression by APCs has a 
profound impact on T-subset generation. When APCs present antigen in the context of 
Jag1  overexpression,  induction  of  Treg  cells  from  naive  T  cells  has  been  observed; 
these  Treg  cells  were  shown  to  inhibit  immune  responses  and  transfer  tolerance  to 
recipient  mice 190.  In  another  study,  Jag1  was  overexpressed  in  Epstein-Barr  virus-
positive lymphoblastic B-cell lines. Upon co-cultivation with autologous T cells, they 
acquired  a  regulatory  behavior  with  increased  IL-10  production  and  the  potential  to 
downmodulate proliferation and cytotoxic function of effector T cells 191. Furthermore, 
the  in-vivo administration of Jag-2 expressing hematopoietic progenitor cells in NOD 
mice caused an expansion of a peripheral Treg cell pool, mediated by Notch3 activation. 
In  contrast  to  this,  Dll4  downmodulates  induction  of  Treg  cells.  In  a  model  of  EAE, 
treatment with a Dll4 blocking mAb increased Treg cell numbers and decreased EAE 
severity  by  downmodulating  the  effector  TH1/TH17  response.  It  is  proposed  that  Dll4 
inhibits the Janus kinase 3 (JAK3)-induced STAT5 phosphorylation, which is important 
for TGF-β mediated induction of Treg cells 166, 192. Therefore, we can summarize that 
Jag-ligands promote Treg cell generation, whereas Dll4 ligand inhibits this process. 
The involvement of Notch receptors has also been studied. Global treatment with GSIs 
in-vitro blocks the TGF-β mediated upregulation of Foxp3 gene expression. In the same 
study, TGF-β induced Smad3 was shown to interact with Notch1, and blocking of this 
interaction  seems  to  hinder  peripheral  Treg  cell  induction.  Once,  in  the  same  study, 
GSIs were applied systemically, downregulation of Foxp3 expression was followed by 
liver lymphocyte infiltration. In-vitro studies showed that Treg cells from GSI-treated 
animals had reduced suppressive capacity as well as reduced Foxp3 expression, leading 
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to the escape of autoimmune effector T cells 193. A third report investigated the binding 
of Rbpj in combination with Notch1-ICD at the Foxp3 promoter. The Foxp3 promoter 
contains a highly conserved RBPJ-binding site meeting the consensus sequence criteria 
C(T)GTGGGAA. The authors showed that the N1ICD-Rbpj complex could act as trans-
activator at this site, confirmed also by Chromatin-IP experiments 194. 
The Notch3 receptor, overexpressed on Treg cells compared to Tconv cells, also has a 
function for Treg cell induction. When Notch3-ICD was overexpressed in thymocytes 
and  T  cells,  more  Treg  cells  and  enhanced  CD25  expression  have  been  reported. 
Interestingly, it was noted that Notch3-dependent Foxp3 gene induction relies on NFκB 
pathway components, and both Rbpj and NFκB have overlapping binding sites at the 
Foxp3 gene promoter. It was noted that Protein-kinase Cθ (PKCθ), involved in 
canonical  NFκB  activation,  serves  as  downstream  target  of  Notch3-  and  TCR-based 
signals. If both Notch3-IC and PKCθ were deleted, less Treg cells were produced. This 
deletion also impaired peripheral Treg generation and Foxp3 expression levels. On the 
other  hand,  the  upregulation  of  Notch3  expression  lead  to  the  expansion  of  the  Treg 
niche while remaining fully suppressive, indicating that Notch3 can influence Treg cell 
homeostasis  and  function  via  cooperative  effects  with  PKCθ  and  NFκB  signaling 
components 195.  In  summary,  Notch  1  and  3  might  play  important  roles  for  the 
homeostasis and function of Treg cells – Notch1 mediating TGF-β induced peripheral 
Treg induction, and Notch3 influencing thymic Treg cell induction via the PKCθ- NFκB 
axis. Since our study misses Notch 3 protein and mRNA expression data in Treg cells 
from wild type and Foxp3CreRbpjΔ/Δ mice, we are currently performing these 
experiments. 
Notch signaling has also been studied under disease conditions. Two studies evaluated 
the  influence  of  Notch  in  the  control  of  graft  versus  host  disease  (GVHD) 196,  197. 
Expression  of  dnMAML1,  a  Notch  pathway  downmodulator,  in  mature  CD4pos  and 
CD8pos T cells reduced GvHD severity and organ damage, decreased the pro-
inflammatory  environment,  and  lead  to  increased  Treg  cell  expansion.  Furthermore, 
Notch-defective T cells retained their graft versus tumor activity and were still able to 
mediate anti-leukemia efficiencies. Once animals were systematically treated with GSIs, 
GvHD  was  prevented,  but  side  effects  at  the  intestinal  epithelium  occurred.  These 
findings  lead  the  authors  to  investigate  more  closely  how  Notch  signaling  mediates 
autoimmune  effects.  When  they  blocked  Notch  1  or  2  and  Dll1  or  4  with  blocking 
antibodies, it was shown that these signaling pathways are actively involved in 
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mediating  GvHD,  with  Notch1  and  Dll4  being  most  potent.  A  combined  blockade  of 
Dll1 and Dll4 lead to prevention of GvHD, without any intestinal pathology. 
Interestingly, Treg cells continuously expanded following this treatment. Similar results 
have been obtained in reports studying aplastic anemia 198 and vascular inflammation 
199: GSI treatment or specific Notch1 deletion have been shown to be beneficial in both 
pathological scenarios, both reporting a potential role of Notch signaling in preventing 
TH1 differentiation and in promoting Treg cell induction. Taken together, these studies 
indicate that Notch signaling mediates multifaceted functions in T cells. Whereas Notch 
signaling  is  pivotal  for  the  thymic  and  peripheral  induction  of  Treg  cells,  it  is  also 
implicated in disease progression and severity of autoimmune disease. Therefore, one 
can infer that Notch has a strong context-dependent way of action, and detailed studies 
for its functions in T-cell subpopulations under steady state and disease conditions are 
required. To put it into context with our results, we stained for the expression of Notch1 
and  Notch2  in  Treg  cells  from  sick  Foxp3 CreRbpjΔ/Δ  and  Foxp3Cre  mice  (data  not 
shown). Again, we did not detect any changes in Notch receptor expression, indicating 
that the above-mentioned effects of Notch signaling on T H subset generation might not 
be relevant in our model. 
But  what  happens  once  Notch  signaling,  in  the  form  of  over  expression  of  Notch 
intracellular  domain,  is  constantly  active  in  Treg  cells? A  recent  2015  study  by 
Charbonnier and co-workers addressed the impact of Notch signaling in Treg cells with 
the  aid  of  various  genetic  models 200.  First,  the  authors  investigated  the  effects  of 
defective Notch receptor generation in Treg cells. Therefore, they selectively deleted the 
Pofut1 gene, encoding an enzyme required for the fucosylation of Notch receptors, in 
Treg cells. The observed a decrease in peripheral CD3 and CD4 T cell numbers, with an 
increase in naive Treg cells (relative to other CD4 T cells). The expression intensities of 
key Treg proteins such as Foxp3, CD25, CTLA-4, Helios, and Nrp-1 were increased in 
peripheral Treg cells. Thymus-resident Treg cells, which just started to express Foxp3 
and its linked transgene, the Cre recombinase, did not experience the consequences of 
Notch signaling deficiencies yet and were normal in number and frequency. To identify 
whether the effects of Notch-receptor deletion were canonical, the authors performed a 
Treg-specific Rbpj knockout, yielding pretty much the same results as described above: 
increased  Treg  cell  numbers  and  increased  expression  of  key  Treg  proteins.  One  can 
conclude  that  loss-of-function  mutations  of  all  Notch  receptors  in  already-developed 
Treg cells increase their concomitant expression of CD25, Helios, and Nrp-1, increasing 
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the fitness of Treg cells under steady state conditions. Our data from young and healthy 
Foxp3CreRbpjΔ/Δ mice also show that Treg cells in these mice are, at least based on key 
protein  expression  and  in-vitro  assay  performance,  equally  functional  as  compared  to 
wild type Treg cells. 
To study the effects of defective Notch signaling in Treg cells under disease conditions, 
the authors induced GvHD by lethal irradiation of donor mice followed by transfer of 
HLA-mismatched splenocytes. When they co-transferred either Rbpj-deficient or 
Notch-deficient Treg cells, GvHD was attenuated. This again indicates elevated fitness 
and  potency  of  Notch-deficient  Treg  cells.  Furthermore,  they  observed  a  strongly 
increased  Treg  compartment,  both  in  frequency  and  absolute  numbers,  alongside  a 
downregulation of apoptosis markers on Treg cells. Therefore, Notch-signaling 
deficiency  protects  Treg  cells  from  early  apoptosis,  and  increases  their  potency  to 
down-modulate GvHD in a transfer model. 
To study the effects of Notch overactivity in already-developed Treg cells, the authors 
overexpressed Notch1-ICD in Treg cells. They observed increased expression of typical 
Notch target genes such as Hes1, Hey1, and Dtx1. The animals suffered from 
lymphoproliferative disease with large-vessel vasculitis and organ infiltrations, along an 
expansion of memory effector T cells with increased IFN-γ expression. The Treg cell 
compartment  was  decreased,  and  markers  for  apoptosis  were  increased.  Furthermore, 
Treg cells exhibited less expression of CD25, CTLA-4, OX40, Helios, Nrp-1 and Eos. 
Treg cells showed defects in suppressive capacity, and were less stable when adoptively 
transferred, albeit being demethylated at the CNS2 locus.  The above-mentioned defects 
in Treg cells were alleviated once Rbpj was co-deleted while overexpressing Notch1-
ICD.  This  indicates  that  canonical  Notch  signaling  is  responsible,  once  active,  for  a 
competitive disadvantage in Treg cells. This translates into a reduction Treg cell number 
and  suppressive  capacity,  finally  leading  to  effector  cell  escape,  lymphoproliferation, 
and  autoimmune  disease.  Notch  signaling  can  mediate  this  via  its  direct  binding  to 
Foxp3-regulated genes, where it can antagonize Foxp3 binding or revert the epigenetic 
marks  set  by  Foxp3.  Furthermore,  Notch  is  implicated  in  the  ability  of  Treg  cells  to 
abort TH1 programming of effector T cells. 
To summarize, the above-mentioned study investigated the role of Notch signaling for 
the  Treg  cell  compartment.  It  showed  that  a  deletion  of  Notch  components  increased 
Treg  frequency  and  fitness,  while  an  overexpression  of  Notch1-IC  caused  increased 
Treg apoptosis with decreased Treg functionality, finally leading to systemic 
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autoimmunity.  It  was  proposed  that  Notch1-IC  overexpressing  Treg  cells  lose  their 
ability to control T H1 responses: normally, Treg cell run only a certain part of the T H1 
differentiation  program  to  preserve  their  potential  to  suppress  T H1  effector  T  cell 
responses. With Notch1-IC overactive, this blockade is bypassed and Treg cells acquire 
the ability to make pro-inflammatory cytokines while unable to downregulate effector T 
cells, rendering them unable to control peripheral immune tolerance. 
Taking this information into account, we can conclude the following from our study of 
Rbpj-deficient Treg cells: a deficiency in Rbpj protects Treg cells from early apoptosis, 
thereby increasing Treg cell numbers. Furthermore, our data link the IL7R and Dtx-1 to 
this deletion, enabling a molecular understanding of the increased fitness and 
proliferation  of  Rbpj-deficient  Treg  cells.  Furthermore,  even  though  Treg  cells  from 
Foxp3CreRbpjΔ/Δ animals were still suppressive in-vitro (based on our data) and 
protected against GvHD in a transfer model (based on 200), autoimmune pathology still 
evoked in this model, not appreciated in the previously-mentioned study. Interestingly, 
these  pathological  evaluations  mimic  observations  in  human  patients  suffering  from 
Omenn syndrome: studies report hepatomegaly, splenomegaly, and lymphadenopathy, 
as well as erythroderma (inflammatory skin disease) and chronic diarrhea. Furthermore, 
serum IgE levels are elevated, autoantibodies are generated and more IL-4 cytokine is 
produced. Closer examination revealed that these patients suffer from impaired T-cell 
development  in  the  thymus 201,  202.  It  would  be  interesting  to  investigate  whether 
patients  have  mutations  in  Rbpj,  Dtx1,  or  Il7r  genes  in  their  Treg  compartment, 
probably  also  leading  to  increased  Treg  cell  numbers  and  thereby  mimicking  our 
genetic  deletion  approach.  Interestingly,  one  study  already  indicated  development  of 
this disease in a patient with mutations in the Il7ra gene, although care must be taken 
since this receptor has multifaceted roles in thymic T-cell development and post-thymic 
T-cell homeostasis 203. 
Taken  together,  we  showed  that  Rbpj,  commonly  expressed  in  Treg  cells,  might  be 
involved  in  the  regulation  of  homeostasis  and  function  of  these  cells.  Its  selective 
knockout causes a moribund increase in Treg cell frequency, and renders them defective 
to  control  autoimmune  responses  over  time.  Therefore,  manipulations  at  the  Rbpj 
signaling axis might on the one hand promote Treg proliferation and survival, but might 
also render them defective for their most important function, the suppression of 
autoimmune events.  
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Implications of this work for future studies and research 
Initially,  we  set  the  goal  that  our  studies  presented  in  this  thesis  would  enhance  the 
knowledge about transcriptional control of Treg cells and thereby provide a benefit for 
society.  Indeed,  we  investigated  the  epigenetic  status  of  the  Foxp3  gene  and  its 
promoter in detail, providing additional knowledge about CG-dinucleotide methylation-
based control at this locus. Since the selected demethylation of the TSDR in Treg cells 
is  being  used  as  clinical  marker  for  Treg  cells  (Epiontis  GmbH,  part  of  the  Immune 
Tolerance  Network),  our  detailed  analysis  of  the  Foxp3  gene  can  provide  additional 
probes for epigenetic diagnosis of Treg cell characteristics for the clinic. Furthermore, 
our  whole-genome  based  epigenetic  analysis  of  Treg  cells  from  fat,  skin,  liver,  and 
lymph  nodes  will  allow  the  precise  detection  of  tissue-based  differences  in  the  CG 
methylation status. Once we detect and analyze Treg-specific and tissue-specific 
epigenetic  alterations,  this  knowledge  can  be  used  for  the  development  of  additional 
diagnostic tests. Importantly, since we already know that tissue-resident Treg cells take 
on specific effector functions, our methylation data will provide new insight into tissue-
specific adaption of not only Treg cells, but also T cells in general. This could, one day, 
allow  the  specific  manipulation  of  tissue-resident  Treg  cell  frequency  or  function, 
clinically relevant in many disease such as diabetes (fat-resident Treg cells), psoriasis 
and  other  autoimmune  skin  diseases  (skin-resident  Treg  cells),  or  hepatitis  (liver-
resident Treg cells). 
Next,  we  identified  a  repressive  complex  at  the  Foxp3  gene  promoter,  which  might 
enhance or even block Foxp3 protein expression. Since many studies search for Foxp3-
regulating  small  molecules  or  proteins,  our  data  could  allow  the  prediction  of  such 
interactions and explain the efficacy of certain drugs identified with these screens. One 
day,  this  knowledge  might  be  used  for  the  in-vivo  manipulation  of  Foxp3  promoter 
occupancy – with the goal to adjust Foxp3 expression strength therapeutically.  
Finally,  in  our  Rbpj  study,  we  identified  a  novel,  Notch-independent  axis  regulating 
Treg  cell  homeostasis  and  function.  We  observed  that  mice  with  Rbpj-deficient  Treg 
cells  develop  autoimmune  disease  over  time.  Interestingly,  these  mice  have  highly 
elevated Treg cell numbers, and these Treg cells are functional and suppressive in-vitro. 
Still, they lost their in-vivo functionality, indicating that Rbpj has a Notch-independent 
role to maintain proper performance of Treg cells. Understanding the detailed 
mechanisms of action, these findings could eventually allow the fine-regulation of Treg 
cell number and function in-vivo, becoming a clinically relevant treatment option. 
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10.1 List of antibodies used for flow cytometry and FACS 
Antigen Label Clone Isotype Supplier Cat-# 
Biotin APC NA Streptavidin BioLegend 405207 
Biotin APC/Cy7 NA Streptavidin BioLegend 405208 
Biotin PE NA Streptavidin BioLegend 405204 
Biotin PE/Cy7 NA Streptavidin BioLegend 405206 
Biotin Brilliant UV 737 NA Streptavidin BD 564293 
Biotin Horserad. peroxidase NA Streptavidin BioLegend 405210 
Viability dye DAPI NA NA BD 564907 
Viability dye eFluor506 NA NA eBioscience 65-0866 
Viability dye 7AAD NA NA BioLegend 640934 
CD3 Purified Okt3 Mouse IgG2a κ BioLegend 317304 
CD3ε Pacific Blue 145-2C11 Arm. Hamster IgG BioLegend 100334 
CD3ε Purified 145-2C11 Arm. Hamster IgG BioLegend 100302 
CD3ε Brilliant Violet 711 145-2C11 Arm. Hamster IgG BioLegend 100241 
CD4 APC RM4-5 Rat IgG2a κ BioLegend 100516 
CD4 APC/Cy7 GK1.5 Rat IgG2b κ BioLegend 100414 
CD4 Biotin RM4-5 Rat IgG2a κ BioLegend 100508 
CD4 Brilliant Violet 421 GK1.5 Rat IgG2b κ BioLegend 100437S 
CD4 FITC RM4-5 Rat IgG2a κ BioLegend 100510 
CD4 Pacific Blue RM4-5 Rat IgG2a κ BioLegend 100531 
CD4 Brilliant Violet 711 RM4-5 Rat IgG2a κ BioLegend 100550 
CD4 Brilliant Violet 605 RM4-5 Rat IgG2a κ BioLegend 100548 
CD4 PE RM4-5 Rat IgG2a κ BioLegend 100512 
CD4 PE/Cy7 RM4-5 Rat IgG2a κ BioLegend 100528 
CD4 PerCP/Cy5.5 RM4-5 Rat IgG2a κ BioLegend 100540 
CD4 Brilliant UV 395 GK1.5 Rat IgG2b κ BD 563790 
CD4 Biotin OKT4 Mouse IgG2b κ BioLegend 317406 
CD8a APC 53-6.7 Rat IgG2a κ BioLegend 100712 
CD8a Biotin 53-6.7 Rat IgG2a κ BioLegend 100704 
CD8a FITC 53-6.7 Rat IgG2a κ BioLegend 100706 
CD8a Pacific Blue 53-6.7 Rat IgG2a κ BioLegend 100725 
CD8a Brilliant Violet 605 53-6.7 Rat IgG2a κ BioLegend 100744 
CD8a PE/Cy7 53-6.7 Rat IgG2a κ BioLegend 100722 
CD8a PerCP/Cy5.5 53-6.7 Rat IgG2a κ BioLegend 100734 
CD11b PerCP/Cy5.5 M1/70 Rat IgG2b κ BioLegend 101228 
CD19 APC 6D5 Rat IgG2a κ BioLegend 115512 
CD19 APC/Cy7 6D6 Rat IgG2a κ BioLegend 115530 
CD19 Biotin 6D5 Rat IgG2a κ BioLegend 115504 
CD19 FITC 6D5 Rat IgG2a κ BioLegend 115506 
CD19 PE/Cy7 6D5 Rat IgG2a κ BioLegend 115520 
CD19 Pacific Blue 6D5 Rat IgG2a κ BioLegend 115523 
CD25 APC PC61 Rat IgG1 λ BioLegend 102012 
CD25 Biotin PC61 Rat IgG1 λ BioLegend 102004 
CD25 PE PC61 Rat IgG1 λ BioLegend 102008 
CD25 PE/Cy7 PC61 Rat IgG1 λ BioLegend 102016 
CD25 Biotin BC96 Mouse IgG1 κ BioLegend 302624 
CD28 Purified 37.51 Syr. Hamster IgG BioLegend 102102 
CD44 Pacific Blue IM7 Rat IgG2b κ BioLegend 103020 
CD44 Brilliant Violet 421 IM7 Rat IgG2b κ BioLegend 103039 
CD45 APC/Cy7 30-F11 Rat IgG2b κ BioLegend 103116 
CD45.1 PerCP/Cy5.5 A20 Mouse (A. SW)IgG2a κ BioLegend 110728 
CD45.1 PE/Cy7 A20 Mouse (A. SW)IgG2a κ BioLegend 110730 
CD45.2 Pacific Blue 104 Mouse (SJL) IgG2a κ BioLegend 109820 
CD45.2 PerCP/Cy5.5 104 Mouse (SJL) IgG2a κ BioLegend 109828 
CD45.2 Alexa Fluor 647 104 Mouse (SJL) IgG2a κ BioLegend 109818 
CD45.2 APC/Cy7 104 Mouse (SJL) IgG2a, κ BioLegend 109824 
CD49b Biotin DX5 Rat IgM κ BioLegend 108904 
CD62L APC MEL-14 Rat IgG2a κ BioLegend 104412 
CD62L APC/Cy7 MEL-14 Rat IgG2a κ BioLegend 104428 
CD62L PerCP/Cy5.5 MEL-14 Rat IgG2a κ BioLegend 104432 
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CD69 PerCP/Cy5.5 H1.2F3 Arm. Hamster IgG BioLegend 104522 
CD90.1 FITC OX-7 Mouse IgG1 κ BioLegend 202504 
CD90.1 Pacific Blue OX-7 Mouse IgG1 κ BioLegend 202522 
CD90.1 APC/Cy7 OX-7 Mouse IgG1 κ BioLegend 202520 
CD90.1 PE OX-7 Mouse IgG1 κ BioLegend 202524 
CD90.1 PE/Cy7 OX-7 Mouse IgG1 κ BioLegend 202518 
CD90.2 APC/Cy7 30-H12 Rat IgG2b κ BioLegend 105328 
CD90.2 APC 30-H12 Rat IgG2b κ BioLegend 105312 
CD103 PE 2E7 Arm. Hamster IgG BioLegend 121406 
CD127 Biotin A7R34 Rat IgG2a κ BioLegend 135005 
CD127 Brilliant Violet 605 A7R34 Rat IgG2a κ BioLegend 135025 
CD127 Brilliant UV 737 SB/199 Rat IgG2b κ BD 564399 
CD127 Brilliant Violet 421 A7R34 Rat IgG2a κ BioLegend 135024 
CD152/CTLA-4) PE UC10-4B9 Arm. Hamster IgG BioLegend 106305 
CD304 (Nrp-1) Alexa Fluor 488 N43-7 Rat IgG2a κ MBL M169-A48 
CD357 (GITR) FITC DTA-1 Rat IgG2b λ BioLegend 126308 
I-A/I-E (MHC II) Biotin M5/114.15.2 Rat IgG2b κ BioLegend 107603 
I-A/I-E (MHC II) PE/Cy7 M5/114.15.2 Rat IgG2b κ eBioscience 107629 
I-A/I-E (MHC II) Pacific Blue M5/114.15.2 Rat IgG2b κ BioLegend 107620 
I-A/I-E (MHC II) PE M5/114.15.2 Rat IgG2b κ BioLegend 107607 
I-A/I-E (MHC II) APC/Cy7 M5/114.15.2 Rat IgG2c κ BioLegend 107627 
KLRG1 Biotin 2F1 Syr. Hamster IgG2 κ BD 550863 
KLRG1 PE 2F1 Syr. Hamster IgG BioLegend 138407 
Ly6-C APC/Cy7 HK1.4 Rat IgG2c κ BioLegend 128025 
Ly6-C PerCP/Cy5.5 HK1.4 Rat IgG2c κ BioLegend 128012 
NK1.1 Biotin PK136 Mouse IgG2a κ BioLegend 108703 
Notch1 Brilliant Violet 421 HMN1-12 Arm. Hamster IgG Biolegend 130615 
Notch2 APC HMN2-35 Arm. Hamster IgG Biolegend 130713 
Annexin-V PE NA NA BioLegend 640934 
FoxP3 Purified FJK-16s Rat IgG2a κ eBioscience 14-5773-82 
FoxP3 PE FJK-16s Rat IgG2a κ eBioscience 12-5773-82 
FoxP3 APC FJK-16s Rat IgG2a κ eBioscience 17-5773-82 
Helios PE 22F6 Arm. Hamster IgG BioLegend 137206 
Bcl-2 Alexa Fluor 488 BCL/10C4 Mouse IgG1 κ BioLegend 633506 
IFN-γ PE XMG1.2 Rat IgG1 κ BioLegend 505808 
IFN-γ APC XMG1.2 Rat IgG1 κ BioLegend 505809 
IL-10 PE JES5-16E3 Rat IgG2b κ BioLegend 505008 
IL-17A PE TC11-18H10.1 Rat IgG1 κ BioLegend 506903 
IL-2 PE JES6-5H4 Rat IgG2b κ BioLegend 503808 
IL-2 APC MQ1-17H12 Rat IgG2a, κ  BioLegend 500311 
IL-4 PE 11B11 Rat IgG1 κ BioLegend 504103 
IL-17A PE TC11-18H10.1  Rat IgG1 κ BioLegend 506903 
TNF-α PE MP6-XT22 Rat IgG1 κ BioLegend 506305 
pStat5 (pY694) Alexa Fluor 647 4/P-STAT3 Mouse IgG2a κ BD 612599 
Caspase-3 PE NA NA Abcam Ab65617 
GATA-3 Alexa Fluor 647 16E10A23 Mouse IgG2b κ Biolegend 653809 
T-bet Alexa Fluor 647 4B10 Mouse IgG1 κ Biolegend 644803 
IRF4 Alexa Fluor 647 IRF4.3E4 Rat IgG1 κ Biolegend 646407 
Ki-67 PE B56 Mouse IgG1 κ BD 556027 
Isotype control PE RTK2071 Rat IgG1 κ BioLegend 400407 
Isotype control PE RTK4530 Rat IgG2b κ BioLegend 400608 
Isotype control PE HTK888 Arm. Hamster IgG BioLegend 400907 
Isotype control Alexa Fluor 488 MOPC-21 Mouse IgG1 κ BioLegend 400129 
Isotype control Alexa Fluor 488 RTK2758 Rat IgG2a κ BioLegend 400525 
Isotype control Alexa Fluor 647 RTK2758 Rat IgG2a κ BioLegend 400526 
Isotype control Alexa Fluor 647 MOPC-173 Mouse IgG2a κ BioLegend 400234 
Isotype control Brilliant Violet 421 RTK2758 Rat IgG2a κ BioLegend 400535 
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10.2 List of mouse strains 
Name Official name Origin 
C57BL/6 C57BL/6  Jackson # 664 
Charles River Breeding or 
Jackson Laboratories  
Foxp3YFP, Cre  B6.129(Cg)-Foxp3
tm4(YFP/cre)Ayr/J 
Jackson #016959 
A. Rudensky, MSKCC, New 
York, USA 
Foxp3GFP B6.129(Cg)-Foxp3
tm3(DTR/GFP)Ayr/J 
Jackson #016958 
A. Rudensky, MSKCC, New 
York, USA 
Foxp3GFP CD45.1 B6.SJL-Ptprc
aPepcb/BoyJ 
Jackson #002014 Jackson Laboratories  
Foxp3GFP CD90.1 B6.PL-Thy1
aCyJ 
Jackson #000406 Jackson Laboratories  
NotcheGFP B6.SJL/J)F2 Tg(Cp-EGFP)25Gaia/ReyaJ Jackson #018322 Jackson Laboratories  
RAG2-/- B6-Rag2tm1Fwa  Jackson #008449 
Shinkai Y et al., "RAG-2-deficient mice 
lack mature lymphocytes owing to 
inability to initiate V(D)J 
rearrangement." Cell 1992 Mar 
6;68(5):855-67 [PMID 15477487] 
Rbpjflx/flx N/A 
Nakhai H., Siveke J.T., Klein B., et al., 
Conditional ablation of Notch signaling 
in pancreatic development. 
Development. 2008 Aug;135(16):2757-
65. Epub 2008 Jul 17 [PMID 18635610] 
NICDLSL N/A  
Murtaugh LC; Stanger BZ; Kwan KM; 
Melton DA. 2003. Notch signaling 
controls multiple steps of pancreatic 
differentiation. Proc Natl Acad Sci U S 
A 100(25):14920-5. [PMID 14657333] 
Dnmt1chip N/A 
Broske AM et al., “DNA methylation 
protects hematopoietic stem cell 
multipotency from myeloerythroid 
restriction.” Nat Genet 2009 Nov 41; 
1207-1215 [PMID 19801979] 
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10.3 List of bisuflite primers used for 454 pyrosequencing 
# Region Direction Barcode Primer plus adaptor sequence plus barcode 
          
0 1 ForP TATATC CGTATCGCCTCCCTCGCGCCATCAGTATATCAGGATGTTAGGGTATTAAAGGTTGG 
0 1 RevP TATATC CTATGCGCCTTGCCAGCCCGCTCAGTATATCCCAATTTTCCTAAAACCAACAATAT 
0 2 ForP TATATC CGTATCGCCTCCCTCGCGCCATCAGTATATCTATATTTTTAGATGATTTGTAAAGGGTAAA 
0 2 RevP TATATC CTATGCGCCTTGCCAGCCCGCTCAGTATATCACCTAACTTATAAAAAACTACCACATTATC 
0 3.1 ForP TATATC CGTATCGCCTCCCTCGCGCCATCAGTATATCAGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTG 
0 3.1 RevP TATATC CTATGCGCCTTGCCAGCCCGCTCAGTATATCTCTTACRTAACACAAACAAAAAATCAATTAAATAC 
0 3.2 ForP TATATC CGTATCGCCTCCCTCGCGCCATCAGTATATCGTTGTGGTATTGTGTTTGGTATATG 
0 3.2 RevP TATATC CTATGCGCCTTGCCAGCCCGCTCAGTATATCACACTTAATTCAAATAATCAAATTCATAAT 
0 4 ForP TATATC CGTATCGCCTCCCTCGCGCCATCAGTATATCTGGGTTTTTTTGGTATTTAAGAAAG 
0 4 RevP TATATC CTATGCGCCTTGCCAGCCCGCTCAGTATATCAAAAAACAAATAATCTACCCCACAA 
0 5 ForP TATATC CGTATCGCCTCCCTCGCGCCATCAGTATATCTGAAAGGTTATAATGAAATGATAAGTTTAA 
0 5 RevP TATATC CTATGCGCCTTGCCAGCCCGCTCAGTATATCATTACCATAACTTCCCCAAAAATAC 
0 6 ForP TATATC CGTATCGCCTCCCTCGCGCCATCAGTATATCTGATTGTTAATTTTGTTTTTGATTG 
0 6 RevP TATATC CTATGCGCCTTGCCAGCCCGCTCAGTATATCCAACCTCAATCTCATAATTTTAACC 
          
1 1 ForP CCACGC CGTATCGCCTCCCTCGCGCCATCAGCCACGCAGGATGTTAGGGTATTAAAGGTTGG 
1 1 RevP CCACGC CTATGCGCCTTGCCAGCCCGCTCAGCCACGCCCAATTTTCCTAAAACCAACAATAT 
1 2 ForP CCACGC CGTATCGCCTCCCTCGCGCCATCAGCCACGCTATATTTTTAGATGATTTGTAAAGGGTAAA 
1 2 RevP CCACGC CTATGCGCCTTGCCAGCCCGCTCAGCCACGCACCTAACTTATAAAAAACTACCACATTATC 
1 3.1 ForP CCACGC CGTATCGCCTCCCTCGCGCCATCAGCCACGCAGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTGT 
1 3.1 RevP CCACGC CTATGCGCCTTGCCAGCCCGCTCAGCCACGCTCTTACRTAACACAAACAAAAAATCAATTAAATAC 
1 3.2 ForP CCACGC CGTATCGCCTCCCTCGCGCCATCAGCCACGCGTTGTGGTATTGTGTTTGGTATATG 
1 3.2 RevP CCACGC CTATGCGCCTTGCCAGCCCGCTCAGCCACGCACACTTAATTCAAATAATCAAATTCATAAT 
1 4 ForP CCACGC CGTATCGCCTCCCTCGCGCCATCAGCCACGCTGGGTTTTTTTGGTATTTAAGAAAG 
1 4 RevP CCACGC CTATGCGCCTTGCCAGCCCGCTCAGCCACGCAAAAAACAAATAATCTACCCCACAA 
1 5 ForP CCACGC CGTATCGCCTCCCTCGCGCCATCAGCCACGCTGAAAGGTTATAATGAAATGATAAGTTTAA 
1 5 RevP CCACGC CTATGCGCCTTGCCAGCCCGCTCAGCCACGCATTACCATAACTTCCCCAAAAATAC 
1 6 ForP CCACGC CGTATCGCCTCCCTCGCGCCATCAGCCACGCTGATTGTTAATTTTGTTTTTGATTG 
1 6 RevP CCACGC CTATGCGCCTTGCCAGCCCGCTCAGCCACGCCAACCTCAATCTCATAATTTTAACC 
          
2 1 ForP GAGAGA CGTATCGCCTCCCTCGCGCCATCAGGAGAGAAGGATGTTAGGGTATTAAAGGTTGG 
2 1 RevP GAGAGA CTATGCGCCTTGCCAGCCCGCTCAGGAGAGACCAATTTTCCTAAAACCAACAATAT 
2 2 ForP GAGAGA CGTATCGCCTCCCTCGCGCCATCAGGAGAGATATATTTTTAGATGATTTGTAAAGGGTAAA 
2 2 RevP GAGAGA CTATGCGCCTTGCCAGCCCGCTCAGGAGAGAACCTAACTTATAAAAAACTACCACATTATC 
2 3.1 ForP GAGAGA CGTATCGCCTCCCTCGCGCCATCAGGAGAGAAGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTGT 
2 3.1 RevP GAGAGA CGTATCGCCTCCCTCGCGCCATCAGGAGAGATCTTACRTAACACAAACAAAAAATCAATTAAATAC 
2 3.2 ForP GAGAGA CGTATCGCCTCCCTCGCGCCATCAGGAGAGAGTTGTGGTATTGTGTTTGGTATATG 
2 3.2 RevP GAGAGA CTATGCGCCTTGCCAGCCCGCTCAGGAGAGAACACTTAATTCAAATAATCAAATTCATAAT 
2 4 ForP GAGAGA CGTATCGCCTCCCTCGCGCCATCAGGAGAGATGGGTTTTTTTGGTATTTAAGAAAG 
2 4 RevP GAGAGA CTATGCGCCTTGCCAGCCCGCTCAGGAGAGAAAAAAACAAATAATCTACCCCACAA 
2 5 ForP GAGAGA CGTATCGCCTCCCTCGCGCCATCAGGAGAGATGAAAGGTTATAATGAAATGATAAGTTTAA 
2 5 RevP GAGAGA CTATGCGCCTTGCCAGCCCGCTCAGGAGAGAATTACCATAACTTCCCCAAAAATAC 
2 6 ForP GAGAGA CGTATCGCCTCCCTCGCGCCATCAGGAGAGATGATTGTTAATTTTGTTTTTGATTG 
2 6 RevP GAGAGA CTATGCGCCTTGCCAGCCCGCTCAGGAGAGACAACCTCAATCTCATAATTTTAACC 
          
3 1 ForP ATTATA CGTATCGCCTCCCTCGCGCCATCAGATTATAAGGATGTTAGGGTATTAAAGGTTGG 
3 1 RevP ATTATA CTATGCGCCTTGCCAGCCCGCTCAGATTATACCAATTTTCCTAAAACCAACAATAT 
3 2 ForP ATTATA CGTATCGCCTCCCTCGCGCCATCAGATTATATATATTTTTAGATGATTTGTAAAGGGTAAA 
3 2 RevP ATTATA CTATGCGCCTTGCCAGCCCGCTCAGATTATAACCTAACTTATAAAAAACTACCACATTATC 
3 3.1 ForP ATTATA CGTATCGCCTCCCTCGCGCCATCAGATTATAAGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTGT 
3 3.1 RevP ATTATA CTATGCGCCTTGCCAGCCCGCTCAGATTATATCTTACRTAACACAAACAAAAAATCAATTAAATAC 
3 3.2 ForP ATTATA CGTATCGCCTCCCTCGCGCCATCAGATTATAGTTGTGGTATTGTGTTTGGTATATG 
3 3.2 RevP ATTATA CTATGCGCCTTGCCAGCCCGCTCAGATTATAACACTTAATTCAAATAATCAAATTCATAAT 
3 4 ForP ATTATA CGTATCGCCTCCCTCGCGCCATCAGATTATATGGGTTTTTTTGGTATTTAAGAAAG 
3 4 RevP ATTATA CTATGCGCCTTGCCAGCCCGCTCAGATTATAAAAAAACAAATAATCTACCCCACAA 
3 5 ForP ATTATA CGTATCGCCTCCCTCGCGCCATCAGATTATATGAAAGGTTATAATGAAATGATAAGTTTAA 
3 5 RevP ATTATA CTATGCGCCTTGCCAGCCCGCTCAGATTATAATTACCATAACTTCCCCAAAAATAC 
3 6 ForP ATTATA CGTATCGCCTCCCTCGCGCCATCAGATTATATGATTGTTAATTTTGTTTTTGATTG 
3 6 RevP ATTATA CTATGCGCCTTGCCAGCCCGCTCAGATTATACAACCTCAATCTCATAATTTTAACC 
          
4 1 ForP TCCGTC CGTATCGCCTCCCTCGCGCCATCAGTCCGTCAGGATGTTAGGGTATTAAAGGTTGG 
4 1 RevP TCCGTC CTATGCGCCTTGCCAGCCCGCTCAGTCCGTCCCAATTTTCCTAAAACCAACAATAT 
4 2 ForP TCCGTC CGTATCGCCTCCCTCGCGCCATCAGTCCGTCTATATTTTTAGATGATTTGTAAAGGGTAAA 
4 2 RevP TCCGTC CTATGCGCCTTGCCAGCCCGCTCAGTCCGTCACCTAACTTATAAAAAACTACCACATTATC 
4 3.1 ForP TCCGTC CGTATCGCCTCCCTCGCGCCATCAGTCCGTCAGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTGT 
4 3.1 RevP TCCGTC CTATGCGCCTTGCCAGCCCGCTCAGTCCGTCTCTTACRTAACACAAACAAAAAATCAATTAAATAC 
4 3.2 ForP TCCGTC CGTATCGCCTCCCTCGCGCCATCAGTCCGTCGTTGTGGTATTGTGTTTGGTATATG 
4 3.2 RevP TCCGTC CTATGCGCCTTGCCAGCCCGCTCAGTCCGTCACACTTAATTCAAATAATCAAATTCATAAT 
4 4 ForP TCCGTC CGTATCGCCTCCCTCGCGCCATCAGTCCGTCTGGGTTTTTTTGGTATTTAAGAAAG 
4 4 RevP TCCGTC CTATGCGCCTTGCCAGCCCGCTCAGTCCGTCAAAAAACAAATAATCTACCCCACAA 
4 5 ForP TCCGTC CGTATCGCCTCCCTCGCGCCATCAGTCCGTCTGAAAGGTTATAATGAAATGATAAGTTTAA 
4 5 RevP TCCGTC CTATGCGCCTTGCCAGCCCGCTCAGTCCGTCATTACCATAACTTCCCCAAAAATAC 
4 6 ForP TCCGTC CGTATCGCCTCCCTCGCGCCATCAGTCCGTCTGATTGTTAATTTTGTTTTTGATTG 
4 6 RevP TCCGTC CTATGCGCCTTGCCAGCCCGCTCAGTCCGTCCAACCTCAATCTCATAATTTTAACC 
          
5 1 ForP ATGTCA CGTATCGCCTCCCTCGCGCCATCAGATGTCAAGGATGTTAGGGTATTAAAGGTTGG 
5 1 RevP ATGTCA CTATGCGCCTTGCCAGCCCGCTCAGATGTCACCAATTTTCCTAAAACCAACAATAT 
5 2 ForP ATGTCA CGTATCGCCTCCCTCGCGCCATCAGATGTCATATATTTTTAGATGATTTGTAAAGGGTAAA 
5 2 RevP ATGTCA CTATGCGCCTTGCCAGCCCGCTCAGATGTCAACCTAACTTATAAAAAACTACCACATTATC 
5 3.1 ForP ATGTCA CGTATCGCCTCCCTCGCGCCATCAGATGTCAAGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTGT 
5 3.1 RevP ATGTCA CTATGCGCCTTGCCAGCCCGCTCAGATGTCATCTTACRTAACACAAACAAAAAATCAATTAAATAC 
5 3.2 ForP ATGTCA CGTATCGCCTCCCTCGCGCCATCAGATGTCAGTTGTGGTATTGTGTTTGGTATATG 
5 3.2 RevP ATGTCA CTATGCGCCTTGCCAGCCCGCTCAGATGTCAACACTTAATTCAAATAATCAAATTCATAAT 
5 4 ForP ATGTCA CGTATCGCCTCCCTCGCGCCATCAGATGTCATGGGTTTTTTTGGTATTTAAGAAAG 
5 4 RevP ATGTCA CTATGCGCCTTGCCAGCCCGCTCAGATGTCAAAAAAACAAATAATCTACCCCACAA 
5 5 ForP ATGTCA CGTATCGCCTCCCTCGCGCCATCAGATGTCATGAAAGGTTATAATGAAATGATAAGTTTAA 
5 5 RevP ATGTCA CTATGCGCCTTGCCAGCCCGCTCAGATGTCAATTACCATAACTTCCCCAAAAATAC 
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5 6 ForP ATGTCA CGTATCGCCTCCCTCGCGCCATCAGATGTCATGATTGTTAATTTTGTTTTTGATTG 
5 6 RevP ATGTCA CTATGCGCCTTGCCAGCCCGCTCAGATGTCACAACCTCAATCTCATAATTTTAACC 
          
6 1 ForP TGTTGT CGTATCGCCTCCCTCGCGCCATCAGTGTTGTAGGATGTTAGGGTATTAAAGGTTGG 
6 1 RevP TGTTGT CTATGCGCCTTGCCAGCCCGCTCAGTGTTGTCCAATTTTCCTAAAACCAACAATAT 
6 2 ForP TGTTGT CGTATCGCCTCCCTCGCGCCATCAGTGTTGTTATATTTTTAGATGATTTGTAAAGGGTAAA 
6 2 RevP TGTTGT CTATGCGCCTTGCCAGCCCGCTCAGTGTTGTACCTAACTTATAAAAAACTACCACATTATC 
6 3.1 ForP TGTTGT CGTATCGCCTCCCTCGCGCCATCAGTGTTGTAGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTGT 
6 3.1 RevP TGTTGT CTATGCGCCTTGCCAGCCCGCTCAGTGTTGTTCTTACRTAACACAAACAAAAAATCAATTAAATAC 
6 3.2 ForP TGTTGT CGTATCGCCTCCCTCGCGCCATCAGTGTTGTGTTGTGGTATTGTGTTTGGTATATG 
6 3.2 RevP TGTTGT CTATGCGCCTTGCCAGCCCGCTCAGTGTTGTACACTTAATTCAAATAATCAAATTCATAAT 
6 4 ForP TGTTGT CGTATCGCCTCCCTCGCGCCATCAGTGTTGTTGGGTTTTTTTGGTATTTAAGAAAG 
6 4 RevP TGTTGT CTATGCGCCTTGCCAGCCCGCTCAGTGTTGTAAAAAACAAATAATCTACCCCACAA 
6 5 ForP TCCGTC CGTATCGCCTCCCTCGCGCCATCAGTGTTGTTGAAAGGTTATAATGAAATGATAAGTTTAA 
6 5 RevP TCCGTC CTATGCGCCTTGCCAGCCCGCTCAGTGTTGTATTACCATAACTTCCCCAAAAATAC 
6 6 ForP TCCGTC CGTATCGCCTCCCTCGCGCCATCAGTGTTGTTGATTGTTAATTTTGTTTTTGATTG 
6 6 RevP TCCGTC CTATGCGCCTTGCCAGCCCGCTCAGTGTTGTCAACCTCAATCTCATAATTTTAACC 
          
7 1 ForP CAATAA CGTATCGCCTCCCTCGCGCCATCAGCAATAAAGGATGTTAGGGTATTAAAGGTTGG 
7 1 RevP CAATAA CTATGCGCCTTGCCAGCCCGCTCAGCAATAACCAATTTTCCTAAAACCAACAATAT 
7 2 ForP CAATAA CGTATCGCCTCCCTCGCGCCATCAGCAATAATATATTTTTAGATGATTTGTAAAGGGTAAA 
7 2 RevP CAATAA CTATGCGCCTTGCCAGCCCGCTCAGCAATAAACCTAACTTATAAAAAACTACCACATTATC 
7 3.1 ForP CAATAA CGTATCGCCTCCCTCGCGCCATCAGCAATAAAGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTGT 
7 3.1 RevP CAATAA CTATGCGCCTTGCCAGCCCGCTCAGCAATAATCTTACRTAACACAAACAAAAAATCAATTAAATAC 
7 3.2 ForP CAATAA CGTATCGCCTCCCTCGCGCCATCAGCAATAAGTTGTGGTATTGTGTTTGGTATATG 
7 3.2 RevP CAATAA CTATGCGCCTTGCCAGCCCGCTCAGCAATAAACACTTAATTCAAATAATCAAATTCATAAT 
7 4 ForP CAATAA CGTATCGCCTCCCTCGCGCCATCAGCAATAATGGGTTTTTTTGGTATTTAAGAAAG 
7 4 RevP CAATAA CTATGCGCCTTGCCAGCCCGCTCAGCAATAAAAAAAACAAATAATCTACCCCACAA 
7 5 ForP CAATAA CGTATCGCCTCCCTCGCGCCATCAGCAATAATGAAAGGTTATAATGAAATGATAAGTTTAA 
7 5 RevP CAATAA CTATGCGCCTTGCCAGCCCGCTCAGCAATAAATTACCATAACTTCCCCAAAAATAC 
7 6 ForP CAATAA CGTATCGCCTCCCTCGCGCCATCAGCAATAATGATTGTTAATTTTGTTTTTGATTG 
7 6 RevP CAATAA CTATGCGCCTTGCCAGCCCGCTCAGCAATAACAACCTCAATCTCATAATTTTAACC 
          
8 1 ForP GCTACC CGTATCGCCTCCCTCGCGCCATCAGGCTACCAGGATGTTAGGGTATTAAAGGTTGG 
8 1 RevP GCTACC CTATGCGCCTTGCCAGCCCGCTCAGGCTACCCCAATTTTCCTAAAACCAACAATAT 
8 2 ForP GCTACC CGTATCGCCTCCCTCGCGCCATCAGGCTACCTATATTTTTAGATGATTTGTAAAGGGTAAA 
8 2 RevP GCTACC CTATGCGCCTTGCCAGCCCGCTCAGGCTACCACCTAACTTATAAAAAACTACCACATTATC 
8 3.1 ForP GCTACC CGTATCGCCTCCCTCGCGCCATCAGGCTACCAGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTGT 
8 3.1 RevP GCTACC CTATGCGCCTTGCCAGCCCGCTCAGGCTACCTCTTACRTAACACAAACAAAAAATCAATTAAATAC 
8 3.2 ForP GCTACC CGTATCGCCTCCCTCGCGCCATCAGGCTACCGTTGTGGTATTGTGTTTGGTATATG 
8 3.2 RevP GCTACC CTATGCGCCTTGCCAGCCCGCTCAGGCTACCACACTTAATTCAAATAATCAAATTCATAAT 
8 4 ForP GCTACC CGTATCGCCTCCCTCGCGCCATCAGGCTACCTGGGTTTTTTTGGTATTTAAGAAAG 
8 4 RevP GCTACC CTATGCGCCTTGCCAGCCCGCTCAGGCTACCAAAAAACAAATAATCTACCCCACAA 
8 5 ForP GCTACC CGTATCGCCTCCCTCGCGCCATCAGGCTACCTGAAAGGTTATAATGAAATGATAAGTTTAA 
8 5 RevP GCTACC CTATGCGCCTTGCCAGCCCGCTCAGGCTACCATTACCATAACTTCCCCAAAAATAC 
8 6 ForP GCTACC CGTATCGCCTCCCTCGCGCCATCAGGCTACCTGATTGTTAATTTTGTTTTTGATTG 
8 6 RevP GCTACC CTATGCGCCTTGCCAGCCCGCTCAGGCTACCCAACCTCAATCTCATAATTTTAACC 
          
9 1 ForP CGTACG CGTATCGCCTCCCTCGCGCCATCAGCGTACGAGGATGTTAGGGTATTAAAGGTTGG 
9 1 RevP CGTACG CTATGCGCCTTGCCAGCCCGCTCAGCGTACGCCAATTTTCCTAAAACCAACAATAT 
9 2 ForP CGTACG CGTATCGCCTCCCTCGCGCCATCAGCGTACGTATATTTTTAGATGATTTGTAAAGGGTAAA 
9 2 RevP CGTACG CTATGCGCCTTGCCAGCCCGCTCAGCGTACGACCTAACTTATAAAAAACTACCACATTATC 
9 3.1 ForP CGTACG CGTATCGCCTCCCTCGCGCCATCAGCGTACGAGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTGT 
9 3.1 RevP CGTACG CTATGCGCCTTGCCAGCCCGCTCAGCGTACGTCTTACRTAACACAAACAAAAAATCAATTAAATAC 
9 3.2 ForP CGTACG CGTATCGCCTCCCTCGCGCCATCAGCGTACGGTTGTGGTATTGTGTTTGGTATATG 
9 3.2 RevP CGTACG CTATGCGCCTTGCCAGCCCGCTCAGCGTACGACACTTAATTCAAATAATCAAATTCATAAT 
9 4 ForP CGTACG CGTATCGCCTCCCTCGCGCCATCAGCGTACGTGGGTTTTTTTGGTATTTAAGAAAG 
9 4 RevP CGTACG CTATGCGCCTTGCCAGCCCGCTCAGCGTACGAAAAAACAAATAATCTACCCCACAA 
9 5 ForP CGTACG CGTATCGCCTCCCTCGCGCCATCAGCGTACGTGAAAGGTTATAATGAAATGATAAGTTTAA 
9 5 RevP CGTACG CTATGCGCCTTGCCAGCCCGCTCAGCGTACGATTACCATAACTTCCCCAAAAATAC 
9 6 ForP CGTACG CGTATCGCCTCCCTCGCGCCATCAGCGTACGTGATTGTTAATTTTGTTTTTGATTG 
9 6 RevP CGTACG CTATGCGCCTTGCCAGCCCGCTCAGCGTACGCAACCTCAATCTCATAATTTTAACC 
          
10 1 ForP ACTCTC CGTATCGCCTCCCTCGCGCCATCAGACTCTCAGGATGTTAGGGTATTAAAGGTTGG 
10 1 RevP ACTCTC CTATGCGCCTTGCCAGCCCGCTCAGACTCTCCCAATTTTCCTAAAACCAACAATAT 
10 2 ForP ACTCTC CGTATCGCCTCCCTCGCGCCATCAGACTCTCTATATTTTTAGATGATTTGTAAAGGGTAAA 
10 2 RevP ACTCTC CTATGCGCCTTGCCAGCCCGCTCAGACTCTCACCTAACTTATAAAAAACTACCACATTATC 
10 3.1 ForP ACTCTC CGTATCGCCTCCCTCGCGCCATCAGACTCTCAGTGTTTAGTTTTTGTTTTTTTTTTAGGTTTTGT 
10 3.1 RevP ACTCTC CTATGCGCCTTGCCAGCCCGCTCAGACTCTCTCTTACRTAACACAAACAAAAAATCAATTAAATAC 
10 3.2 ForP ACTCTC CGTATCGCCTCCCTCGCGCCATCAGACTCTCGTTGTGGTATTGTGTTTGGTATATG 
10 3.2 RevP ACTCTC CTATGCGCCTTGCCAGCCCGCTCAGACTCTCACACTTAATTCAAATAATCAAATTCATAAT 
10 4 ForP ACTCTC CGTATCGCCTCCCTCGCGCCATCAGACTCTCTGGGTTTTTTTGGTATTTAAGAAAG 
10 4 RevP ACTCTC CTATGCGCCTTGCCAGCCCGCTCAGACTCTCAAAAAACAAATAATCTACCCCACAA 
10 5 ForP ACTCTC CGTATCGCCTCCCTCGCGCCATCAGACTCTCTGAAAGGTTATAATGAAATGATAAGTTTAA 
10 5 RevP ACTCTC CTATGCGCCTTGCCAGCCCGCTCAGACTCTCATTACCATAACTTCCCCAAAAATAC 
10 6 ForP ACTCTC CGTATCGCCTCCCTCGCGCCATCAGACTCTCTGATTGTTAATTTTGTTTTTGATTG 
10 6 RevP ACTCTC CTATGCGCCTTGCCAGCCCGCTCAGACTCTCCAACCTCAATCTCATAATTTTAACC 
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10.4 List of Sybr primers and Taqman probes used for qPCR 
Taqman Probes for qPCR with Taqman Master Mix 
Gene name Primer name / Order number Conjugate 
Mouse Dtx-1 Mm00492297_m1 FAM 
Mouse Dtx-2 Mm00470116_m1 FAM 
Mouse Foxp3 Mm00475162_m1 FAM 
Mouse Hes1 Mm01342805_m1 FAM 
Mouse Hey1 Mm00468865_m1 FAM 
Mouse HPRT Mm01318746_g1 FAM 
Mouse HPRT Mm03024075_m1 FAM 
Mouse Il2ra Mm01340213_m1 FAM 
Mouse Il7r Mm00434295_m1 FAM 
Mouse Notch1 Mm00435249_m1 FAM 
Mouse Notch2 Mm00803072_m1 FAM 
Mouse Notch3 Mm01345646_m1 FAM 
Mouse Notch4 Mm00440525_m1 FAM 
Mouse GATA-3 Mm00484683_m1 FAM 
Mouse Tbx21 Mm00450960_m1 FAM 
Mouse IRF4 Mm00516431_m1 FAM 
Mouse Rbpj Mm0070450_m1 FAM 
Mouse Rbpj Mm01217627_g1 FAM 
 
Sybr Primers for the detection of common Treg / Tconv genes and general immunophenotyping 
Gene name Primer name Sequence 
Mouse Atf3 Atf3_Syb_ForP1 GAGGATTTTGCTAACCTGACACC 
Mouse Atf3 Atf3_Syb_RevP1 TTGACGGTAACTGACTCCAGC 
Mouse cActin cActin_for GTTTGAGACCTTCAACACCCCA 
Mouse cActin cActin_rev GACCAGAGGCATACAGGGACA 
Mouse CCL2 CCL2_Syb_ForP2 AGGTCCCTGTCATGCTTCTG 
Mouse CCL2 CCL2_Syb_RevP2 GCTGCTGGTGATCCTCTTGT 
Mouse Ccl4 (MiP-1) Ccl4_Syb_ForP1 ATGAAGCTCTGCGTGTCTG  
Mouse Ccl4 (MiP-1) Ccl4_Syb_RevP1 GAAACAGCAGGAAGTGGGAG  
Mouse CCL5 (Rantes) CCL5_Syb_ForP2 CTGCTGCTTTGCCTACCTCT 
Mouse CCL5 (Rantes) CCL5_Syb_RevP2 CCCACTTCTTCTCTGGGTTG 
Mouse Cd200r1 CD200R1_ForP1 AGGCATTTCCAGTATCACAAGG 
Mouse Cd200r1 CD200R1_RevP1 CCAATGGCCGACAAAGTAAGG 
Mouse Cd4 CD4_ForP1 TCCTAGCTGTCACTCAAGGGA 
Mouse Cd4 CD4_RevP1 TCAGAGAACTTCCAGGTGAAGA 
Mouse Cd8a CD8a_ForP1 CCGTTGACCCGCTTTCTGT 
Mouse Cd8a CD8a_RevP1 CGGCGTCCATTTTCTTTGGAA 
Mouse Cd8b CD8b_ForP1 CTCTGGCTGGTCTTCAGTATGA 
Mouse Cd8b CD8b_RevP1 TCTTTGCCGTATGGTTGGTTT 
Mouse Crp Crp_Syb_ForP1 GCTACTCTGGTGCCTTCTGAT 
Mouse Crp Crp_Syb_RevP1 CAGTAAAGGTGTTCAGTGGCTTC 
Mouse Ctla4 CTLA4_ForP1 GCTTCCTAGATTACCCCTTCTGC 
Mouse Ctla4 CTLA_RevP1 CGGGCATGGTTCTGGATCA 
Mouse Cxcl1 CXCL1 ForP1 CTGGGATTCACCTCAAGAACATC 
Mouse Cxcl1 CXCL1 RevP1 CAGGGTCAAGGCAAGCCTC 
Mouse CXCL1 CXCL1_Syb_ForP1 CTGGGATTCACCTCAAGAACATC 
Mouse CXCL1 CXCL1_Syb_RevP1 CAGGGTCAAGGCAAGCCTC 
Mouse Cxcl10 Cxcl10_Syb_ForP1 CTCATCCTGCTGGGTCTGAG 
Mouse Cxcl10 Cxcl10_Syb_RevP1 CCTATGGCCCTCATTCTCAC  
Mouse Dapl1 Dapl1_ForP1 ATGGCAAACGAAGTACAAGTTCT 
Mouse Dapl1 Dapl1_RevP1 TCTTTCCAAAACGCCCATCTC 
Mouse Foxp3 mFoxp3_Syb_ForP1 AGAAGCTGGGAGCTATGCAG 
Mouse Foxp3 mFoxp3_Syb_RevP1 TACTGGTGGCTACGATGCAG 
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Mouse Gata3 Gata3 ForP CTCGGCCATTCGTACATGGAA 
Mouse Gata3 Gata3 RevP GGATACCTCTGCACCGTAGC 
Mouse HPRT HPRT SYB forP2 CTTTGCTGACCTGCTGGATT 
Mouse HPRT HPRT SYB revP2 TATGTCCCCCGTTGACTGAT 
Mouse Ifng Ifng_Syb_ForP1 CAGCAACAGCAAGGCGAAA 
Mouse Ifng Ifng_Syb_RevP1 CTGGACCTGTGGGTTGTTGAC 
Mouse Il10 IL-10_Syb_ForP1 ATCGATTTCTCCCCTGTGAA 
Mouse Il10 IL-10_Syb_RevP1 TGTCAAATTCATTCATGGCCT 
Mouse Il17a IL17A ForP TTTAACTCCCTTGGCGCAAAA 
Mouse Il17a IL17A RevP CTTTCCCTCCGCATTGACAC 
Mouse IL1b IL1b_Syb_ForP1 AGTTGACGGACCCCAAAAG 
Mouse IL1b IL1b_Syb_RevP1 CTTCTCCACAGCCACAATGA 
Mouse Il2 IL2_ForP TGAGCAGGATGGAGAATTACAGG 
Mouse Il2 IL2_RevP GTCCAAGTTCATCTTCTAGGCAC 
Mouse Il2ra IL2ra_ForP1 AACCATAGTACCCAGTTGTCGG 
Mouse Il2ra IL2ra_RevP1 TCCTAAGCAACGCATATAGACCA 
Mouse Il2rb IL2rb_ForP1 TGGAGCCTGTCCCTCTACG 
Mouse Il2rb IL2rb_RevP1 TCCACATGCAAGAGACATTGG 
Mouse Il4 IL4 ForP GGTCTCAACCCCCAGCTAGT 
Mouse Il4 IL4 RevP GCCGATGATCTCTCTCAAGTGAT 
Mouse Il6 Il6_Syb_ForP1 GATGGATGCTACCAAACTGGA 
Mouse Il6 Il6_Syb_RevP1 TCTGAAGGACTCTGGCTTTG 
Mouse Il7 IL7_ForP TTCCTCCACTGATCCTTGTTCT 
Mouse Il7 IL7_RevP AGCAGCTTCCTTTGTATCATCAC 
Mouse Itgam (CD11b) Itgam_Syb_ForP1 ATTCGGTGATCCCTTGGATT  
Mouse Itgam (CD11b) Itgam_Syb_RevP1 GTTTGTTGAAGGCATTTCCC  
Mouse Lrcc32 Lrcc32_ForP1_MD TCAGCGTCGAGAGCAAGTG 
Mouse Lrcc32 Lrcc32_RevP1_MD GTAGAGAGCTTGGATGTCCAGT 
Mouse Lrcc32 Lrcc32_ForP2_MD GGACATCCAAGCTCTCTACTTGT 
Mouse Lrcc32 Lrcc32_RevP2_MD GAGGAAGCTAATCTGGTTGTCAC 
Mouse LT alpha LT alpha ForP CCACCTCTTGAGGGTGCTTG 
Mouse LT alpha LT alpha RevP CATGTCGGAGAAAGGCACGAT 
Mouse NKg7 Nkg7_ForP1 TCAAGTCCAGACATTCTTCTCCT 
Mouse NKg7 Nkg7_RevP1 CACAAGGTTTCATACTCAGCCC 
Mouse Plac8 Plac8_ForP1 GCTCAGGCACCAACAGTTATC 
Mouse Plac8 Plac8_RevP1 GCTGCCACTTGACATCCAAGA 
Mouse RBPJ RBPJ_Sybr_E5-6_ForP AACAGCGATGACATTGGTGTG 
Mouse RBPJ RBPJ_Sybr_E5-6_RevP ACCGAAGGCGATTGAACAGTG 
Mouse RBPJ RBPJ_Sybr_E6-7_ForP TTTCCACGCCAGTTCACAACA 
Mouse RBPJ RBPJ_Sybr_E6-7_RevP TCTGCCCGTAATGGATGTAGC 
Mouse RBPJ RBPJ_Sybr_E2-3_ForP CTCCACCCAAACGACTCACTA 
Mouse RBPJ RBPJ_Sybr_E2-3_RevP TCCAACCACTGCCCATAAGATA 
Mouse RBPJ RBPJ_Sybr_E1_ForP ATGCCCTCCGGTTTTCCTC 
Mouse RBPJ RBPJ_Sybr_E1_RevP GGACAAGCCCTCCGAGTAGT 
Mouse RORgT RORgT ForP GACCCACACCTCACAAATTGA 
Mouse RORgT RORgT RevP AGTAGGCCACATTACACTGCT 
Mouse Saa1 Saa1_Syb_ForP1 AGTCTGCCATGGAGGGTTTT 
Mouse Saa1 Saa1_Syb_RevP1 CCCGAGCATGGAAGTATTTG 
Mouse St8Sia6 St8Sia6_ForP1 TCCTGCGTATGCTCTGGTG 
Mouse St8Sia6 St8Sia6_RevP1 CTGTTCCTGGTGCGTGGTA 
Mouse T-bet T-bet ForP AGCAAGGACGGCGAATGTT 
Mouse T-bet T-bet RevP GGGTGGACATATAAGCGGTTC 
Mouse Tgfb1 Tgfb1_Syb_ForP1 GGAGAGCCCTGGATACCAA 
Mouse Tgfb1 Tgfb1_Syb_RevP1 AGGGTCCCAGACAGAAGTTG 
Mouse Tnf Tnf_Syb_ForP1 CCACCACGCTCTTCTGTCTAC 
Mouse Tnf Tnf_Syb_RevP1 AGGGTCTGGGCCATAGAACT 
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Sybr Primers for Chromatin IP target binding verification 
Gene name Primer name Sequence 
Mouse Dtx1 Dtx1_RBPJ-BS1_Sybr_ForP1 CCTCCCTGGGAAGCTGAG 
Mouse Dtx1 Dtx1_RBPJ-BS1_Sybr_RevP1 GCTCTGATGAAGCCCAGGT 
Mouse Dtx1 Dtx1_RBPJ-BS2_Sybr_ForP1 AAAAGGGAGTTCTTGTGAAGCA 
Mouse Dtx1 Dtx1_RBPJ-BS2_Sybr_RevP1 ATTTCCCAGCCTTCCCTGT 
Mouse Hes1 Hes1_RBPJ-BS1_Sybr_ForP1 CATTTCCTTTCTGCCCAGTAG 
Mouse Hes1 Hes1_RBPJ-BS1_Sybr_RevP1 GCCCATTCATTCCTCTCTTG 
Mouse Hes1 Hes1_RBPJ-BS2_Sybr_ForP1 GCGTGTCTCTTCCTCCCATT 
Mouse Hes1 Hes1_RBPJ-BS2_Sybr_RevP1 GGCCTCTATATATATCTGGGACTGC 
Mouse Hes1 Hes1_RBPJ-BS3_Sybr_ForP1 CACAGCGGGACTCCTTTTAC 
Mouse Hes1 Hes1_RBPJ-BS3_Sybr_RevP1 CTTCGCCTCTTCTCCATGAT 
Mouse IL7R RBPJ FR1 FORP1           TGCCCTGAATTTCATCCAGAA 
Mouse IL7R RBPJ FR1 FORP2           TTTCAGCCCTGCCTTAACTG 
Mouse IL7R RBPJ FR1 REVP1           ACGTCTGGCCTTGAACTTTC 
Mouse IL7R RBPJ FR1 REVP2           TTACAAGGTACGTCTGGCCT 
Mouse IL7R RBPJ FR2 FORP1           GAAAGTTCAAGGCCAGACGT 
Mouse IL7R RBPJ FR2 FORP2           AGGCCAGACGTACCTTGTAA 
Mouse IL7R RBPJ FR2 REVP1           TGAGAAGGATTCAACTGCGTG 
Mouse IL7R RBPJ FR2 REVP2           CTGGGGAACGGTGGTAATGA 
Mouse IL7R RBPJ RR1 FORP1          ACCCAAGTTGTCATTTCCGTG 
Mouse IL7R RBPJ RR1 FORP2           TGTCATTTCCGTGAAGATACCAC 
Mouse IL7R RBPJ RR1 REVP1           CAGGTACACTCAGATGTCCAGA 
Mouse IL7R RBPJ RR1 REVP2           AGGTTTTCACTAGGTTTTCAGGT 
Mouse IL7R RBPJ FR3 FORP1           GGAGAGAGTGAAAATTCCCAACT 
Mouse IL7R RBPJ FR3 REVP1           TGGAGTTCTGTAGGCCTTTTG 
Mouse IL7R RBPJ FR3 REVP2           TCTATTTGGAGTTCTGTAGGCCT 
Mouse IL7R RBPJ RR2 FORP1          ATAGCTGGTCAGTGGCCA 
Mouse IL7R RBPJ RR2 FORP2          TTAGCAACAACTGATATGAGCAC 
Mouse IL7R RBPJ RR2 REVP1           ACAATGTCACAAAAGCATGGG 
Mouse IL7R RBPJ RR2 REVP2           CTGCTGTGTTACCTCTCTTTCC 
Mouse IL7R RBPJ RR3 FORP1          CCCATGCTTTTGTGACATTGT 
Mouse IL7R RBPJ RR3 FORP2          GGAAAGAGAGGTAACACAGCAG 
Mouse IL7R RBPJ RR3 REVP1           AGGCTGGTGTGTCTTTTGGT 
Mouse IL7R RBPJ RR3 REVP2           TGTGGGCCTTTTATAGCAGAG 
Mouse IL7R RBPJ IR1 FORP1            CAGCAGAGACAACAGGATGG 
Mouse IL7R RBPJ IR1 REVP              CTGTGGTGGGAGAACTGAGT 
Mouse IL7R RBPJ IR2 FORP1            TGTGGAAGCTGAACAACACTC 
Mouse IL7R RBPJ IR2 REVP              TTGGGTATGTTGTGGCTTCA 
Mouse IL7R RBPJ IR3 FORP1            TGCAGATGTCCATGGTCTGT 
Mouse IL7R RBPJ IR3 REVP              TAGCAGTACAGGCCACTCAC 
Mouse IL7R RBPJ IR4 FORP1            AAGGCTGCTAATTCCACCCT 
Mouse IL7R RBPJ IR4 REVP              AAGTACTTGGGTCAGGAGGC 
 
Sybr Primers for Foxp3-promoter binding protein – gene expression verification in murine cells 
Gene name Primer name Sequence 
Mouse Cux1 mCux1_Sybr_ForP1 TGACCTGAGCGGTCCTTACA 
Mouse Cux1 mCux1_Sybr_RevP1 TGGGGCCATGCCATTTACATC 
Mouse Hnrnpab mHnrnpab_Sybr_ForP1 ATGGCGGCTACGACTACTC 
Mouse Hnrnpab mHnrnpab_Sybr_RevP1 GCTGGCTCTTTCCGTAATTTGT 
Mouse Hnrnpd mHnrnpd_Sybr_ForP1 GTGAAGTTGTAGACTGCACTCTG 
Mouse Hnrnpd mHnrnpd_Sybr_RevP1 CCAAAACCCCTTGATCGCC 
Mouse Hnrnpk mHnrnpk_SybrP_ForP1 CAGCTCCCGCTCGAATCTG 
Mouse Hnrnpk mHnrnpk_SybrP_RevP1 ACCCTATCAGGTTTTCCTCCAA 
Mouse Naa38 mNaa38_Sybr_ForP1 GGCTGTTATTACTTCTGATGGCA 
Mouse Naa38 mNaa38_Sybr_RevP1 ACACCACTTGTTCTACTCCCT 
Mouse Nfya mNfya_Sybr_ForP1 GTTAATGGTGCAAGTCAGTGGA 
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Mouse Nfya mNfya_Sybr_RevP1 TCTGCTGTAAACCTTGTGTTCC 
Mouse Pcbp1 mPcbp1_SybrP_ForP1 GACGCCGGTGTGACTGAAA 
Mouse Pcbp1 mPcbp1_SybrP_RevP1 GTCAGCGTGATGATCCTCTCC 
Mouse Pcbp2 mPcbp2_SybrP_ForP1 GCCAGATTTGACCAAGCTGC 
Mouse Pcbp2 mPcbp2_SybrP_RevP1 GAGCTGGATTCAATGCCACTG 
Mouse Rfx1 mRfx1_Sybr_ForP1 GTTCACGTTGCTCAAGAGGTA 
Mouse Rfx1 mRfx1_Sybr_RevP1 TACTGGTAGGTGCTAGAGCGG 
Mouse Rfx1 mRfx1_Sybr_ForP2 AGTACCCGGAGACGCCTATC 
Mouse Rfx1 mRfx1_Sybr_RevP2 CTGCCGGACACATACATGG 
Mouse Rpa1 mRpa1_SybrP_ForP1 ACATCCGTCCCATTTCTACAGG 
Mouse Rpa1 mRpa1_Sybr_RevP1 CTCCCTCGACCAGGGTGTT 
Mouse Sf1 mSf1_Sybr_ForP1 AGCCGATGGAACCAAGACAC 
Mouse Sf1 mSf1_Sybr_RevP1 GCACTATGTAAGCTCTTTCCTGT 
Mouse Sf1 mSf1_Sybr_ForP2 AGAAGACCTGACTCGTAAACTGC 
Mouse Sf1 mSf1_Sybr_RevP2 CCCTCGCTGTTGTAGATTGGT 
Mouse Snapc1 mSnapc1_Sybr_ForP1 CGCTTCCAAGAGATGGACAG 
Mouse Snapc1 mSnapc1_Sybr_RevP1 CGTGTGTGGAGGCAAAAAGTAG 
Mouse Ssbp1 mSsbp1_Sybr_ForP1 CAACAAATGAGATGTGGCGATCA 
Mouse Ssbp1 mSsbp1_Sybr_RevP1 ACGAGCTTCTTACCAGCTATGA 
Mouse Tfcp2 mTfcp2_Sybr_ForP1 TGAGTGATGTCCTCGCATTGC 
Mouse Tfcp2 mTfcp2_Sybr_RevP1 TCGTTCTCATTATCGGGAGGC 
Mouse Tgif2 mTgif2_Sybr_ForP1 ATGTCGGACAGCGATCTAGG 
Mouse Tgif2 mTgif2_Sybr_RevP1 TCCCGGAGGATCTTTACTGAC 
Mouse Thap11 mThap11_Sybr_ForP1 ATGCCTGGCTTTACGTGCT 
Mouse Thap11 mThap11_Sybr_RevP1 GGTGGGTTGGAAGGTGGAG 
Mouse Ybx1 mYbx1_Sybr_ForP1 CAGACCGTAACCATTATAGACGC 
Mouse Ybx1 mYbx1_Sybr_RevP1 ATCCCTCGTTCTTTTCCCCAC 
Mouse Zfp574 mZfp574_Sybr_ForP1 ACATTGAGCACCGCTATGTCT 
Mouse Zfp574 mZfp574_Sybr_RevP1 CTCTCTTGGATGAGGGTCTGATA 
Mouse Zfp691 mZnf691_Sybr_ForP1 GGAGAAGGGGCTAAACCTTGG 
Mouse Zfp691 mZnf691_Sybr_RevP1 GCAGTGACTTTCTGCCTTGTCT 
Mouse Zfp691 mZnf691_Sybr_ForP2 GGAGAGTGGATGGCTCAAAGG 
Mouse Zfp691 mZnf691_Sybr_RevP2 CGTTCTCAGGTTGGAGGTATTGT 
Mouse Zfp691 mZnf691_Sybr_ForP3 ATACCTCCAACCTGAGAACGC 
Mouse Zfp691 mZnf691_Sybr_RevP3 GGCGCATTGGTAGTGCTTC 
Mouse Zfp692 mZfp692_Sybr_ForP1 GGTGCTCCTGTCTCACACAC 
Mouse Zfp692 mZfp692_Sybr_RevP1 CTGCTTAGGTACATCTGAAGGTG 
 
Sybr Primers for Foxp3-promoter binding protein – gene expression verification in human cells 
Gene name Primer name Sequence 
Human Cux1 Human Cux1_Sybr_ForP1 GAAGAACCAAGCCGAAACCAT 
Human Cux1 Human Cux1_Sybr_RevP1 AGGCTCTGAACCTTATGCTCA 
Human Foxp3 hFoxp3_Sybr_ForP1 GTGGCCCGGATGTGAGAAG 
Human Foxp3 hFoxp3_Sybr_RevP1 GGAGCCCTTGTCGGATGATG 
Human Hnrnpab Human Hnrnpab_Sybr_ForP1 ACCGAGAACGGACATGAGG 
Human Hnrnpab Human Hnrnpab_Sybr_RevP1 GCCACCAACGAACATTTTTCC 
Human Hnrnpd Human Hnrnpd_Sybr_ForP1 GCGTGGGTTCTGCTTTATTACC 
Human Hnrnpd Human Hnrnpd_Sybr_RevP1 TTGCTGATATTGTTCCTTCGACA 
Human Hnrnpk Human Hnrnpk_SybrP_ForP1 CAATGGTGAATTTGGTAAACGCC 
Human Hnrnpk Human Hnrnpk_SybrP_RevP1 GTAGTCTGTACGGAGAGCCTTA 
Human Hnrnpk Human Hnrnpk_SybrP_ForP2 GCAGGAGGAATTATTGGGGTC 
Human Hnrnpk Human Hnrnpk_SybrP_RevP2 TGCACTCTACAACCCTATCGG 
Human Naa38 Human Naa38_Sybr_ForP1 GCATTCGCATGACAGATGGAC 
Human Naa38 Human Naa38_Sybr_RevP1 CGACGGCTTGAGGAACTCC 
Human Nfya Human Nfya_Sybr_ForP1 CAGTGGAGGCCAGCTAATCAC 
Human Nfya Human Nfya_Sybr_RevP1 CCAGGTGGGACCAACTGTATT 
Human Nfya Human Nfya_Sybr_ForP2 TGAAGGGCAGACCATCGTCTA 
Human Nfya Human Nfya_Sybr_RevP2 TCCTGTTTGAACAATCTGTGCT 
Human Pcbp1 Human Pcbp1_SybrP_ForP1 GCCGGTGTGACTGAAAGTG 
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Human Pcbp1 Human Pcbp1_SybrP_RevP1 CCCAATGATGCTTCCTACTTCC 
Human Pcbp1 Human Pcbp1_SybrP_ForP2 AAGAAAGGGGAGTCGGTTAAGA 
Human Pcbp1 Human Pcbp1_SybrP_RevP2 GCCGGTCAGAGTGATGATTCTC 
Human Pcbp2 Human Pcbp2_SybrP_ForP1 ACTCTCACCATCCGGCTACTT 
Human Pcbp2 Human Pcbp2_SybrP_RevP1 TCGCGCATCTTCTTAACTGATTC 
Human Pcbp2 Human Pcbp2_SybrP_ForP2 GCGCAGATCAAAATTGCGAAC 
Human Pcbp2 Human Pcbp2_SybrP_RevP2 ATATTGAGCCAGGCTAATGCTG 
Human Rfx1 Human Rfx1_Sybr_ForP1 CGTGGCTCAAGAGGTGCAG 
Human Rfx1 Human Rfx1_Sybr_RevP1 TCTCGGGATAGGAGTAGGTGC 
Human Rfx1 Human Rfx1_Sybr_ForP2 CGGCAAGCACCAGCTACTAC 
Human Rfx1 Human Rfx1_Sybr_RevP2 GGACACGTACATGGGCATGG 
Human Rpa1 Human Rpa1_SybrP_ForP1 GGGGATACAAACATAAAGCCCA 
Human Rpa1 Human Rpa1_Sybr_RevP1 CGATAACGCGGCGGACTATT 
Human Rpa1 Human Rpa1_SybrP_ForP2 CGGGAATGGGTTCTACTGTTTC 
Human Rpa1 Human Rpa1_Sybr_RevP2 CGAGCACAAATGGTCCACTTG 
Human Sf1 Human Sf1_Sybr_ForP1 GAAGACCTGACTCGTAAACTGC 
Human Sf1 Human Sf1_Sybr_RevP1 CCTCGCTATTGTAGATGGGCT 
Human Sf1 Human Sf1_Sybr_ForP2 GGAGCGGCACAACCTCATC 
Human Sf1 Human Sf1_Sybr_RevP2 CCGGATCATAATCTTGGCATTGC 
Human Snapc1 Human Snapc1_Sybr_ForP1 CGGACAGTGTACGCTTCGAG 
Human Snapc1 Human Snapc1_Sybr_RevP1 ATCGCCAAGCCAAAGCTAAAG 
Human Snapc1 Human Snapc1_Sybr_ForP2 AGAGTTGGTGCTTTGTATCTGC 
Human Snapc1 Human Snapc1_Sybr_RevP2 GCTCTGTCTAGTCGTAGCTTCC 
Human Ssbp1 Human Ssbp1_Sybr_ForP1 TGAGTCCGAAACAACTACCAGT 
Human Ssbp1 Human Ssbp1_Sybr_RevP1 CCTGATCGCCACATCTCATTAG 
Human Ssbp1 Human Ssbp1_Sybr_ForP2 ACTGGGTGATGTCAGTCAAAAG 
Human Ssbp1 Human Ssbp1_Sybr_RevP2 TGCTTGTCGCCTCACATTATT 
Human Tfcp2 Human Tfcp2_Sybr_ForP1 TCTGGCCGACGAAGTGATTG 
Human Tfcp2 Human Tfcp2_Sybr_RevP1 ATCAGGAGGCAAACTCGACTC 
Human Tfcp2 Human Tfcp2_Sybr_ForP1 GTGTTCCATGACAGAAGGCTT 
Human Tfcp2 Human Tfcp2_Sybr_RevP1 TTATACCCACAGACATCGGGAT 
Human Tgif2 Human Tgif2_Sybr_ForP1 TGACCCCTGGTAGCACACTTA 
Human Tgif2 Human Tgif2_Sybr_RevP1 GTGGTGGCGTGTTGAAGAGT 
Human Thap11 Human Thap11_Sybr_ForP1 ATGCCTGGCTTTACGTGCT 
Human Thap11 Human Thap11_Sybr_RevP1 GCGTCCTTTGGAAACGTGTAG 
Human Thap11 Human Thap11_Sybr_ForP2 ATACTGGCTCCGACCATTCG 
Human Thap11 Human Thap11_Sybr_RevP2 CTTGGCCTCAGTGAGACGC 
Human Ybx1 Human Ybx1_Sybr_ForP1 GGGGACAAGAAGGTCATCGC 
Human Ybx1 Human Ybx1_Sybr_RevP1 CGAAGGTACTTCCTGGGGTTA 
Human Ybx1 Human Ybx1_Sybr_ForP2 CCCCAGGAAGTACCTTCGC 
Human Ybx1 Human Ybx1_Sybr_RevP2 AGCGTCTATAATGGTTACGGTCT 
Human Zfp574 Human Zfp574_Sybr_ForP1 ACATTGAGCACCGCTATGTCT 
Human Zfp574 Human Zfp574_Sybr_RevP1 CCTGCACAAGGGTCTGATAGA 
Human Zfp574 Human Zfp574_Sybr_ForP1 AGACCCTTGTGCAGGAGAG 
Human Zfp574 Human Zfp574_Sybr_RevP1 GTGGTGCCTTAGGTGATGGC 
Human Zfp691 Human Znf691_Sybr_ForP1 GAGCAGAGTCCAGAACCACAC 
Human Zfp691 Human Znf691_Sybr_RevP1 GCAGTTCATCCGACAGGCT 
Human Zfp691 Human Znf691_Sybr_ForP2 TCGGATGAACTGCAAGAAACTC 
Human Zfp691 Human Znf691_Sybr_RevP2 TGTGTTCTCAGGTTGGAGGTA 
Human Zfp692 Human Zfp692_Sybr_ForP1 TTCCGCACTAGCAGCAACC 
Human Zfp692 Human Zfp692_Sybr_RevP1 AAACCCGCATATCTCACACTG 
Human Zfp692 Human Zfp692_Sybr_ForP2 TGTGAGATATGCGGGTTTACCT 
Human Zfp692 Human Zfp692_Sybr_RevP2 TGACTCTTGAGGGGCTAGAAG 
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TOPO Cloning Primers for inverted ChIP candidate proteins and Foxp3 promoter luciferase cloning 
Gene name Primer name Sequence 
Human Cux1 Human Cux1_Sybr_ForP1 GAAGAACCAAGCCGAAACCAT 
Human Cux1 Human Cux1_Sybr_RevP1 AGGCTCTGAACCTTATGCTCA 
Cux1 Cux1_TOPO_ForP1 CACCATGGCGGCCAATGTG 
Cux1 Cux1_TOPO_RevP1 TCAGAACTCCCATTCGATGGGC 
Cux1 Cux1_TOPO_ForP2 CACCATGGCGGCCAATGTGGGAT 
Cux1 Cux1_TOPO_RevP2 TCAGAACTCCCATTCGA 
Cux1 Cux1_TOPO_ForP3 CACCATGGCGGCCAATGT 
Foxp3 promoter 0-500 FoxpP3_1_500_RevP1 ACTGCTAGAGGGGGATCAGC 
Foxp3 promoter 0-500 FoxpP3_1_500_ForP1_Bio BIO-CAAAACTGCAGGCAGGCTTCAGATCCCTTCT 
Foxp3 promoter 0-500 FoxpP3_1_500_RevP1_XhoI CTAGCTCGAGACTGCTAGAGGGGGATCAGC 
Foxp3 promoter 0-500 FoxpP3_1_500_ForP1_SbfI GATCCCTGCAGGGCAGGCTTCAGATCCCTTCT 
Foxp3 promoter 1000-1500 FoxpP3_1000_1500_RevP1 CCAGGGTCCTAGTCCTGTCA 
Foxp3 promoter 1000-1500 FoxpP3_1000_1500_ForP1_Bio BIO-CAAAACTGCAGGTTGGCTTCAGGAAAACTGG 
Foxp3 promoter 1000-1500 FoxpP3_1000_1500_XhoI CTAGCTCGAGCCAGGGTCCTAGTCCTGTCA 
Foxp3 promoter 1000-1500 FoxpP3_1000_1500_ForP1_SbfI GATCCCTGCAGGGTTGGCTTCAGGAAAACTGG 
Foxp3 promoter 500-1000 FoxpP3_500_1000_RevP1 CTGCCATGTGAATGGGAAG 
Foxp3 promoter 500-1000 FoxpP3_500_1000_ForP1_Bio BIO-CAAAACTGCAGCCTGGGCCGCTATGTGTAT 
Foxp3 promoter 500-1000 FoxpP3_500_1000_XhoI CTAGCTCGAGCTGCCATGTGAATGGGAAG 
Foxp3 promoter 500-1000 FoxpP3_500_1000_ForP1_SbfI GATCCCTGCAGGCCTGGGCCGCTATGTGTAT 
HnrnpAB Hnrnpab_TOPO_ForP1 CACCATGTCGGACGCGG 
HnrnpAB Hnrnpab_TOPO_RevP1 TCAGTATGGCTTGTAGTTATTCTG 
Hnrnpab Hnrnpab_TOPO_ForP2 CACCATGTCGGACGCGGCTGA 
HnrnpAB Hnrnpab_TOPO_RevP2 TCAGTATGGCTTGTAGTTAT 
Hnrnpab Hnrnpab_TOPO_ForP3 CACCATGTCGGACGCG 
Hnrnpd Hnrnpd_TOPO_ForP1 ATGTCGGAGGAGCAGTTC 
Hnrnpd Hnrnpd_TOPO_RevP1 TTAGTATGGTTTGTAGCTATTTTG 
Hnrnpd Hnrnpd_TOPO_ForP2 CACCATGTCGGAGGAGCAGTTC 
Hnrnpd Hnrnpd_TOPO_ForP3 CACCATGTCGGAGGAGCAGTTCGGA 
Hnrnpd Hnrnpd_TOPO_RevP2 TTAGTATGGTTTGTAGCTA 
Hnrnpd Hnrnpd_TOPO_ForP4 CACCATGTCGGAGGAGCAG 
Hnrnpdl Hnrnpdl_TOPO_ForP1 CACCATGGAGGTCCCGCC 
Hnrnpdl Hnrnpdl_TOPO_RevP1 TTAGTAGGGCTGGTAATTGTTCT 
Hnrnpdl Hnrnpdl_TOPO_RevP2 TTAGTAGGGCTGGTAATT 
HnrnpK Hnrnpk_TOPO_ForP1 CACCATGGAGACCGAACAGC 
HnrnpK Hnrnpk_TOPO_RevP1 TTAGAAAAACTTTCCAGAATACTGC 
Mysm1 Mysm1_TOPO_ForP1 CACCATGGAGGCGGAGGAG 
Mysm1 Mysm1_TOPO_RevP1 TTACATGAACAATTCCTTTGTACTAT 
Naa38 Naa38_TOPO_ForP1 CACCATGACGTCTGCTTTGGAG 
Naa38 Naa38_TOPO_RevP1 TCAGTGTGCTACGGAGTTCAGA 
Nfya Nfya_TOPO_ForP1 CACCATGGAGCAGTATACGACAAA 
Nfya Nfya_TOPO_RevP1 TTAGGAAACTCGGATGATCTGTGTCA 
Pcbp1 Pcbp1_TOPO_Forp1 CACCATGGACGCCGGTGT 
Pcbp1 Pcbp1_TOPO_RevP1 CTAGCTGCACCCCATCCCCT 
Pcbp2 Pcbp2_TOPO_ForP1 CACCATGGACACCGGTGTGATT 
Pcbp2 Pcbp2_TOPO_RevP1 CTAGCTGCTCCCCATGCCA 
Plac8 Plac8_RevP1 GCTGCCACTTGACATCCAAGA 
Rfx1 Rfx1_TOPO_ForP1 CACCATGGCAACACAGTCCTATGT 
Rfx1 Rfx1_TOPO_RevP1 TTAGCTGGAGGGCAGGG 
Rpa1 Rpa1_TOPO_ForP1 CACCATGGTGGGACACCTGAG 
Rpa1 Rpa1_TOPO_RevP1 TCACATGTTCTTCCTGATGTTCGC 
Sf1 Sf1_TOPO_ForP1 CACCATGGCGACCGGAG 
Sf1 Sf1_TOPO_RevP1 CTAGTTCTGTGGTGGAGGCGG 
Snapc1 Snapc1_TOPO_ForP1 CACCATGGGGACTCCTGCG 
Snapc1 Snapc1_TOPO_RevP1 TCAGCATTTTCTCTTCCTCTTGGG 
Ssbp1 Sspb1_TOPO_ForP1 CACCATGTTTCGAAGACCTGTGTT 
Ssbp1 Sspb1_TOPO_RevP1 CTACGCCAACCCTTCCAATGAA 
Tfcp2 Tfcp2_TOPO_ForP1 CACCATGGCCTGGGCTCTG 
Tfcp2 Tfcp2_TOPO_RevP1 CTACTTGAGAATGACATGATAGCT 
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Tgif2 Tgif2_TOPO_ForP1 CACCATGTCGGACAGCGATCTAG 
Tgif2 Tgif2_TOPO_RevP1 CTACTTGGCGTTTTCTGAGACG 
Thap11 Thap11_TOPO_ForP1 CACCATGCCTGGCTTTACGT 
Thap11 Thap11_TOPO_RevP1 TCACATGCCGTGCTTCTTACG 
Ybx1 Ybx1_TOPO_ForP1 CACCATGAGCAGCGAGGCC 
Ybx1 Ybx1_TOPO_RevP1 TTACTCAGCCCCGCCCTGC 
Zfp574 Zfp574_TOPO_ForP1 CACCATGACTGAGGAGAGTGAAGAGA 
Zfp574 Zfp574_TOPO_RevP1 TCAGCCACTGATCTGGACCCC 
Zfp691 Zfp691_TOPO_ForP1 CACCATGGGCAGCGAGAAGG 
Zfp691 Zfp691_TOPO_RevP1 TTAGCTAAAATCCTTCTCATCTTG 
Zfp692 Zfp692_TOPO_ForP1 CACCATGGCCTCTCCGGT 
Zfp692 Zfp692_TOPO_RevP1 CTAACTTTTCTCTCTGTTCCTGG 
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10.5 List of commercial kits used for RNA/DNA purification 
and chemical modifications 
Kit name Supplier Order number 
AllPrep DNA/RNA Mini Kit Quiagen 80204 
BCA Protein Assay Kit Pierce 23225 
Dual-Light Luciferase and Beta-Gal Reporter Gene 
Assay System ThermoFisher T1003 
Epi tec Bisulfite Kit QIAGEN  59104 
NxTRACT-1KT Sigma 031 M 4035 
PureLink PCR purification kit Life Technologies K3100-01 
PureLink HiPure Plasmid Midiprep Kit Life Technologies K2100-05 
PureLink Quick Plasmid Miniprep Kit Life Technologies K2100-11 
QIA amp DNA Micro Kit QIAGEN  56304 
Quick g DNA Micro Prep Zymo Research D3020 
RNeasy Microarray Tissue Mini Kit Quiagen 73304 
RNeasy Mini Kit Quiagen 74104 
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10.6 List of cytokines used for cell culture 
Kit name Supplier Order number 
Human IL-2 PeproTech 212-12-B 
Mouse IL-6 PeproTech 216-16 
Mouse IL7 R&D 407-ML 
Mouse IL-10 PeproTech 210-10 
Mouse IFNy PeproTech 315-05 
Human TGF ß1 PeproTech 100-21 
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10.7 List of chemicals and products used for experiments 
Kit name Supplier Order number 
Accucheck counting Beads Invitrogen PCB 100 
Acetic acid 100% Merck 100063.25 
Acetone VWR 20,066,296 
ACK Lysing Buffer Lonza 10-548E 
Agar Agar Roth 5210.3 
Agarose NEEO Ultra Roth 2267.4 
Albumin Fraction V Roth 8076.1 
Ammonium bicarbonate Fulka 9830 
Ammonium chloride Roth K298.2 
Ammonium hydroxide MB Biomedical 193854 
Ammonium peroxysulfate Serva 13375 
Ammonium sulfate Roth 3746.1 
Ampicillin So salt Roth K029.1 
autoMACS Running Buffer Miltenyi Biotec 130-091-221 
Betaine Sigma B2629 
Bovine Serum Albumin Sigma A4503 
Brefeldin A Solution (1000x) BioLegend 420601 
Bromphenol blue sodium salt AppliChem A1120 
Calcium chloride dihydrate AppliChem A 3587 
Casein Hydrolysate Fluka 22090 
CFSE Life Technologies C34554 
Chloramphenicol Roth 3886.2 
Chloroform Sigma 24216 
Click:T EdU buffer additive Life Technologies C10425 
Coelenterazine Promega S2001 
Collagenase D  Roche 11088 866 001 
Collagenase from Clostridium histolyticum Type IV Sigma C5138 
Collagenase II Sigma C6885 
Collagenase IV Gibco 17104-019 
Collagenase VIII Sigma C2139 
dNTPs Life Technologies 10297-018 
D-Luciferin Pierce 88293 
DPBS Life Technologies 14190-094 
Diphtheria Toxin From Corynebacterium Sigma D0564 
Dithiothreitol Biorad 161-0611 
Dithiothreitol high purity GERBU 1008 
DMEM Life Technologies 41965 
DMEM Life Technologies 21063-029 
DMSO (Dimethylsulfoxid) 100% BioLabs B0515A 
DMSO molecular biology grade Genaxxon Bio M6324.0100 
DNA Marker 2-log Ladder BioLabs N3200L 
DNA Marker Gen Ladder 100bp BioLabs M3094 
Dnase I  Roche REF11284 932 001 
DNase I,Lyo. Roche 11284932001 
DT Sigma D0564 
DTT Life Technologies R0861 
Dulbecco`s Modified Eagle Med. wo Arginine Lysine Life Technologies ME100073L1 
Ethanol 70% Roth T913-3 
Ethanol 99,8%   Roth 9065.1 
Ethidiumbromide 1% Roth 2218.1 
Ethylenediamine tetraacetic acid  Sigma E 9884 
Fast 96 well "ROI" Plates AB 4432426 
Fast 96 well Calibration Plate AB 4432414 
Ficoll-Paque Plus GE Healthcare 17-1440-03 
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Formalin solution 10% (v/v) T.J.Baker  Foxp3 Staining Buffer Set eBiosciences REF 00-5523-00 
Foxp3 Staining Buffer Set => 10x Perm Buffer eBiosciences REF 00-8333-56 
Foxp3 Staining Buffer Set => Fixation Perm Diluent eBiosciences REF 00-5223-56 
Foxp3 Staining Buffer Set => Fixation Perm conc. eBiosciences REF 00-5123-43 
Freund`s Adjuvant Gerbu 1842 
Gelatine Solution 0,1% in PBS PAN P06-20410 
Glucose AppliChem A1422 
Glycerol bidistilled 99,5% VWR 24,388,295 
Glycine Gerbu 10,231,000 
Glyo Blue Ambion AM 9516 
Goat IGG MP #55397 
Heparin 5000U/ml Biochrom L6510 
Hepes 1M Biowest L0180-100 
Hepes ultrapure Biomol 5,288,100 
Hexadimethrine bromide Sigma H9268 
Histopaque 1077 Sigma 10771 
Hoechst 33342 trihydrochlorid trihydrate Life Technologies REF H3570 
Hoechst 33342, Trihydrochloride, trihydrat  Life Technologies H3570 
home made Taq Polymerase NA NA 
Hy Clone HyPure Molecular Biology Grade Water Thermo Scientific SH 30538.03 
Hyaloronidase Sigma H3884 
Hydrochlorid acid  37% VWR 20,252,290 
Hydrochlorid acid 1M VWR 30,024,290 
Hygromycin B Roth CP13.1 
IGEPAL CA-630 MP 198596 
Incidin Foam Ecolab YFS 16 
Ingenio Solution Mirus MIR 50111 
Ionomycin calcium salt Cayman 10004974 
IPTG Roth 2316.4 
Isopentan e Lager 13090 
Kanamycin sulfate Roth T832.2 
LB Medium (Luria /Miller) Roth x968.1 
Lipofectamine 2000 1mg/ml Life Technologies 11668-027 
Lipopolysaccharides f. Escherichia coli 055B5 Sigma L2880 
Lysozyme Sigma L6876 
Magnesium chloride hex hydrate Roth 2189.1 
May Grünwald´s azur eosine-methylene blue solution Merck 109,204 
MEM Alpha Medium Life Technologies 22561-021 
MEM NEAA Life Technologies 11140-35 
Mercaptoethanol Sigma M6250 
Methanol Ph Eur VWR  MicroBeads anti Biotin Miltenyi Biotec 120-000-900 
Milk powder Roth T145.2 
Mouse Serum Biowest S2160-010 
Sodium carbonate Roth A 135.1 
Sodium dihydrogen carbonate AppliChem A1940 
Neomycin sulfate Roth 8668.1 
Nonidet P40 AppliChem A1694 
Opti MEM Life Technologies 31985-047 
Passive Lysis Buffer 5X Promega E1941 
Paraformaldehyde Roth 0335.3 
PBS Dialysed Life Technologies 26400-036 
Phenol Roth A156.1 
PMA Biomol AG-CN2-0010-M001 
Polybrene in PBS Sigma #107689 
Polyethylenglycol 4000 Merck 109,727 
Ponceau S Solution  AppliChem A2935 
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Potassium chloride Roth 6781.1 
Potassium Phosphate 1M Sigma P8709 
Potassiumdihydrogenphosphate 98% Roth P018.2 
Potassiumhydrogencarbonate 99% Roth X 887.2 
Propanol Roth 6752.2 
Propidium iodine MP Biomedicals 195458 
Protease Inhibitor cocktail complete EDTA-free  Roche 11873580 001 
Proteinase K from Engyodontium albumin Sigma P6556 
Puromycin Roth #0240.1 
Puromycin Dihydrochlorid Roth 0240.1 
Rnase Inhibitor AB 100021540 
SDS, 20% Solution BioRad 161-0418 
SDS, ultrapure Roth 2326.1 
Sodium azide AppliChem A1430 
Sodium bisulfide Sigma 243973 
Sodium chloride 99,8% Roth 9265.1 
Sodium deoxycholate AppliChem A1531 
Sodium hydroxid  99% p.A. Roth 677.1 
Sodium hydroxid 1N VWR 31,627,290 
Sodium hydroxid 1N VWR 31,627,290 
Sodium ortho vanadate AppliChem A2196 
Sodium Pyruvate Solution 100mM PAA S11-003 
Sodium acetate Roth 6773.2 
Superscript 2 Life Technologies 18064-14 
SYBR Green Master mix  AB 4367659 
T cell stimulation Dynabeads mouse T Activator CD3/CD28 Life Technologies 11456D 
T cell stimulation Dynabeads mouse T Activator CD3/CD28 Life Technologies 11452D 
Taq Man Gene Expression Master Mix AB 4369016 
Th DNA Ligase BioLabs M0202 
Thioglycollate Broth  Fluka 70157 
Tissue- Tek Sakura 4566 
Trans T 293 Reagent Mirus MIR 2700 
TRIS Pufferan Roth 4855.1 
Tris ultrapure  AppliChem SAP 12681 
TRIS- hydrochloride 99% Roth 9090.3 
Triton X 100 Roth 3051.3 
Trizma acetat Sigma T1258 
Trizol Reagent  Life Technologies 15596018 
Tropix Accelerator II AB T2182 
Tropix Galacton-Plus AB T2189 
Tropix Lysis Sol. AB T2071 
Trypsin / EDTA Life Technologies 25300-054 
Tryptone/Peptone ex casein Roth 8952.3 
TSA Cyanine 3 System  Perkim Elmer NEL 704A001KT 
Tween 20  MP Tween201 
Urea Sigma U5378 
Water sterile, Nuclease free US Biological W0900 
Western Blot Stripping Buffer Thermo Scientific 46428 
Western Lightning Plus ECL Perkin Elmer NEL 105001EA 
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10.8 List of buffers 
Buffer name Recipe 
ACK lysis buffer 
1X PBS 
0.15M NH4Cl 
10mM KHCO 3 
0.1mM Na2-EDTA 
Complete medium for cell 
culture 
1X DMEM 
10% (v/v) FCS 
10mM HEPES 
100U/mL Penicillin 
100µg/mL Streptomycin 
1mM sodium pyruvate 
FACS buffer 
1X PBS 
1% (v/v) FCS 
0.1 % (v/v) NaN 3 
LB medium 
Distilled water 
0.5% (w/v) yeast extract 
1.0% (w/v) tryptone 
0.5 % (w/v) NaCl 
PBS 1X 
Distilled water 
0.27mM KCl 
13.7mM NaCk 
10mM Na2HPO4 
0.2mM KH2PO4 
PBS-T 1X PBS 0.1% (v/v) Tween 20 
Renilla Buffer 
80mM K2HPO4 
20mM KH2PO4 
100mM NaCL 
1mM EDTA 
Luciferase Buffer 
10mM TRIS-acetate 
10mM Mg-acetate 
1mM EDTA 
Renilla  
Measurement  
Buffer 
10 mL Renilla Buffer plus 10 µL Renilla substrate (Coelenterazine) 
Luciferase  
Measurement 
Buffer 
15 mL Luciferase Buffer plus 1 aliquot luciferin (5 mg) and 1 aliquot 
ATP (200mM) 
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10.9 Equipment and software 
Equipment Manufacturer 
AutoMACS Separator Miltenyi Biotec 
Bacterial Incubator GFL technologies 
Cell Culture Hood Thermo Fisher 
Cell Culture Incubator Eppendorf 
Centrifuges Eppendorf 
Electrophoresis Neolab 
FACS ARIA II and III cell sorter BD Biosciences 
LSR Fortessa II and LSR II flow cytometer BD Biosciences 
Canto II and BD Accuri flow cytometer BD Biosciences 
Ultra-deep freezer, freezer, fridge Liebherr and Thermo Fisher 
PCR master cycler Eppendorf 
Nanodrop 2000 Thermo Fisher 
UV gel documentation Neolab 
Viia 7 Real time PCR system Life technologies 
Western Blot detection system Life technologies 
Sonication bath Diagenode 
454 pyrosequencing machine Roche 
Illumina Beadchip machine Illumina 
Next generation sequencing  Illumina 
Electroporation machine BioRad 
Luminometer Berthold Technologies 
  
Software Developer 
Adobe Illustrator and Photoshop Adobe Systems 
Endnote Thomson Reuters 
FACS DIVA BD Biosciences 
FlowJo Treestar / Thermo Fisher 
ImageJ 64 ImageJ freeware 
Microsoft Office Microsoft 
Graphpad Prism Graphpad 
Viia 7 software Applied Biosystems 
 
